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Background
Tuberculous meningitis (TBM) is a common form of tuberculosis in high 
TB incidence settings. However, the burden of disease and outcome in 
affected adults is unknown in Cape Town. The diagnosis of TBM is often 
challenging, particularly in HIV co-infected patients and no standardized 
clinical case definition exists. An emerging complication that contributes 
to poor outcome in HIV-associated TBM is neurological TB immune 
reconstitution inflammatory syndrome (TB-IRIS). 
Methods
A consensus clinical TBM case definition was developed following a TBM 
meeting that I co-ordinated. I led two observational studies that determined 
the burden of HIV-associated TBM and neurological TB-IRIS at a district-
level hospital in Cape Town. Patients with HIV-associated TBM were 
prospectively enrolled in a third cohort study to determine the clinical and 
immunological characteristics of paradoxical TBM-IRIS. 
Results
TBM accounted for 57% of meningitis cases over a 6-months period; 88% 
of these patients were HIV-infected. At six months follow-up, mortality in 
HIV-associated TBM patients was 48%. Neurological TB-IRIS accounted 
for 21% of patients who presented with central nervous system (CNS) 
deterioration during the first year of antiretroviral therapy (ART) over a one-
year period. TBM-IRIS developed in 47% of HIV-associated TBM patients 
and associated with extensive cerebrospinal fluid (CSF) inflammation both at 
TBM diagnosis and at TBM-IRIS presentation. Patients who did not develop 
TBM-IRIS, but who were culture-positive for Mycobacterium tuberculosis 
from CSF at TBM diagnosis, showed an immunological phenotype similar 
to TBM-IRIS patients; however neutrophils were increased in TBM-IRIS 
patients compared to culture-positive TBM-non-IRIS patients, both at TBM 
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diagnosis and two weeks after ART initiation.
Conclusions
HIV-associated TBM is a common cause of meningitis with a poor 
outcome in Cape Town. TBM-IRIS is a frequent complication of ART in 
HIV-associated TBM patients. CSF Mycobacterium tuberculosis culture 
positivity drives an inflammatory response that manifests as TBM-IRIS in 
most, but not all TBM patients. Neutrophils associate closely with the CNS 
inflammation that characterizes TBM-IRIS. An intensified TB treatment 
regimen with increased CSF penetration early during TB treatment may 
lead to improved mycobacterial clearance from the CNS, which may result 
in improved outcome during TBM treatment and a reduced frequency of 
TBM-IRIS. We aim to test this hypothesis in future studies.
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Tuberculosis (TB) remains a leading cause of mortality and morbidity 
worldwide; in 2012, 1.3 million deaths were attributed to TB with almost a 
quarter of these occurring in HIV-infected persons 1. South Africa bears the 
brunt of the TB/HIV co-infection burden accounting for 20-30% of affected 
persons globally. Tuberculous meningitis (TBM) is the most devastating 
form of TB with an associated mortality during treatment of 28% of HIV-
uninfected 2, and 58% of HIV-infected 3, patients in TBM randomized 
controlled trials. This is in stark contrast to results from randomized 
controlled trials performed in other forms of HIV-associated TB such as 
pulmonary 4, and pulmonary plus extra-pulmonary (other than TBM) cases 5, 
which report mortality during TB treatment of <3%, and <18%, respectively. 
HIV-infected patients, particularly those with severe immunosuppression, 
are at increased risk of disseminated forms of TB, such as meningitis that 
accounts for up to 19% of all hospitalized HIV-associated TB cases 6. TBM 
is a common cause of meningitis in high HIV/TB co-infection settings, and 
accounted for 28% of microbiologically confirmed cases at GF Jooste 
Hospital between 2006 and 2008 7. HIV-infected TBM patients frequently 
present with atypical cerebrospinal fluid (CSF) findings, which may delay 
diagnosis and treatment initiation 8-10. Due to limited epidemiological data 
the burden of TBM disease is uncertain in high HIV/TB co-infection settings 
such as South Africa and the outcome in affected adults has not been 
determined in Cape Town. 
Clinicians face considerable challenges in the diagnosis and management 
of TBM 11: disease pathogenesis remains poorly understood; rapid, sensitive 
and affordable diagnostic tests are lacking; and optimal management has 
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not been established by randomized controlled trials. Further research is 
urgently required, but the low frequency with which a definitive diagnosis 
is established presents a major obstacle. Detection of acid-fast bacilli 
and/or culture isolation of Mycobacterium tuberculosis from CSF has 
been reported with high frequency in some studies 12, 13, but remains the 
exception in most 14-19. The diagnosis usually relies on clinical evidence 
which combines supportive clinical, laboratory and radiological findings, 
but standardised diagnostic criteria for TBM applicable to HIV-infected and 
uninfected patients did not exist prior to 2010.
  
It is estimated that more than 2.1 million people were receiving ART in 2012 
in South Africa, compared to ~1.8 million in 2011 and ~50 000 in 2004 20, 
21. Despite the benefit of ART in improving clinical outcome in TB/HIV co-
infected patients 22, patients may deteriorate clinically after commencing 
ART due to the immune reconstitution inflammatory syndrome (IRIS) 23, 24. 
IRIS occurs as a result of an exuberant inflammatory response towards 
previously diagnosed or occult opportunistic pathogens 25; it has been 
described in relation to many pathogens, with mycobacteria being most 
frequently implicated 23.  TB-IRIS may present in one of two recognised 
ways; firstly, as paradoxical worsening of symptoms after commencement 
of ART and secondly, as an unmasking syndrome 25. Paradoxical TB-IRIS 
occurs in 8-54% of TB/HIV co-infected patients after starting ART 25, 26. 
Common manifestations include lymph node enlargement and pulmonary 
involvement 23-25, 27, 28. Neurological TB-IRIS, although accounting for over 
10% of paradoxical TB-IRIS cases at GF Jooste Hospital 29, is less well 
documented; by 2010 only one clinical case series 29, 30 and a handful 
of case reports existed 27, 28, 31-37. Neurological TB-IRIS may present as 
meningitis 28, 29, 33, 35, 37, brain tuberculomas 27-29, 31, 32, 36, 37, brain abscess 32, 34 
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and radiculomyelitis 29, 35. Outcome in neurological TB-IRIS is poor; in one 
case series published from Cape Town, mortality at 6 months follow-up 
was 13% and 17% of patients were lost to follow-up 29. 
Although recent studies have advanced understanding of TB-IRIS through 
the identification of several cellular, immunological and genetic factors 
that associate with the syndrome, the immunopathogenesis remains 
unclear and no diagnostic test exists 38. Thus far explorations of immune 
biomarkers implicated in TB-IRIS pathogenesis have focused mainly on 
those measured in the blood compartment, which is likely an incomplete 
representation of the immune response in affected tissues, e.g. lungs or 
CNS.
Key research aims
The key research objectives addressed in this thesis were developed to 
address gaps in knowledge of HIV-associated TBM. They include:
1) To establish a consensus clinical case definition for TBM for use in 
clinical research.
2) To describe the presentation and outcome of patients with TBM in 
a high burden HIV setting and investigate the predictors of mortality 
in these patients.
3) To describe the causes of CNS deterioration in HIV-infected patients 
during the first year of ART and to determine the proportion of these 
cases who presents with neurological TB-IRIS.
4) To determine the proportion of patients with HIV-associated TBM 
who develop paradoxical TBM-IRIS.
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5) To describe the clinical and laboratory findings and outcomes of 
paradoxical TBM-IRIS. 
6) To investigate the immunopathogenesis of TBM-IRIS, with a focus 
on inflammatory markers in the CSF of affected patients. 
Setting
The clinical studies were conducted at GF Jooste Hospital, a public sector 
referral hospital, in Cape Town in the Western Cape Province of South 
Africa. The hospital is located in Manenberg on the Cape Flats and at the 
time of the studies served adults from a catchment population of 1.3 million 
people. The high-density low-income communities served by GF Jooste 
Hospital included Khayelitsha, Gugulethu, Mitchells Plain and Nyanga. At 
the start of the studies (2009-2010) the reported TB case notification rate 
exceeded 1500 cases per 100 000 people per year and 70 percent of TB 
cases were HIV-infected in Khayelitsha, where approximately 430 patients 
were enrolled into ART care monthly 39. Eleven primary-level ART clinics 
and 16 TB clinics were situated in the GF Jooste Hospital referral area. 
Most patients who attended these clinics did not have health insurance. 
Therefore, most patients who presented with significant clinical deterioration 
at these facilities including all meningitis suspects, were referred to GF 
Jooste Hospital for assessment and management.
The immunological studies were performed in the laboratory of Robert J 
Wilkinson at the Institute of Infectious Disease and Molecular Medicine at 
the Faculty of Health Sciences of the University of Cape Town. 
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Chronology of studies
The prospective observational study to describe causes of CNS 
deterioration during the first year of ART was designed in 2007. Seventy-
five participants were enrolled from November 2007 through October 2008. 
Data analysis and publication of the manuscript (presented in Part 2 of 
Chapter 4) occurred in 2010.
 
The prospective observational study to investigate the frequency and 
characteristics of TBM-IRIS was designed in 2008. The study recruited 
patients from March 2009 through October 2010 and patient follow-up was 
completed by July 2011. The study screened 67 patients with meningitis of 
whom 34 patients with TBM were included in the final analysis. The clinical 
characteristics of these patients were published in 2013 and are presented 
in Chapter 5. In addition, 18 HIV-infected patients without meningitis who 
were not receiving ART were enrolled as control participants. A manuscript 
describing the immunological findings of TBM and control participants has 
been submitted for publication and is presented in Chapter 6.
The consensus clinical case definition for TBM presented in Chapter 3 arose 
from a TBM workshop held in May 2009 in Cape Town. I was responsible 
for leading the organization of the meeting held by the University of Cape 
Town. Fourty-one participants from seven countries (South Africa, the 
United Kingdom, Vietnam, India, the United States of America, Malawi, and 
Indonesia) attended the meeting. The aim of this meeting was to develop a 
clinical case definition for TBM that would be applicable to all TBM cases, 
regardless of HIV status or age, for use in research. Following the meeting, 
I was given the role of heading the writing committee for the consensus 
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case definition manuscript. Over the following year I combined criteria 
suggested during the meeting and those found relevant from my literature 
review to produce a draft manuscript that presented this case definition. 
After members of the writing committee provided input, I finalized the 
manuscript that was published in 2010.
The retrospective study describing the frequency, presentation and 
outcome of TBM patients was designed in 2010. Laboratory records 
of all 698 patients who underwent a lumbar puncture from March 2009 
through October 2009 were reviewed. Medical records of 182 patients with 
suspected TBM were reviewed and the presentation and outcome of 120 
patients with TBM were described in a manuscript published in 2011.  This 
manuscript is presented in Part 1 of Chapter 4.
Outline of the thesis
In Chapter 2 (background and literature review) a detailed literature review 
of the clinical and laboratory features and outcome of HIV-infected TBM 
compared to findings in HIV-uninfected patients is presented. Diagnostic 
and therapeutic challenges are also discussed with specific reference to 
the treatment of HIV and paradoxical TB-IRIS. This review was published 
in 2010. Recent advances in knowledge of HIV-associated TBM and 
neurological TB-IRIS published since 2010 and a section on TB-IRIS 
pathogenesis have been included as an addendum to this chapter.
In Chapter 3 the consensus clinical case definition for TBM is presented. 
This case definition (for use in clinical research) was developed to be 
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uniformly applicable, irrespective of the patient’s age or HIV infection status 
or the resources available in the research setting.
In Chapter 4 two descriptive studies are presented that aimed to determine 
the burden of HIV-associated TBM and neurological TB-IRIS at a district-
level hospital in Cape Town. Firstly, in a retrospective study that describes 
the frequency, presentation and outcome of TBM, we also determined 
risk factors for inhospital and 6-month mortality in HIV-associated TBM. 
Secondly, in a prospective study we determined the incidence of referral for 
CNS deterioration during the first year of starting ART and the contribution 
of neurological TB-IRIS to this deterioration.
In Chapter 5 the prospective clinical study of patients with HIV-associated 
TBM is presented.  The aim of this study was to describe the clinical and 
laboratory features, and to determine the outcome, of patients who develop 
TBM-IRIS.
In Chapter 6 the immunological findings in patients who developed TBM-
IRIS is described and compared to those in patients who did not develop 
TBM-IRIS. The aim of this study was to investigate immunopathogenic 
mechanisms in TB-IRIS by determining inflammatory mediators at the site-
of-disease (i.e. CSF). 
Chapter 7 provides an integrated narrative of the thesis that synthesises 
the major findings from all chapters. Conclusions of the thesis as a whole 
are drawn, the implications of the research for the TBM field in general 
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s u m m a r y
HIV-associated tuberculous meningitis (TBM) poses significant diagnostic and therapeutic challenges
and carries a dismal prognosis. In this review, we present the clinical features and management of HIV-
associated TBM, and compare this to disease in HIV-uninfected individuals. Although the clinical
presentation, laboratory findings and radiological features of TBM are similar in HIV-infected and HIV-
uninfected patients, some important differences exist. HIV-infected patients present more frequently
with extra-meningeal tuberculosis and systemic features of HIV infection. In HIV-associated TBM, clinical
course and outcome are influenced by profound immunosuppression at presentation, emphasising the
need for earlier diagnosis of HIV infection and initiation of antiretroviral treatment.
 2010 Elsevier Ltd. All rights reserved.
Introduction
Tuberculosis (TB) remains the most important infectious cause
of death worldwide, with an estimated 1.82 million deaths in 2008,
including 0.52 million deaths in persons co-infected with the
human immunodeficiency virus (HIV).1 HIV-infected persons may
present with unusual clinical features of TB,2 and are at risk of
developing disseminated forms of TB, such as tuberculous menin-
gitis (TBM).3,4 HIV-associated TBM poses significant diagnostic and
therapeutic challenges and carries a dismal prognosis.5e10 In this
review, we present the clinical features and laboratory findings of
HIV-associated TBM. We also discuss the management of HIV-
associated TBM, compared to TBM in HIV-uninfected individuals.
Clinical presentation
Several studies have investigated the effect of HIV infection on
the clinical presentation of TBM in adults and children
(Table 1).3e21 The differences between the clinical, laboratory and
radiological features of TBM in HIV-infected and HIV-uninfected
persons are presented in Table 2.
TBM occurs most commonly in children under the age of five
years,22 although delayed exposure to Mycobacterium tuberculosis
(M.tb) and/or selection bias may influence the age distribution in
different settings. A second peak occurs during the third and fourth
decades of life. The mean/median age at presentation is 23e67
months in HIV-infected children, versus 35e39 months in HIV-
uninfected children.5,8,17With the exception of two studies,7,11 most
of the evidence suggests that HIV co-infection does not significantly
influence the age of clinical presentation in adults (mean/median
age 26e37 years in HIV-infected persons versus 28e46 years in
HIV-uninfected persons).4,6,9,12,14,18,19
The symptoms, the interval from symptoms to clinical pre-
sentation, and the neurological findings at clinical presentation
are similar in HIV-infected and HIV-uninfected patients
(Table 2).3e9,11,13e15,17,19 One study found a higher prevalence of
cognitive dysfunction in HIV-infected adults not receiving anti-
retroviral therapy (ART) compared with HIV-uninfected adults
(32% versus 0%, p ¼ 0.001),6 whereas another study found a lower
prevalence of impaired consciousness in HIV-infected children not
receiving ARTcomparedwith HIV-uninfected children (73% versus
50%, odds ratio [OR] 0.37, 95% confidence interval [CI] 0.15e0.91).8
Regardless of HIV status, patients commonly present with severe
disease, defined as modified British Medical Research Council
(BMRC) grade II or III TBM; this is strongly associated with poor
outcome.7,9,18,20
Abnormal clinical findings outside the central nervous system
(CNS) occur more frequently in HIV-infected patients. Children are
more likely to be malnourished,8,17 while both adults and children
* Corresponding author. Tel.: þ27 79 501 3242; fax: þ27 21 692 0289.
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exhibit other clinical features of HIV disease.3,8,9 HIV-infected
patients are also more likely to have disseminated TB or extra-
meningeal involvement (i.e. involvement of organs other than the
CNS), including pulmonary, nodal, genitourinary, spinal, pleural and
abdominal disease.4,7,14 Tuberculin skin test positivity is variable in
HIV-infected patients.3e5,8,12,17
Most studies report similar frequencies of chest radiograph
(CXR) abnormalities in HIV-infected and HIV-uninfected patients
(53e67% versus 47e82%, respectively)3,11,12,15 e.g. active TB, (46%
versus 38%, respectively);7 adenopathy (3e60% versus 0e37%,
respectively);3e5,8 and miliary TB (10e33% versus 20e44%, respec-
tively).5,7,8,11,12,15 One study in children (not receiving ART),8 and one
in adults (40% of whom were receiving ART),4 found more CXR
abnormalities in HIV-infected than HIV-uninfected cases (85%
versus 65%, and 62% versus 33% (p¼ 0.04), respectively). Abdominal
ultrasoundmay assist TB diagnosis; one study identified abdominal
lymphadenopathy in more than half of HIV-infected patients.3 M.tb
may be cultured from the blood,18,19 or urine3 of HIV-infected
patients, especially from those with disseminated disease. Lip-
oarabinomannan, a mycobacterial cell wall component, may be
detected in the urine.23
Cerebrospinal fluid features
The cerebrospinal fluid (CSF) typically has a clear appearance,
a leucocytosis (10e1000 � 106 cells/l; mostly lymphocytes), a raised
protein concentration (>0.5 g/l), and adecreasedCSF tobloodglucose
ratio (<0.5).24 Most studies report similar CSF findings in HIV-infec-
ted and HIV-uninfected patients (Table 2).3e5,7,8,11e15,25 In contrast,
Thwaites et al. reported a reduced CSFwhite cell count (WCC) inHIV-
infected adults not receiving ARTcompared to HIV-uninfected adults
(152 � 106 cells/l versus 356 � 106 cells/l, p ¼ 0.007).16 Two studies
reported similar findings, as well as significantly decreased CSF
protein concentrations in HIV-infected adults.6,10
Atypical CSF findings occur in a substantial proportion of
HIV-infected TBM patients, potentially causing diagnostic uncer-
tainty and delayed treatment. Croda et al. reported the combination
of pleocytosis (>5 � 106 cells/l), elevated CSF protein levels
(>0.45 g/l) and reduced CSF glucose levels (<2.5 mmol/l) in only
64% of culture-confirmed HIV-infected TBM patients, a third of
whom were known to be receiving ART.19 A normal CSF
WCC,10,11,14,19 protein concentration,3,4,11,12,14,19 glucose concentra-
tion,3,11,12,14,15,19 and even a completely normal CSF,3,14,19,25 have all
been reported in HIV-associated TBM. In one study, 33% of
HIV-infected TBM patients with a CD4þ T-lymphocyte count less
than 50 cells/ml had a normal CSF WCC.10 Lymphocytes are the
dominant CSF cell type in HIV-uninfected TBM patients3,7,11,14,25
whereas neutrophils frequently predominate, and account for up
to 70%of the CSF cell population, inHIV-infected TBMpatients.9,14,25
The diagnostic gold standard for TBM is microbiological confir-
mation, either by visualization of acid-fast bacilli (AFB) in, or culture
of M.tb from, the CSF. Some studies have achieved extremely high
Table 1





















Berenguer et al.3 Spain 37 Adults Retrospective, observational 100 Not stated 38% Not stated In-hospital
Dube et al.11 USA 15 Adults Retrospective, observational 100 At least 6 Not stated Not stated In-hospital
Yechoor et al.12 USA 20 Adults Retrospective, observational 75 9 32% Not stated 9 months
Porkert et al.13 USA 16 Adults Retrospective, observational 100 Not stated Yes, number
not stated
Not stated 6 months
Karstaedt et al.14 South
Africa
39 Adults Retrospective, observational 100 Not stated Yes, number
not stated
Not stated In-hospital
Topley et al.5 South
Africa
10 Children Retrospective, observational 10 9e12 100% Not stated 6e12 months
Katrak et al.6 India 22 Adults Prospective, observational 32y Not stated Not stated 0 6 months
Schutte et al.15 South
Africa
20 Adults Prospective, observational Not stated Not stated Not stated Not stated Treatment
completion
Thwaites et al.16 Vietnam 11 Adults Prospective, observational 100 9 No 0 In-hospital
Thwaites et al.7 Vietnam 96 Adults Randomized, placebo-
controlled
42 9 50% 0 9 months
Karande et al.17 India 8 Children Prospective, observational Not stated Not stated 100% Not stated In-hospital
van der Weert et al.8 South
Africa
34 Children Retrospective, observational 36 { 6 100% 0 6 months




Cecchini et al.18 Argentina 101 Adults Retrospective, observational 100 Not stated Not stated Not stated In-hospital
Torok et al.9 Vietnam 58 Adults Prospective, observational 93 9 100% 4 yy 9 months
Torok et al.20 Vietnam 253 Adults Randomized, placebo-
controlled
62 9 100% 253 {{ 9 months
Croda et al.19 Brazil 108 Adults and
children
Retrospective, observational 100 9 100% 36 *** In-hospital, and
9 months
Cecchini et al.10 Argentina 101 Adults Retrospective, observational 100 Not stated Not stated Not stated In-hospital
Pepper et al.21 South
Africa
13 Adults Prospective, Observational yyy 15 At least 9 100% 13 6 months post
TBM-IRIS
n, number of patients; %, percentage of patients; TBM, tuberculous meningitis; TB, tuberculosis; M.tb, Mycobacterium tuberculosis; ART, antiretroviral therapy.
* Including patients with cerebrospinal fluid smear positive for acid-fast bacilli and/or culture positive for M.tb, unless otherwise stated.
y Including patients with brain autopsy evidence of M.tb infection.
{ Including patients who cultured M.tb from gastric aspirate.
** 15 patients were receiving one or more antiretroviral drug at time of TBM diagnosis; ART was started during TBM treatment in 24 patients.
yy 4 patients were started on ART during TBM treatment; 3 patients had a history of ART exposure prior to TBM diagnosis.
{{ Patients were started on ART during TBM treatment.
*** 36 patients were receiving ART at time of TBM diagnosis; 63 patients had a history of ART exposure prior to TBM diagnosis.
yyy Study conducted in patients who developed paradoxical tuberculous meningitis immune reconstitution inflammatory syndrome (TBM-IRIS).
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rates (>80%) of microbiological confirmation;9,26,27 a number of
factors (e.g. large CSF volumes, prolongedmicroscopic examination,
and multiple CSF samples) have shown an improvement of diag-
nostic yield.26,27 In the majority of studies, however, TBM diagnosis
is presumptive and based on a combination of clinical, laboratory
and radiological findings,6,28e32 emphasising the need for devel-
opment of a standardized case definition.33 Although similar
microbiological confirmation rates have been reported in HIV-
infected and HIV-uninfected patients,3,4,6,8,11e13 the numbers of
culture-confirmed cases in most studies are low. Thwaites et al.
isolated M.tb from a greater proportion of patients (42% of HIV-
infected patients not on ART versus 30% of HIV-uninfected patients,
p¼ 0.029)7 and from significantly smaller volumes of CSF (1.5 ml in
HIV-infected patients versus 4 ml in HIV-uninfected patients
p ¼ 0.001).27 Torok et al. cultured M.tb from CSF in 88% of HIV-
infected TBM patientsmost of whomwere not on ARTand observed
that the quantity of bacilli seen in the CSF smear appeared to be
higher.9 This is supported by autopsy findings of AFB in the cerebral
parenchyma and meninges of HIV-infected patients not on ART,
which was not observed in HIV-uninfected patients.6
One of the major difficulties encountered in clinical practice is
distinguishing TBM from other subacute meningoencephalitides in
HIV-infected patients. Notably, cryptococcal meningitis (CM),
which also occurs frequently in severely immunosuppressed
patients, may present with similar clinical and laboratory
features.34e38 Other relatively common HIV-related CNS diseases,
such as cytomegalovirus encephalitis, cerebral toxoplasmosis and
primary CNS lymphoma, may also mimic TBM.39 Diagnostic algo-
rithms have been derived in order to distinguish TBM from other
causes of meningitis, including bacterial meningitis.31,32,40,41 One of
these algorithms demonstrated high sensitivity (96e99%) and
moderate specificity (72e82%) when evaluated prospectively in
HIV-uninfected patients,42,43 but sensitivity (78%) and specificity
Table 2
Comparison of clinical, laboratory and radiological features in HIV-infected and
HIV-uninfected patients with tuberculous meningitis*.
HIV-infected HIV-uninfected
Age
Children: months, mean/median5,8,17 23e67 35e39
Adults: years, mean/median4,6,7,9,11,12,14,18,19 26e37 28e46
History/symptoms
TB contact positive, %5,17 70e75 37e57
Previous TB, %4,7e9,11,13,18,19 8e58 0e25




y Fever, % 3,4,6,11,13e15,17,19 68e100 45e97
Headache/irritability, %3,4,6,8,11,13,15,19 41e100 22e100
Malaise, %3,13 27e44 22e32
Weight loss, %6,8 18e47 3e51
Nausea/vomiting, %3,4,6,8,13,19 26e50 22e54
Seizures, %3e5,8,14,17,19 3e50 0e64
Examination findings
{Mantoux test positive %
Children5,8,17 13e45 18e77
Adults3,4,12 33e50 42e80
Weight for age (Z-score), children, mean5,8 �1.77 to �2.58 �1.2e1.77
Impaired consciousness, %3e6,8,11,14,19 30e74 23e73
GCS, mean/median7,9,15 12e13 13e14
BMRC grade at presentation, %3,5,7e9,12e14,17e19
Grade 1 0e50 0e34
Grade 2 35e80 42e82
Grade 3 0e63 0e88
Meningeal signs, %3,4,6,8,11,14,15,17,19 19e100 44e100
Cranial nerve palsies, %6e8,17 13e77 30e52
Hemiplegia, %6e8 19e36 15e34
**Focal neurological deficit, %3e5,9,11,13,14,17,19 16e80 11e80
Paraplegia, %6,7 4e23 8e16
Blood investigations










Hematocrit,%, mean/median7,9,13 33.9e34.8 35.5e36.8
Cerebrospinal fluid (CSF) parameters
White cell count, � 106 cells/l,
mean/median3,4,6,7,9e14,16,19,25
47e438 11e356
Lymphocyte count, � 106 cells/l,
mean/median4,5,8,15
89e219 13e179
Neutrophil count, cells � 106/l, mean5,8,15 18e69 50e87
Protein, g/l, mean/median3e15,19,25 0.52e2.88 0.78e3.48
Glucose, mmol/l, mean/median3e6,8,10e15,19,25 1.3e2.7 1.1e2.8
Glucose, CSF: Blood ratio, median7,9,19 0.27e0.3 0.29
Adenosine deaminase, IU/l, mean/median3,4,15 10e12.6 13.5e16
{{AFB stain positive, % 3,4,6,8,9,11,13 0e69 0e26
M.tb culture positive, %4,6,7,9,12 0e88 0e78
***Extrameningeal tuberculosis 3,4,6,10,14,17,19 48e100 9e75
Chest radiography
Abnormal, %3,4,8,11,12,15 53e85 33e82
Miliary tuberculosis, %5,7,8,11,12,15 10e33 18e44
Adenopathy, %3e5,8 3e60 0e37
Parenchymal infiltrate, %3,4,8,12,15 22e49 7e55
Cerebral imaging
Neuroimaging abnormalities, %3e5,12,13,15,18,19 55e100 50e90




Cerebral atrophy, %5,6,8,12 5e57 5e17
Infarcts/non-enhancing lesion, %3,6,8,13,15 13e50 6e44







Fever clearance time, days, median3,7 8 9
Coma clearance time, days, median7 7 7
In-hospital mortality, %3,10,11,14,17,19 13e72 18e64
yyyIn-hospital survival without
neurological deficit, % 3,15,17
38e61 19e74
{{{Mortality at 6-months follow-up, % 5,6,8,13 24e50 0e22
yyySix-months survival without
neurological deficit, % 6,8
29e36 55e60




TB, tuberculosis; GCS, Glasgow Coma Scale; BMRC, BritishMedical Research Council;
M.tb, Mycobacterium tuberculosis; BCG, Bacille Calmette-Guerin.
* Including studies conducted in HIV-infected�HIV-uninfected adults and
children.
y Including fever as symptom or sign.
{ Positive Mantoux test criteria include: skin test reaction� 5 mm of induration if
child had close contact with infected adult or, �10 mm of induration if not17; skin
test reaction� 15 mm of induration if child is HIV-uninfected and received BCG,
or� 10 mm induration if no BCG received or child is HIV-infected5; skin test reac-
tion � 5 mm of induration if patient is HIV-infected or, � 10 mm of induration if
patient is HIV-uninfected4,8,12.
** Including studies which exclude 6th cranial nerve palsies3,14.
yy Including CD4þ T-lymphocyte count for HIV-uninfected patients from one
study11.
{{ Including studies which only include patient who 1) cultured M.tb from
CSF3,11,13,25 or; 2) had positive CSF polymerase chain reaction for M.tb complex25.
*** Diagnosed by clinical, radiological or microbiological findings.
yyy Includes percentage of total number of patients.
{{{ Including deaths attributed exclusively to tuberculous meningitis13.
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(43%) declined markedly when it was used in a population with
high HIV prevalence.44 In addition to CSF Gram stain and bacterial
culture (to exclude pyogenic bacterial meningitis), India ink
microscopy, cryptococcal latex agglutination test and/or fungal
culture (to exclude CM) are essential investigations in HIV-infected
patients presenting with suspected TBM. Other laboratory tests
that may assist in excluding alternative diagnoses include: 1) CSF
viral nucleic acid amplification assays for viral meningitis; 2) CSF
and serum syphilis antibody assays for neurosyphilis; and 3) serum
Toxoplasma gondii antibody assays for toxoplasma encephalitis.
Laboratory features
A number of studies have compared the baseline laboratory
features of TBM in HIV-infected and HIV-uninfected patients.
Several studies have found haemoglobin (Hb) concentrations to be
significantly reduced in HIV-infected compared with HIV-unin-
fected TBM patients.6,8,17 Karande et al. reported that moderate to
severe anaemia (Hb <80 g/l) was more frequent in HIV-infected
compared with HIV-uninfected childrenwith TBM (63% versus 12%,
p ¼ 0.008).17 Thwaites et al. reported a significantly lower median
haematocrit in HIV-infected adults not on ART compared with HIV-
uninfected adults with TBM (33.9 versus 36.8, p < 0.001), a factor
which was independently associated with death (OR 0.83, 95% CI
0.73e0.94, p ¼ 0.005).7 Some studies have reported significantly
lower values of blood WCC in HIV-infected patients,6,7,13,16 while
others have indicated a trend.5,8,11,15 One study has shown
a significant reduction in platelet count in HIV-infected TBM chil-
dren not on ART.8
While serum sodium levels are typically decreased in TBM
patients, some studies suggest that serum sodium levels are lower
in HIV-infected compared to HIV-uninfected patients.5,7,11,13 Torok
et al. found that severe hyponatremia in a cohort of HIV-infected
TBM patients (most of whomwere not on ART) was independently
associated with an earlier time to death (adjusted hazard ratio
[AHR], 0.93; 95% CI, 0.89 to 0.98; p ¼ 0.002).9 Finally Thwaites et al.
showed that hepatic transaminases were significantly elevated in
HIV-infected adults not on ART compared with HIV-uninfected
adults with TBM, a finding which may be related to higher rates of
hepatitis B virus co-infection in this group.7
Radiological features
Cerebral imaging is an invaluable tool in the diagnosis of TBM.
Radiological features of TBM include one or more of the following
findings: hydrocephalus; basal meningeal enhancement; infarction;
and tuberculoma(ta).45e47 The frequency of cerebral imaging abnor-
malities is similar in HIV-infected and HIV-uninfected TBM patients
(55e100% versus 50e90%, respectively) (Table 2).3,5,12,13,15,18,19 Only
one study reports significantly more abnormalities on brain
computed tomography (CT) (74% versus 37%, p¼ 0.03) andmagnetic
resonance imaging (100% versus 64%, p ¼ 0.04) in HIV-infected
compared with HIV-uninfected adults.4
Most studies report no difference in the presence of meningeal
enhancement between HIV-infected and HIV-uninfected TBM
patients.3,5,12,13,15,17 Two studies report that basal meningeal
exudates occur less frequently in HIV-infected patients not on ART
compared to HIV-uninfected patients (33e38% versus 71e82%,
respectively).6,8 One study, conversely, showed a trend towards an
increase in meningeal enhancement in HIV-infected patients, 40%
of whom were receiving ART.4
Although the proportion of patients with hydrocephalus
(obstructive and non-obstructive) is similar between the 2
groups,3,4,8,11e13,17 obstructive hydrocephalus occurs less frequently
in HIV-infected patients compared with HIV-uninfected patients
(0e6% versus 20e64%, respectively).6,8 Katrak et al. proposed that
the reduced meningeal enhancement and obstructive hydroceph-
alus observed in HIV-infected patients not on ART was due to
severe immune suppression causing a reduced inflammatory
response.6 This was supported by post-mortem findings. CT brain
studies showed that cerebral atrophy was significantly more
frequent in HIV-infected patients not on ART compared with
HIV-uninfected adults (44% versus 5%),6 and children (57% versus
17%).8
Contrast enhancing lesions occur with similar frequency in HIV-
infected and HIV-uninfected TBM patients3,6,13 although one small
study reported more mass lesions in HIV-infected compared with
HIV-uninfected patients (60% versus 14%, p ¼ 0.01).11 Whereas
a contrast-enhancing lesion in a HIV-uninfected TBM patient
intuitively represents a tuberculoma, the differential diagnosis is
broader in HIV-infected patients and includes cerebral toxoplas-
mosis6 and primary CNS lymphoma.48,49 Indeed Katrak et al.
diagnosed concomitant cerebral toxoplasmosis (by histology in five
patients and by response to anti-toxoplasmosis treatment in one
patient) in all HIV-infected TBM patients who presented with
granulomata on CT brain.6 Further reports of TBM/toxoplasmosis
co-infection in HIV-infected individuals have been published.3,20
Clinical algorithms may assist with presumptive diagnosis and
initial management of HIV-infected patients presenting with focal
brain lesions50,51 but patients who deteriorate on empirical anti-
microbial treatment may require a brain biopsy to confirm the
diagnosis.
Medical management
The optimal treatment of TBM remains uncertain, as no
randomized, controlled trials have determined the optimal drug
combination, doses or duration of treatment.24 Recommended
first-line agents for the treatment of TBM include a backbone of
rifampicin and isoniazid for nine to 12 months with pyrazinamide
plus ethambutol or streptomycin or ethionamide during the initial
phase (two months).24 Isoniazid52 and pyrazinamide53 have
excellent CSF penetration and are considered to be invaluable in the
treatment of TBM. In contrast, the CSF penetration of rifampicin is
poor, reaching concentrations only slightly in excess of the
minimum inhibitory concentration against M.tb.52 Although the
role of rifampicin in the treatment of TBM has been challenged,
evidence for its benefit is clear. While isoniazid resistance, with or
without streptomycin resistance, has no significant effect on long-
term outcome in adults with TBM, combined rifampicin and
isoniazid resistance (multidrug resistance [MDR]) is associated
with an increased mortality rate.54 Plasma rifampicin concentra-
tions may be reduced in HIV-infected patients compared to HIV-
uninfected patients.55 This raises the concern that low rifampicin
concentrations in CSF may result in sub-optimal TBM treatment in
HIV-infected patients.
Infection with drug-resistant M.tb further complicates the
treatment of TBM in HIV-infected patients. HIV-infected patients
with TBM frequently present with a history of previous TB (8%e58%
of patients).4,7e9,11,13,18,19 Isoniazid and streptomycin resistance
have been associated with HIV infection16 and prolonged clearance
of M.tb from the CSF,54 but have not been found to be associated
with worse outcome.
By contrast, MDR-TBM has an extremely poor prognosis with
a reported mortality of up to 100%.9,19,54,56e58 This may partly be
explained by delayed diagnosis and treatment resulting from the
time taken to perform culture and drug susceptibility testing.
Thwaites et al. found an independent association between MDR-
TBM and HIV infection,54 which occurred in 13% of HIV-infected
and 4% of HIV-uninfected patients.7 Other studies similarly found
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a higher proportion ofMDR-TB in HIV-infected comparedwith HIV-
uninfected patients (42% versus 5% of isolates).16,18 When treated
appropriately, MDR-TBM in HIV-infected patients is not invariably
fatal.19,56,58 A high index of suspicion for the diagnosis should be
maintained, especially in patients with a prior history of TB.19
Although corticosteroids improve the prognosis in HIV-unin-
fected persons with TBM,59e62 its benefit in HIV-infected patients is
uncertain. A Cochrane systematic review concluded that data
regarding the benefit of adjuvant corticosteroids in HIV-infected
patientswith TBMwas inconclusive.62 It is commonpractice inmany
settings to use corticosteroids in HIV-infected patients with TBM,
and some studies have suggested a benefit in these patients.12,59 A
randomized, placebo-controlled trial of dexamethasone in Viet-
namese adults with TBM showed a non-significant reduction in
mortality at nine months in HIV-infected patients not on ART.59
Yechoor et al. found that not receiving corticosteroids was inde-
pendently associated with a higher mortality at nine months in
a predominantly HIV-infected patient population. However, corti-
costeroids may potentially cause harm in HIV-infected patients by
exacerbating immune suppression and increasing the risk of infec-
tions or the development or exacerbation of Kaposi’s sarcoma.63e65
Surgical management
Although medical therapy is the mainstay of treatment for TBM,
surgical interventions may be required to assist in diagnosis,
treatment of mass lesions or their complications, as well as treat-
ment of hydrocephalus.66 The presence of hydrocephalus in TBM
patients is associated with a poor prognosis67e70 but the manage-
ment of hydrocephalus remains controversial as well-designed
prospective randomized trials have not been conducted.71 Surgical
options include one or more of the following: external ventricular
drainage, ventriculo-peritoneal (VP) shunting, and endoscopic
third ventriculostomy (ETV).71,72 Literature regarding the optimal
surgical management of TBM-related hydrocephalus in HIV-infec-
ted patients is scarce. Nadvi et al. reported a dismal prognosis at
one-month follow-up in patients who underwent VP shunting; 10/
15 HIV-infected patients died compared to 4/15 HIV-uninfected
patients.73 The association between severe disease at presentation
and poor outcome after VP shunting in TBM is well-recognised.72,74
However, in the study by Nadvi et al., 80% of HIV-infected patients
presented withmilder disease severity (grade 1 and 2 of the Vellore
Grading System75) compared to 47% of HIV-uninfected patients.
The mean CD4þ T-lymphocyte count in HIV-infected patients was
183 cells/ml and no patients received ART. These findings can not
readily be generalized to patients with less severe immune
suppression or those receiving ART. ETV is an emerging treatment
option for TBM-associated hydrocephalus. Case series, using vari-
able entry and outcome criteria, have shown success rates of
41e77% in TBM patients.76e80 One of the major obstacles in the
application and success of this procedure in TBM is the distortion of
brain anatomy by basal inflammatory exudates.72,76,77 Although the
use of ETV in HIV-infected TBM patients has not been studied
explicitly, it is considered to be of benefit in these patients, as:
i) HIV-infected patients may have less basal exudate,6 which allows
permeability of the floor of the third ventricle and better visuali-
zation of basal brain structures and, ii) the potential hazard of shunt
infection/blockage is avoided.71
Treatment of HIV infection
TBM is classified by the World Health Organisation as an HIV
stage 4 disease requiring ART.81 Starting ART during antitubercu-
losis treatment improves outcome in HIV/TB co-infected patients,82
but the optimal time to start ART in these patients is not known.
Initiating ART during antituberculosis treatment may be associated
with overlapping drug toxicities, drugedrug interactions and,
paradoxical TB immune reconstitution inflammatory syndrome
(TB-IRIS), all of which may be detrimental to the patient.55,83
Conversely, delayed initiation of ART may result in progression of
HIV disease and death. Two retrospective studies in HIV/TB co-
infected patients have found a reduced mortality in patients who
commenced ART earlier (within 2 months, compared to later84)
and, in patients with CD4þ T-lymphocyte counts <100 cells/ml, 2
weeks, compared to 8 weeks85 after starting antituberculosis
treatment. In the first randomized, double-blind, placebo-
controlled trial comparing immediate ART (initiated � 7 days after
starting antituberculosis treatment) versus delayed ART (initiated 2
months after starting antituberculosis treatment) in adult patients
showed similar mortalities (76/127 versus 70/126) at nine-month
follow-up.20 Grade 4 adverse events were significantly more
frequent in the immediate ART group (80 vs. 69%; p ¼ 0.04) during
the 12months of follow-up, suggesting that delayed treatment may
be the preferred option.
One of the emerging complications of starting ART in patients
on antituberculosis treatment is paradoxical TB-IRIS.86,87 Paradox-
ical TB-IRIS is characterized by an exuberant inflammatory
response against M.tb antigens in the context of a recovering
immune system. The reported incidence is 8e43%.86 Patients with
paradoxical TB-IRIS typically present with clinical or radiological
deterioration after starting ART, following an initial period of clin-
ical improvement on antituberculosis treatment. Neurological
involvement, documented in 12% of paradoxical TB-IRIS cases, is
fatal in a significant proportion of patients21 (see Figure 1 for
illustrative case). Patients may present with new or worsening
meningitis,21,88,89 tuberculoma,21,90e94 tuberculous brain
abscess,93,95 or radiculomyelitis.21,89 Although paradoxical reac-
tions have been described for HIV-uninfected and HIV-infected
TBM patients not on ART,96e101 paradoxical TB reactions (not
restricted to the CNS) occur at much higher frequency in patients
after initiating ART.102 Diagnosing paradoxical neurological TB-IRIS
is challenging; although case definitions have been published, no
diagnostic test exists, and other causes for deterioration need to be
excluded.21,86 The differential diagnoses of paradoxical neurological
TB-IRIS include: other CNS opportunistic infections; drug-resistant
M.tb infection; non-compliance to antituberculosis treatment; and
drug reactions and toxicities.86 Sub-optimal antituberculosis drug
doses should also be considered. The risk factors for paradoxical TB-
IRIS include: disseminated TB; a shorter time interval from
commencing antituberculosis treatment to initiating ART; severe
immune suppression at TB diagnosis; and a rapid immune recovery
following ART initiation.55 The optimal management of patients
with paradoxical neurological TB-IRIS is unknown. Support for the
benefit of corticosteroids in these patients is derived from anec-
dotal case reports,89,91 one case series,21 and a randomized,
placebo-controlled trial of prednisone in patients with mild to
moderate paradoxical TB-IRIS.103 The latter study showed signifi-
cant symptomatic improvement and shorter duration of hospital-
ization in patients treated with prednisone (at a dosage of 1.5 mg/
kg/day for 2 weeks followed by 0.75 mg/kg/day for 2 weeks)
compared to placebo. However, patients with severe TB-IRIS
manifestations (e.g. neurological IRIS) were not included in this
study. Pepper et al. showed initial clinical improvement in 18/20
patients treated with prednisone for neurological TB-IRIS (at
a starting dose of 1.5 mg/kg/day).21 Six-month survival for the
whole group (n ¼ 23) was 70%. Alternative immunomodulatory
therapies, such as thalidomide, pentoxifylline, montelukast
(a leukotriene antagonist) and infliximab (a tumor necrosis
factorea inhibitor), have been used with success in selected cases
of TB-IRIS involving extra-CNS sites or paradoxical CNS TB reactions
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(in patients not on ART).104 The potential application of these
agents in TBM-IRIS still needs to be determined; their use in these
patients may be limited due to potential serious adverse events.
Outcome
TBM is generally associated with a poor prognosis, even in HIV-
uninfected patients.28,30,59,61 Although one study found that the in-
hospital mortality differed significantly between HIV-infected and
HIV-uninfected patients (63% versus 18%, OR 7.4, 95% CI 3.0e18.5,
p ¼ 0.0000),10 death during hospitalization appears to be similar
between HIV-infected patients (13e72%) and HIV-uninfected
patients (21e64%).3,11,14,17,19 Cecchini et al. reported the following
factors to be significantly associated with death during hospitali-
zation in HIV-infected patients with TBM: BMRC grade II and III
disease; infection with MDR-TB strains; and a CD4þ T-lymphocyte
count less than 50 cells/ml.18 Berenguer et al. found a similar asso-
ciation between a low CD4þ T-lymphocyte count (<200 cells/ml)
and in-hospital mortality by univariate analysis3 but this finding
was not substantiated by other studies.14,15 Other variables asso-
ciated with reduced hospital survival in HIV-infected patients with
TBM include duration of symptoms >14 days3 and reduced Glas-
gow Coma Scale (GCS).15
Most studies report higher rates of death at six to nine months
after initiation of antituberculosis treatment in HIV-infected patients
(24e67%) compared to HIV-uninfected patients (0e30%).5e8,12,28
Factors independently associated with death at six to nine months
of follow-up in HIV-infected patients are: tachycardia,19 increased
TBM grade,7,20 lower haematocrit,7 not receiving corticosteroids,12
and a history of ART prior to presentation.19 Independent predictors
of earlier time todeath inHIV-infectedpatients predominantlynoton
ART include: increased TBM grade, decreased CSF lymphocyte
percentage, and lower serum sodium.9
It is likely that severe immunosuppression and resultant HIV-
related illnesses contribute to the poor outcomes observed in HIV-
infected TBM patients. Most patients are severely immune
suppressed at presentation (median/mean CD4þ T-lymphocyte
count 32e180 cells/ml),3,4,7,9,11e15,18e20 and do not receive ART
during TBM treatment.6e9,16 A low CD4þ T-lymphocyte count has
been associated with a poor outcome by univariate, but not
multivariate, analysis at nine months of follow-up.7,19 This includes
one study in which patients did not receive ART during antituber-
culosis treatment,7 and another, in which a third of patients were
known to be on ART at TBM diagnosis.19 In the latter study, the
authors did not comment on the number of patients who
commenced ART during TBM treatment. In addition, patients who
died were less likely to receive ART.9 Unsurprisingly, a significant
proportion of HIV-infected patients present with concomitant
AIDS-defining illnesses at TBM diagnosis3,4,6,18 or during the course
of TBM treatment.9 This was also observed in patients who
commenced ART following TBM diagnosis.20 Although rarely
reported, AIDS-related illnesses account for up to 50% of patients
with TBM (not on ART) who die.8 Long-termmortality rates are also
high for TBM patients receiving ART during antituberculosis
treatment. In one study, the nine-month mortality in 253 patients
started on ART within 2 months of antituberculosis treatment
initiation (58%) was not markedly different compared to a historic
control group predominantly not exposed to ART from the same
site (67%).9,20 In this study, themedian CD4þ T-lymphocyte count in
patients started on ART was severely suppressed (40 cells/ml) at the
time of TBM presentation, and a large proportion of patients died
prior to peripheral blood HIV viral suppression. Croda et al. report
a high mortality rate at nine months (41%) in a group of HIV-
infected TBM patients, a third of which were known to be on ART at
TBM diagnosis19 Similar to the study by Torok et al. CD4þ T-
lymphocyte counts were severely suppressed at the start of anti-
tuberculosis treatment and did not differ between patients who
were (76 cells/ml) and were not (70 cells/ml) receiving ART. The use
of ART prior to TBM presentation was independently associated
with nine-month mortality. The authors conclude that this unex-
pected finding probably relates to ART discontinuation or irregular
use. It is conceivable that the timing of ART in patients enrolled into
these two studies was ‘a little too late’ for many of them; improved
outcomes might have been observed had ART been commenced
prior to such extreme immunosuppression.
Conclusions
Although the clinical presentation, laboratory findings and
radiological features of TBM are largely similar in HIV-infected and
HIV-uninfected patients, some important differences exist. HIV-
infected patients present more frequently with extra-meningeal
tuberculosis and systemic features of HIV infection. The diagnosis
poses significant challenges as the differential diagnosis is broader,
and CSF parametersmaydiffer, compared toHIV-uninfectedpatients.
The management of HIV-infected TB patients is complicated by the
need to treat both infections simultaneously, in the absence of
a robust evidencebase. InHIV-associatedTBM, the clinical course and
dismal outcome are undoubtedly influenced by profound immuno-
suppression at presentation, emphasising the need for earlier diag-
nosis of HIV infection and initiation of antiretroviral treatment.
Strategies to improve early diagnosis and management of HIV-asso-
ciated TBM are urgently required.
Figure 1. Contrast enhanced axial computed tomography (CT) image showing
multiple tuberculomata, basal meningeal enhancement and hydrocephalus in
a patient with tuberculous meningitis immune reconstitution inflammatory
syndrome. A 41-year-old HIV-infected female (baseline CD4þ T-lymphocyte count
123 cells/ml) was diagnosed with tuberculous meningitis; cerebrospinal fluid cultured
Mycobacterium tuberculosis susceptible to rifampicin and isoniazid. She improved on
antituberculosis treatment and was started on combination antiretroviral therapy
(ART) nine weeks later. Seven days after ART initiation, she developed vomiting and
difficulty walking. CT of the brain performed 18 days after symptom onset showed
multiple ring-enhancing lesions with surrounding oedema, basal meningeal
enhancement, and hydrocephalus with effacement of the fourth ventricle. Her CD4þ T-
lymphocyte count was 253 cells/ml and her HIV viral load was 290 copies/ml. She
continued antituberculosis treatment and ART. Oral prednisone was started at a dose of
1.5 mg/kg/day and weaned over the next 3 months. Six weeks after initial presentation,
her symptoms had resolved and her neurological examination was normal.
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Addendum to Chapter 2
Burden of disease
Recent studies continue to emphasize the significant contribution of TBM 
to the health burden in high TB/HIV co-infection settings. Of HIV-infected 
patients admitted for CNS deterioration to a hospital in Ethiopia, TBM was 
the second most common cause, accounting for 22.5% of cases 1.  In 
a high HIV-prevalence setting in Malawi, M. tuberculosis was the cause 
of 18% of microbiologically confirmed meningitis cases 2. In two studies 
from Cape Town each conducted over three years, TBM accounted for 
28% (n=227) of microbiological confirmed meningitis cases in adults 3,  and 
53% (n=126) of bacterial meningitis (including bacterial and mycobacterial) 
cases in children 4, at a district-level hospital, and a tertiary referral hospital, 
respectively. Studies that define TBM based on laboratory methods are likely 
to underestimate TBM disease prevalence as, in contrast to cryptococcal 
meningitis and bacterial meningitis for which sensitive laboratory-based 
diagnostic methods exist, such tests are insensitive for TBM diagnosis 5.
Clinical and laboratory diagnosis
The most common differential diagnosis for TBM in HIV-infected patients 
is cryptococcal meningitis, which often presents with similar clinical and 
CSF features to that of TBM 1, 2, 6. Although CSF India Ink, crytococcal latex 
agglutination test (CLAT) and/or fungal culture are necessary to rule out CM 
in HIV-infected TBM suspects, these tests are not always readily available 
in resource-poor settings. One study therefore investigated the utility of a 
diagnostic algorithm, based on clinical and routine laboratory findings, to 
distinguish TBM from CM 2. In this study, higher lymphocyte counts (median 
[IQR]; 45 [0-280] versus 0 [0-18] cells/mL), lower CSF opening pressure (200 
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[145–275] versus 270 [160–340] mm H2O), lower GCS (12.5 [8-15] versus 15 
[14-15] /15), more frequent neck stiffness (78.3 versus 54.6 %) and higher 
temperature (mean ± SD; 39.8 ± 13.3 versus 37.2 ± 1.0 oC) distinguished 
CSF culture confirmed TBM (n=46, 89% HIV-infected) from CM (n=112, 
98% HIV-infected) by multivariate analysis 2. However, the diagnostic 
index that included these variables had insufficient sensitivity (83%) and 
specificity (79%) for its clinical application in the diagnostic approach to 
patients with HIV-associated meningitis. 
A second prediction rule for the diagnosis of TBM in high HIV-prevalence 
settings developed during a study from Durban, South Africa, included the 
following factors that significantly associated with a definite diagnosis of 
TBM (i.e. either CSF culture or polymerase chain reaction [PCR] positive for 
M. tuberculosis) by multivariate analysis:  CSF to serum glucose ratio ≤ 0.2 
(score=2), CSF lymphocyte count >200 cells/mL (score=2), CD4 count <200 
cells/mL (score=2) and a negative CLAT result (score=3) 7. A combined score 
of ≥ 6 showed a sensitivity and specificity (95%CI) of 47% (31-64) and 98% 
(90-100), respectively, to diagnose definite TBM. The authors then included 
results of a lipoarabinomannan (LAM) antigen ELISA test performed on 
CSF in their diagnostic algorithm. Detection of LAM, a mycobacterial cell 
wall component, in urine is a useful, rapid diagnostic tool in HIV-associated 
TB patients with severe immunosuppression 8. When CSF LAM (cut off OD 
≥ 0.18) was included in the prediction-rule for definite TBM, the sensitivity 
increased to 63% (47-68) and specificity remained high at 93% (82-98) 7. 
Although this algorithm shows promise as a good rule-in test for TBM in 
high HIV prevalence settings, its diagnostic application would need to be 
confirmed in larger studies. 
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A further laboratory method that is of potential value in the rapid diagnosis 
of TBM is the Xpert MTB/RIF test (Xpert, Cepheid, Sunnyvale, CA, USA), 
a real-time PCR assay for M.  tuberculosis that simultaneously detects 
rifampicin resistance 9. The Xpert assay performs better than microscopy 
in the diagnosis of pulmonary TB in M. tuberculosis culture positive sputum 
samples in both HIV-infected and uninfected patients 9. Promising results 
have recently emerged for the application of Xpert in extra-pulmonary TB 10, 
including TBM 11-13. A meta-analysis of the diagnostic accuracy of the test 
reported a pooled sensitivity (95% CI) of 80.4% (75.0-85.1), and a pooled 
specificity of 86.1% (83.5-88.4) in M. tuberculosis culture positive extra-
pulmonary specimens 10. In a study of TBM patients from Vietnam, the 
overall sensitivity of Xpert was 59.3% (n=108/182, 95% CI: 51.8-66.5) using 
clinical diagnosis as the reference standard and the specificity was 99.5% 
(97.2-100) 11.  In this study, the sensitivity of Xpert was significantly higher 
in HIV-infected compared to HIV-uninfected patients (sensitivity 78.8% 
versus 47.9%, OR: 4.01, 95% CI: 3.65-4.36, p<0.001). In a South African 
study that evaluated Xpert in the diagnosis of TBM in a predominantly 
HIV-infected co-hort (87% of the 204 participants were HIV-infected), the 
sensitivity and specificity of Xpert were 67% (n=36/54, 95%CI: 53-79) and 
94% (n=61/65, 85-98), respectively; this analysis included patients with 
definite TBM and patients with other causes of meningitis 13. Although the 
overall sensitivity decreased to 36% (n= 38/106, 95% CI: 27-46) when 
probable TBM was included in the reference standard, using a larger 
volume (3 ml) of centrifuged CSF compared to 1 ml of neat CSF increased 
the sensitivity markedly from 26% to 65%, in this analysis. In a study 
from India that compared the performance of light-emitting diode (LED) 
auramine fluorescent microscopy and Xpert for the diagnosis of TBM in 
HIV-infected TBM suspects, the number of positive results increased 12 
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fold with Xpert (n=35/142, 24.6%) compared to LED microscopy (n=3/142, 
2.1%) 12.  Although results from these studies are encouraging for the utility 
of Xpert as a rapid rule-in test for TBM, the high costs associated with 
Xpert compared to LED microscopy (cost per test: 16.84 USD vs 0.2 USD), 
may restrict its use in resource-poor settings 12.  
Outcome
Outcome in HIV-associated TBM remains poor in spite of increased 
availability of ART. A study from India reported a 12-month mortality of 51% 
in HIV-infected patients on standard TB treatment, 43% of these patients 
were receiving ART at time of TBM presentation 14. In an Ethiopian study, 
54%  (42/78) of HIV-associated TBM cases, the majority of whom were not 
receiving ART at presentation, died during hospitalization 1. 
Similar to previous studies, Alvarez-Uria et al. reported an association 
between lower CD4 count and mortality during TB treatment in HIV-
associated TBM; adjusted hazard ratio (aHR [95% CI]) for CD4 ≤ 50 /mL = 
1.95 (1.132–3.372) 14. In this study, being on ART for less than six months 
compared to not receiving ART was associated with decreased mortality 
(aHR [95% CI] = 0.56 [0.311–0.995]) and low serum albumin concentration 
(≤ 3.8 g/dL) was an independent risk factor for death 14.
Medical management
The principles of treating TBM are still based on those used in pulmonary 
TB 5, 15, but there is increasing interest in exploring alternative evidence-
based treatment regimens for TBM. Findings from two recent studies 
suggest a mortality benefit from ‘intensified’ treatment regimens early 
during TB treatment in TBM patients. Firstly, a randomized controlled 
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trial with a factorial design investigated the safety and pharmacokinetic 
profiles of higher than normal dose intravenous (IV) rifampicin as well 
as oral moxifloxacin in HIV-infected and -uninfected adults with TBM 
16. Although not powered to detect a mortality benefit, an improved 
outcome was observed in patients receiving IV rifampicin (~13mg/kg/day) 
compared to the oral standard dose (~10mg/kg/day) during the initial two 
weeks of TB treatment; patients who received IV rifampicin had a more 
rapid resolution of coma (median [IQR]; 4 [2-8] versus 5 [3-7] days) and 
reduced mortality at 6-month follow-up compared to those who received 
oral rifampicin (mortality, 34% versus 65% (aHR for death [95% CI]; 0.42 
[0.20–0.91]) p=0.03). Secondly, an observational study in 203 HIV-infected 
TBM patients showed a mortality benefit in patients who received an initial 
intensified regimen of oral higher than normal doses isoniazid (~14mg/kg/
day) and rifampicin (~21mg/kg/day) as well as pyrazinamide, ethionamide 
and levofloxacin for a median of seven days, compared to standard TB 
treatment (including rifampicin, isoniazid, ethambutol and pyrazinamide); 
the aHR (95%CI) for death with standard TB treatment was 2.05 (1.21-
3.42) 14.  A further randomized controlled trial assessing the utility of higher 
doses of oral rifampicin (15mg/kg/day) and oral levofloxacin (20mg/kg/day) 
in improving TBM outcome is currently ongoing in Vietnam 17.
Corticosteroid treatment is associated with improved survival in HIV-
uninfected patients with TBM and is recommended in all affected patients, 
regardless of HIV-status 15, 18. In 2004 results from a randomized controlled 
trial of adjunctive dexamathosone in TBM were reported 18; at 9-months 
follow-up, dexamethasone was associated with a reduced risk of death, 
compared to placebo which was significant in all patients (relative risk [RR] 
[95%CI]; 0.69 [0.52-0.92]; p=0.01). In subgroup analysis, the point estimate 
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of effect was similar in HIV-infected patients (n=98) but did not reach 
statistical significance (stratified RR of death [95 %CI]; 0.78 (0.59-1.04); 
p=0.08). Corticosteroid treatment was further associated with a decrease 
in severe adverse events, in particular hepatitis (0/274 versus 8/271 in the 
placebo group, p=0.004), in all patients. However, the outcome benefit 
seen with adjunctive corticosteroids was of limited duration. In a follow-up 
study, Torok et al. 19 determined outcomes of participants in Thwaites’s trial 
18 who received dexamethasone compared to placebo, two and five years 
after randomization. At 2-years follow-up, survival probability showed only 
a trend to being higher in the dexamethasone arm (0.63 [95%CI= 0.57-
0.69] versus 0.55 [0.49-0.61]; p=0.07) and 5-year survival probability was 
similar (0.54 [0.48-0.60] versus 0.51 [0.45-0.57]; p=0.51). Furthermore, the 
dexamethasone group had a similar proportion of severely disabled patients 
among survivors at five years to the placebo group (17/128, 13.2% versus 
17/116, 14.7%). As the authors suggested, it is likely that dexamethasone 
prevented death at nine months but left more patients disabled; these 
disabled patients then went on to die during the follow-up period.
Strokes occur in 15-58% of TBM patients and may occur prior to, or 
develop during, TB treatment 20. The role of aspirin, an anti-platelet drug 
used widely for the prevention of ischemic stroke, have thus been explored 
in the management of TBM 21, 22. In a randomized controlled trial of aspirin 
in 118 TBM patients (HIV status not reported), aspirin (150mg/day) was 
associated with a non-significant reduction in stroke (as evidenced by MRI 
findings) at 3-months follow-up, compared to the placebo group (24.2 
versus 43.3 %; OR [95%CI]; 0.42 [0.12-1.39]) 21. Importantly, aspirin was 
significantly associated with survival (OR [95% CI]; 3.17 [1.21-8.31]) at 
3-months follow-up, and it was not withdrawn in any patients due to adverse 
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events. Conversely, a randomized controlled trial in 146 children with TBM 
(5 HIV-infected), found no significant benefit for either high-dose (100mg/
kg/day) or low-dose (75mg/day) aspirin compared to placebo in relation to 
morbidity (hemiparesis and developmental outcome) and mortality during 
TB treatment 22. In this study, one death was potentially related to aspirin 
and a second participant was withdrawn due to an aspirin-related adverse 
event. Further studies that include HIV-infected patients are required to 
confirm or refute the role of aspirin in the management of patients with 
TBM.
Treatment of HIV infection
The optimal time of starting ART in patients with HIV-associated TBM 
remains uncertain. Delaying ART in severely immune suppressed persons 
could result in HIV disease progression and increased vulnerability to other 
lethal opportunistic infections. Conversely, early ART initiation in TB patients 
increases the risk of developing TB-IRIS 23-25, which is frequently fatal 
when the CNS is involved 26, 27. In a randomized controlled trial of patients 
with HIV-associated TBM reported in 2009, Torok et al. (referenced as an 
abstract in main text of this Chapter; reference 20) showed no difference 
in 9-months mortality between severely immunosuppressed TBM patients 
(median CD4 count = 41 cells/mL) who started ART immediately (within 
seven days of TB treatment), compared to later (two months after starting 
TB treatment) 28. Since then, results from three randomized controlled trials 
that addressed the question of when to start ART in TB/HIV co-infected 
patients have been published 23-25. These trials either showed a mortality 
benefit 23, or a decrease in the combined endpoint of death or AIDS-defining 
illness 24, 25, with starting ART 2-4 weeks, compared to 8-12 weeks, after TB 
treatment in patients with CD4 counts less than 50 cells /mL, in spite of an 
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increased risk of TB-IRIS in the early ART groups; a similar mortality benefit 
with starting ART early was not seen in patients with higher CD4 counts. 
The majority of patients in these studies had TB outside of the CNS and 
similarly, the majority of IRIS events did not involve the CNS 29-31. Results 
may therefore not be applicable to patients with meningitis, who are at high 
risk of developing life-threatening intracranial TB-IRIS manifestations 32. In 
view of this concern and the finding of an increased frequency of severe 
adverse events in TBM patients who commence ART early 28, current South 
African Department of Health guidelines recommend starting ART 4-6 
weeks after TB treatment in TBM patients, regardless of CD4 count 33.
  
Paradoxical neurological TB-IRIS
Paradoxical TB-IRIS occurs in 8-54% of TB/HIV co-infected patients after 
starting ART 23-25, 34-38; CNS involvement is reported in 0-31% of these 
cases 26, 27, 29, 35, 36, 38. The risk of developing neurological TB-IRIS may be 
increased in patients who initially present with neurological involvement at 
TB diagnosis; in a study from Cape Town, 20% of neurological TB cases 
developed TBM-IRIS after ART initiation 36. TBM-IRIS is the most life-
threatening form of TB-IRIS with studies reporting associated mortality of 
13-75% 26, 27, 38 compared to the 3.2 % estimate for all forms of paradoxical 
TB-IRIS combined 39; however, in one small case series (n=6) no deaths 
were attributed to TBM-IRIS 36.
TB-IRIS pathogenesis
The pathogenesis of TB-IRIS is incompletely defined and no diagnostic 
test exists 40. TB-IRIS typically occurs during the initial immune restoration 
phase following ART initiation that is characterized by a marked increase 
in CD4 count 34. Earlier studies of TB-IRIS immunopathogenesis have 
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therefore focused on the adaptive immune system. Initial studies found 
that TB-IRIS was characterized by an expansion of M. tuberculosis 
antigen-specific CD4 cells after ART initiation compared to patients who 
did not develop TB-IRIS 41. However, subsequent studies have shown 
that these expansions also occur in TB/HIV co-infected patients who do 
not go on to develop TB-IRIS, suggesting a contributing role for other 
factors to TB-IRIS pathogenesis 42. Various recent lines of evidence are 
implicating the innate immune system as an important contributor to TB-
IRIS pathogenesis 40. Lung autopsy findings from a patient with unmasking 
pulmonary TB-IRIS reported in 2009 revealed the presence of CD68+ 
macrophages as the dominant inflammatory cell type 43. Since then, higher 
natural killer cell activation states 44, monocytes 45, the complement system 
46, pattern recognition receptors 47 and cytokines predominantly of myeloid 
origin such as IL-6 38, 48, TNF 48 and IL-18 49, have all been associated with 
TB-IRIS. Further reported associations between diverse inflammatory 
mediators and TB-IRIS in vivo at TB-IRIS presentation include elevated 
blood (serum or plasma) CXCL10 49, IL-10 and IL-22 50, IFN-γ 48 as well as 
matrix metalloproteinase (MMP)-7 51. Inflammatory mediators measured in 
plasma prior to ART initiation found to associate with subsequent TB-IRIS 
include the combination of decreased CCL2 and elevated CXCL10 and 
IL-18 (association was further strengthened in combination with increased 
IFN-γ responses to RD1 antigens and purified protein derivative; AUC 0.9) 
49, and elevated IL-6 38, IFN-γ (in patients not receiving corticosteroids) 52 
and CXCL8 (in patients receiving corticosteroids) 52. 
A potential mechanism by which corticosteroids result in symptomatic 
improvement in TB-IRIS 53 may be through its modulatory effects on 
cytokines and chemokines. Corticosteroids suppressed cytokine/
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chemokine concentrations of IL-6, IL-10, IL-12p40, CXCL10 and TNF 
in blood of TB patients pre-ART 52 and during treatment for TB-IRIS 54. 
Plasma TNF, IFN-γ, IL-6 and CXCL8 were further significantly higher in 
TB-IRIS patients not receiving corticosteroids, but not in those receiving 
corticosteroids, two weeks after ART initiation compared to patients who 
did not develop IRIS 52. All TBM patients receive adjunctive corticosteroids 
for 6-8 weeks as part of routine care; this may reduce the frequency and/or 
severity of TB-IRIS in HIV co-infected TBM patients who initiate ART during 
this period. 
No studies have thus far investigated immunological markers from the 
site-of-disease (e.g. lungs) in patients with TB-IRIS and no reports of 
immunopathogenesis in patients with neurological TB-IRIS exist. An 
excessive intracerebral inflammatory response is considered to be partly 
responsible for the neurological damage in TBM outside of the context of 
IRIS 55; results from studies that investigated markers of inflammation in TBM 
patients could therefore direct research of TBM-IRIS immunopathogenesis. 
Studies in animals and in vitro models indicate that cytokines play an 
important part in the modulation of the immune response to infection 
with M. tuberculosis 56-58, and there is evidence for compartmentalization 
of various cytokines at the site of disease in humans 55, 59. The following 
findings relate to CSF cytokines in TBM: 1) Cytokine concentrations: TBM 
is characterized by increased expression of pro-inflammatory cytokines 
(IFN-γ, TNF, IL-1β, IL-8, IL-6) and the regulatory cytokine IL-10 55, 60-62. 
Some of these inflammatory markers remain high for weeks to months 
after the initiation of TB treatment. 2) Cytokine differences between HIV-
infected and -uninfected patients with TBM: In a study of 497 patients 
(89 HIV-infected), HIV co-infection was associated with six-fold lower IL-10 
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concentrations (log concentration [pg/ml] mean ± SD; 0.71 ±1.02 versus 
1.47 ± 0.79, p<0.0001), and increased IFN-γ/IL-10 ratios (log ratio; 1.6 ± 
0.70 versus 0.97 ± 0.99; p=0.0004) 61; however these associations were not 
confirmed by others 60. HIV-infected and -uninfected patients had similar 
concentrations of other cytokines, including IL-6, IL-8, IFN-γ and TNF 60, 
61. 3) Correlation between cytokine concentrations and severity and 
outcome in TBM: Simmons et al. 61 found that IL-6 concentration was 
independently associated with severe (British Medical Research Council 
[BMRC] grade III) disease (OR [95%CI]; 2.1 [1.1-3.8]; p=0.017) in HIV-
uninfected patients and, death was independently associated with lower 
IFN-γ in HIV-infected patients, at presentation. He and others 62 did not 
find any correlation between TNF and disease severity, however Patel et al. 
60 found a positive correlation between TNF (p=0.008) and IFN-γ (p=0.03) 
concentrations and disease severity (BMRC grade II and III versus I) in HIV-
infected (n=17) and -uninfected (n=10) patients combined. 4) Modulation 
of cytokine levels by corticosteroid therapy: Only a marginal reduction in 
IFN-γ but no other cytokine concentration differences were found in patients 
treated with adjunctive dexamethasone (n=27) compared to patients on TB 
treatment alone (n=25) (mean ± SD; net reduction of IFN-γ during the first 
week of therapy: 2.2 ± 3.3 versus 2.0 ± 5.9 ng/ml; p = 0.06) 63. 
Other inflammatory mediators including MMPs and their inhibitors, tissue 
inhibitors of matrix metalloproteinases (TIMPs), have also been reported 
as markers of disease severity in TBM 64-66. MMPs are a family of zinc-
dependant endopeptidases that degrade extracellular matrix components, 
including those found in the blood-brain-barrier 67.  To protect the host 
during inflammation, the activity of MMPs are inhibited by synchronously 
expressed TIMPs, which bind MMPs in a 1:1 ratio 68. Elevated CSF MMP-
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9 64-66 and MMP-2 64 concentrations and increased MMP-9:TIMP-1 ratios 
65 have been associated with death 66 and neurological complications 64, 
65 in patients with TBM. Cerebrospinal fluid concentrations of MMP-9 
were previously shown to decrease in HIV-uninfected patients receiving 
dexamethasone, compared to those receiving placebo, during TBM 
treatment and it was postulated that this may represent a mechanism by 
which corticosteroids improve outcome in these patients 69.
Treatment and prevention of TB-IRIS
Corticosteroids continue to be the mainstay of paradoxical neurological 
TB-IRIS treatment and few recent studies have investigated alternative 
treatment options 70. In a small case series, three children received 
thalidomide, in addition to high-dose corticosteroids during treatment 
for paradoxical neurological TB-IRIS; ART was interrupted in all cases 71. 
Outcome in these patients was variable:  one died; one recovered over 
months of treatment; and in the third, who had recurrent relapses after 
three attempts to re-introduce ART, the addition of mycophenylate mofetil 
eventually allowed the successful re-initiation of ART. 
Results of the first randomized controlled trial for the prevention of IRIS have 
recently been reported 72. Severely immunosuppressed (CD4 <100/µL) HIV-
infected patients were randomized to receive maraviroc (600 mg twice daily) 
or placebo in addition to standard ART during the first 24 weeks of ART; the 
primary endpoint was the development of IRIS during this period. Maraviroc 
is an antiretroviral agent that blocks HIV entry into host cells through its 
antagonistic binding of chemokine receptor 5 (CCR5) 73. It was therefore 
proposed that maraviroc could potentially down regulate inflammation by 
blocking the binding of natural CCR5 ligands to their receptors, such as 
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CCL3, CCL4, CCL5 and CCL8 73, 74, resulting in a decreased incidence of 
IRIS. Disappointingly, maraviroc was not associated with a decrease in 
either the frequency (33/140, 23.6% versus 31/136, 22.8%), or the severity 
(severe IRIS: 5.5% versus 6.6%), of IRIS events compared to placebo.
Conclusions
HIV-associated TBM is a common devastating disease, particularly in high 
TB/HIV co-infection settings. In addition to challenges with regards to early 
diagnosis and optimal treatment strategies during the initial presenting 
event, neurological TB-IRIS further compromises survival in those patients 
who recover sufficiently to start ART. The pathogenesis of TB-IRIS is 
incompletely understood and no treatment is of known benefit in the 
prevention or treatment of neurological TB-IRIS. A better understanding 
of the immunopathogenesis of TBM-IRIS may direct future research of 
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Personal View
Tuberculous meningitis: a uniform case defi nition for use in 
clinical research
Suzaan Marais, Guy Thwaites, Johan F Schoeman, M Estée Török, Usha K Misra, Kameshwar Prasad, Peter R Donald, Robert J Wilkinson, Ben J Marais
Tuberculous meningitis causes substantial mortality and morbidity in children and adults. More research is urgently 
needed to better understand the pathogenesis of disease and to improve its clinical management and outcome. A 
major stumbling block is the absence of standardised diagnostic criteria. The diff erent case defi nitions used in various 
studies makes comparison of research fi ndings diffi  cult, prevents the best use of existing data, and limits the 
management of disease. To address this problem, a 3-day tuberculous meningitis workshop took place in Cape Town, 
South Africa, and was attended by 41 international participants experienced in the research or management of 
tuberculous meningitis. During the meeting, diagnostic criteria were assessed and discussed, after which a writing 
committee was appointed to fi nalise a consensus case defi nition for tuberculous meningitis for use in future clinical 
research. We present the consensus case defi nition together with the rationale behind the recommendations. This 
case defi nition is applicable irrespective of the patient’s age, HIV infection status, or the resources available in the 
research setting. Consistent use of the proposed case defi nition will aid comparison of studies, improve scientifi c 
communication, and ultimately improve care.
Introduction
Tuberculous meningitis is the most severe form of 
tuberculosis and causes substantial morbidity and 
mortality in adults and children.1–10 The outcome of this 
disease is especially grave in patients with HIV.11–14 
Clinicians face substantial challenges in the diagnosis and 
management of tuberculous meningitis:15 disease 
pathogenesis is poorly understood; rapid, sensitive, and 
aff ordable diagnostic tests are not available; and the best 
management has not been established by randomised 
controlled trials. Further research is urgently needed, but 
the low frequency with which a defi nitive diagnosis is 
established and the absence of a uniform clinical case 
defi nition are major obstacles. Detection of acid-fast bacilli 
(AFB) and culture isolation of Mycobacterium tuberculosis 
from cerebrospinal fl uid (CSF) have been reported with 
high frequency in some studies16,17 but are the exception in 
most.1,7,18,19 Diagnosis usually relies on clinical evidence, 
which combines supportive clinical, laboratory, and 
radiological fi ndings. Standardised diagnostic criteria for 
tuberculous meningitis have not been established, and 
most reports have used diff erent case defi nitions. This 
absence of standardisation makes comparison of research 
fi ndings diffi  cult, prevents the best use of the existing 
data, and limits progress in management. To address 
these issues, an international tuberculous meningitis 
workshop took place in Cape Town, South Africa, in May, 
2009, to establish a consensus case defi nition for 
tuberculous meningitis for use in future clinical research. 
We present the consensus case defi nition, which should 
be uniformly applicable, irrespective of the patient’s age or 
HIV infection status or the resources available in the 
research setting.
The organisers of the meeting invited leading 
tuberculous meningitis researchers and clinicians with 
experience managing patients with tuberculous 
meningitis. 41 participants from seven countries (South 
Africa, the UK, Vietnam, India, the USA, Malawi, and 
Indonesia) attended the meeting. Participants included 
paediatric and adult neurologists, neurosurgeons, 
infectious diseases specialists, microbiologists, 
immunologists, pharmacologists, and clinical trialists. 
13 international tuberculous meningitis experts, all of 
whom have published on the disease in international 
peer-reviewed journals during the past 5 years, presented 
their research fi ndings. On the fi nal day of the meeting, 
the existing diagnostic criteria were assessed and a 
consensus case defi nition for tuberculous meningitis 
was developed. A writing committee of nine members 
was appointed to review the existing data and develop the 
fi nal consensus statement. 
Standardised clinical case defi nition
In the past 5 years, studies have used various case defi nitions 
for tuberculous meningitis (panel 1).1,3,4,8,10,11,17,18,20–24 In most 
defi nitions, patients are given a defi nite, probable, or 
possible tuberculous meningitis status depending on 
clinical, laboratory, and radiological fi ndings. Defi nite 
tuberculous meningitis cases usually include patients with 
AFB on CSF microscopy or M tuberculosis cultured from 
CSF or another CNS source. However, some studies also 
included patients with M tuberculosis identifi ed from 
specimens such as gastric aspirates, urine, or sputum,11,24 
or with M tuberculosis identifi ed by PCR8,25–27 or IgM ELISA.8 
Criteria for probable or possible tuberculous meningitis 
cases diff er greatly between studies, especially between 
studies done in children and adults. Some studies do not 
distinguish between patients with confi rmed and suspected 
tuberculous meningitis.4,7
We propose that patients with suspected tuberculous 
meningitis should be allocated to one of four diagnostic 
categories depending on the strength of clinical, 
laboratory, or radiological fi ndings. The proposed 
categories are defi nite, probable, possible, and not 
tuberculous meningitis (fi gure 1). A patient suspected to 
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having possible or probable tuberculous meningitis, 
depending on initial lumbar puncture or cerebral 
imaging fi ndings. Results from subsequent tests will 
determine the patient’s fi nal diagnostic category—for 
example, a patient will move up to the defi nite tuberculous 
meningitis category if M tuberculosis is cultured from 
their CSF. Conversely, a patient will move down to the 
not tuberculous meningitis category if evidence for an 
alternative diagnosis is identifi ed (panel 2). 
Defi nite tuberculous meningitis
A diagnosis of defi nite tuberculous meningitis is made 
when AFB are seen, M tuberculosis is cultured, or 
M tuberculosis is detected by a reliable molecular method 
from the CSF in someone with symptoms or signs 
suggestive of the disease. AFB seen in the context of 
histological changes consistent with tuberculosis in the 
brain or spinal cord are also diagnostic for tuberculous 
meningitis (mostly seen on autopsy). Identifi cation 
Adults only
Torok (2008)17 
• Patients: HIV seropositive, ≥15 years of age
• Case defi nition includes defi nite and probable tuberculous meningitis 
cases
• Defi nite tuberculous meningitis: CSF smear positive for AFB and/or culture 
positive for Mycobacterium tuberculosis 
• Probable tuberculous meningitis: clinically suspected tuberculous 
meningitis plus one or more of the following four criteria: 
 i) CXR consistent with pulmonary tuberculosis 
 ii) Other specimens (eg, sputum, lymph node, gastric washings)  
 positive for AFB
 iii) Evidence of extrapulmonary tuberculosis
 iv) CT or MRI evidence of tuberculous meningitis
• Patients were excluded if there was microbiological evidence of another 
CNS infection.
Kalita (2007)8 
• Patients: HIV seronegative, ≥13 years of age
• Case defi nition includes defi nite and suggestive tuberculous meningitis 
cases. 
A)  Clinical criteria: meningitic symptoms including fever, headache, 
and vomiting for 2 or more weeks 
B)  Supportive criteria:
i) CSF cells ≥20/μL with predominant lymphocytes, protein ≥2 g/L
ii) CT scan evidence of exudates, infarctions, hydrocephalus, and  
tuberculoma in various combinations 
iii)  Evidence of extra-CNS tuberculosis 
iv) Response to antituberculosis therapy
C)  Exclusion criteria: malaria, septic, fungal, and carcinomatous 
meningitides 
• Defi nite tuberculous meningitis: A and C plus positive PCR for 
M tuberculosis or IgM ELISA , or AFB in CSF smear or culture 
• Suggestive tuberculous meningitis: A, C, and three or more of B 
Thwaites (2004)10 
• Patients: HIV seropositive and negative, >14 years of age
• Case defi nition includes defi nite, probable, and possible tuberculous 
meningitis cases
• Defi nite tuberculous meningitis: clinical meningitis (nuchal rigidity and 
abnormal CSF parameters) and AFB in the CSF
• Probable tuberculous meningitis: clinical meningitis and one or more of 
the following: 
i) Suspected active pulmonary tuberculosis on the basis of CXR
ii) AFB found in any sample other than from the CSF
iii) Clinical evidence of other extrapulmonary tuberculosis
• Possible tuberculous meningitis: clinical meningitis and four or more of 
the following: 
i) History of tuberculousis
ii) Predominance of lymphocytes in the CSF
iii) Illness of more than 5 days in duration 
iv) CSF to blood glucose ratio of less than 0·5 
v) Altered consciousness 
vi) Yellow CSF 
vii) Focal neurological signs
• Patients were subsequently reclassifi ed as having defi nite tuberculous 
meningitis if AFB were seen in or M tuberculosis was cultured from the CSF, 
and as not having tuberculous meningitis if another diagnosis was 
confi rmed by microbiological or histopathological assessment
Adults and children
Nagesh Babu (2008)21 
• Case defi nition includes defi nite and presumptive tuberculous meningitis 
cases
A)  Clinical criteria: fever, headache, meningeal signs, and other clinical 
presentations of meningitis lasting for more than 2 weeks.
B)  CSF criteria: typical features including pleocytosis (>20 cells/μL), 
lymphocytes >60%, protein >1 g/L, and CSF: blood glucose ratio of less 
than 0·6 
C)  Supportive criteria: 
i)  Isolation of M tuberculosis from body secretion other than CSF in 
smear or culture 
ii) CXR fi ndings of pulmonary tuberculosis (reticulonodular pattern in 
upper lobes with or without cavitary lesions) 
iii) Hydrocephalous from brain CT scan 
D)  Negative bacterial and fungal cultures and negative India ink
• Defi nite tuberculous meningitis diagnostic criteria not stated
• Diagnosis of presumptive tuberculous meningitis requires A, B, one or 
more of C, and D to be fulfi lled 
Rafi  (2007)23 
• Patients: HIV seropositive and negative
• Case defi nition includes culture-confi rmed and clinical tuberculous 
meningitis cases
• Diagnosis of clinical tuberculous meningitis requires A, B, and C: 
A) Clinical fi ndings: headache, fever, and vomiting for more than 3 weeks 
B) CSF fi ndings: pleocytosis and high protein concentration 
C) Neuroimaging fi ndings: the presence of a basal exudate with or 
without hydrocephalus
(Continues on next page)
Panel 1: Examples of tuberculousis case defi nitions used for adults, children, or both in the past 5 years 
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of  M tuberculosis from CSF, either by detection of AFB or 
culture, is diffi  cult, but the chances of positive diagnosis 
can be increased by doing more lumbar punctures. From 
an initial lumbar puncture sample, Kennedy and Fallon28 
recorded the sensitivity of microscopy to be 37% and the 
sensitivity of culture to be 52%. When up to four lumbar 
punctures were done, the sensitivity of microscopy 
increased to 87% and the sensitivity of culture increased 
to 83%. Increasing the volume of CSF obtained and 
meticulous microscopy (for at least 30 min) further 
increases the chance of positive diagnosis.16 Although the 
benefi ts of fl uorescence microscopy to detect AFB from 
sputum is well established,29 data on its sensitivity for the 
detection of AFB from CSF are sparse.30 Light-emitting 
diode fl uorescence microscopy systems provide a simple 
and inexpensive alternative to costly mercury vapour 
bulbs,29 but further studies are needed to assess its 
application in the diagnosis of tuberculous meningitis. 
The microscopic observation drug susceptibility assay is 
a liquid culture method that detects characteristic 
M tuberculosis morphology by use of an inverse light 
microscope.31 This technique, which enables simultaneous 
detection of M tuberculosis and determination of drug 
susceptibility, might prove a rapid and sensitive diagnostic 
method for tuberculous meningitis.32
CSF molecular diagnostic methods, such as nucleic 
acid amplifi cation tests4,8,25–27 and M tuberculosis antibody 
detection assays,8 have previously been included in 
diagnostic criteria for tuberculous meningitis. Because 
of their highly variable sensitivity and specifi city, 
both antibody assays33–35 and in-house nucleic acid 
amplifi cation tests18,23 are regarded as experimental. 
Commercial nucleic acid amplifi cation tests generally 
show high specifi cities36 and can therefore be used 
to establish a defi nitive diagnosis in someone with 
symptoms or signs suggestive of tuberculous 
meningitis. However, more data are urgently needed to 
establish the robustness of these tests in fi eld conditions; 
the specifi cities of both culture and PCR methods 
might be compromised in areas endemic for 
tuberculosis because of an increased risk of sample 
cross-contamination.37 The Xpert MTB/RIF assay 
(Cepheid, CA, USA), is one of several methods that 
uses real-time PCR to amplify and detect M tuberculosis 
and identify drug resistance. This is an easy, rapid 
method that was sensitive and highly specifi c in initial 
studies done in patients with pulmonary tuberculosis.38 
Studies are underway to validate these fi ndings and to 
determine this assay’s application in extrapulmonary 
tuberculosis.
(Continued from previous page)
3) Children only
van Well (2009)1 
• Patients: HIV seropositive and negative 
• Case defi nition includes defi nite and probable cases
• Defi nite tuberculous meningitis: M tuberculosis isolated from CSF 
• Probable tuberculous meningitis: clinical signs of meningitis plus 
characteristic CSF fi ndings (macroscopically clear, pleocytosis, raised 
protein, and reduced glucose), plus two or more of the following criteria:
i) Recent poor weight gain (crossing of percentiles on Road to Health card) 
ii) Household contact with sputum smear-positive tuberculosis
iii) CT scan compatible with tuberculous meningitis 
iv) CXR compatible with primary tuberculosis 
v) Positive TST
vi) Other clinical specimens positive for AFB
Andronikou (2006)20 
• Case defi nition includes defi nite and probable cases
A) Clinical criteria:
i) Household tuberculosis contact
ii) Positive Mantoux tests (>15 mm)
iii) Neurological features: depressed level of consciousness, focal 
neurological signs, raised intracranial pressure, seizures, or 
meningism
iv) Systemic upset (in combination with neurological fi ndings): 
failure to thrive, fever, night sweats, proven pulmonary 
tuberculosis, proven abdominal tuberculosis, or evidence of 
extra-neurological involvement
v) Prolonged symptoms for more than 48h
B) CSF criteria:
i) Pleocytosis (>20 cells per μL) with lymphocyte predominance 
(>50%)
ii) Protein concentration greater than age-specifi c normal value; 
especially >1·0 g/L
iii) Chloride <120 mmol/L
iv) Glucose concentration less than 60% of concentration in blood
v) AFB on stains; negative India ink stains for cryptococcosis
vi) Culture positive for tuberculosis
• Defi nite tuberculous meningitis: culture-positive CSF for tuberculosis—ie, 
B(vi) 
• Probable tuberculous meningitis: A (iii) and two other positives from A 
and three positives from B
• Patients are classifi ed as not having tuberculous meningitis if criteria 
are not met or if an alternative diagnosis is made by culture or trial 
of therapy.
Saitoh (2005)4 
• Diagnostic criteria for tuberculous meningitis:
• CSF pleocytosis (≥10 cells per μL ) with one or more of the following: 
i) Positive CSF culture for  M tuberculosis complex organisms 
(M tuberculosis or Mycobacterium bovis) 
ii) Positive  M tuberculosis PCR in CSF 
iii) Positive CSF smear for AFB
iv) Positive gastric aspirate  M tuberculosis culture or AFB smear 
v) Positive TST with clinical evidence of tuberculous meningitis including 
CT fi ndings or close contact with individuals with known or suspected 
tuberculosis.
CSF=cerebrospinal fl uid. AFB=acid fast bacilli. CXR=chest radiograph. TST=tuberculin skin test.
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In summary, a diagnosis of defi nite tuberculous 
meningitis should be made when one or more of the 
following criteria are met: AFB seen in the CSF, 
M tuberculosis cultured from CSF, or a CSF M tuberculosis-
positive commercial nucleic acid amplifi cation test from 
a patient who presents with symptoms or signs suggestive 
of meningitis; or AFB seen in the context of histological 
changes consistent with tuberculosis in the brain or 
spinal cord together with suggestive symptoms or signs 
and CSF changes, or visible meningitis (on autopsy).
Probable and possible tuberculous meningitis 
We propose that the diagnosis of probable or possible 
tuberculous meningitis be determined by a diagnostic 
scoring system (table) that requires the presence of 
symptoms or signs indicative of meningitis plus 
additional clinical, CSF, or imaging criteria, with 
exclusion of the most likely alternative diagnoses. The 
number of points required for a diagnosis of probable 
tuberculous meningitis (≥12 when imaging is available 
or ≥10 when imaging is not available) and the points 
awarded in each category were decided by reviewing 
studies that quantifi ed the diagnostic contribution of 
specifi c variables5,19,25,39 and based on personal experience 
and consensus. The guiding principle was to encourage a 
uniform approach and to ensure diagnostic certainty of 
the highest possible standard, irrespective of the available 
resources. We have considered all available evidence on 
the diff erential diagnostic relevance of clinical variables 
to standardise defi nitions and establish uniformity that 
will allow direct comparison in future tuberculous 
meningitis studies. Thus, although the proposed case 
defi nition requires formal validation in both retrospective 
and prospective studies in various settings, its application 
should encourage identifi cation in reports of the most 
important diagnostic variables and allow more accurate 
comparison of the results of diff erent studies. 
Clinical criteria
The clinical presentation of tuberculous meningitis is 
non-specifi c, especially in the early stages of disease. 
Adults and children typically present with fever, headache, 
irritability, neck stiff ness, and vomiting.1,5–7,11,39,40 These 
symptoms do not, however, distinguish tuberculosis 
from other forms of meningitis.5,19,39,41 Systemic symptoms 
of M tuberculosis infection, such as lethargy, cough, 
weight loss (or poor weight gain in children), and night 
sweats might be suggestive of tuberculosis, but are also 
non-specifi c.1,6,7,11 Unfortunately, many patients present 
with advanced disease and neurological signs, such as 
convulsions, an abnormal mental state, cranial nerve 
palsies, or limb paresis.1,6,7,11,12 Although patients with HIV 
are more likely to present with disseminated tuberculosis 
than patients without HIV,9,12 and might have clinical 
features suggestive of HIV/AIDS,11,17 HIV infection does 
not seem to aff ect the neurological presentation of 
tuberculous meningitis.9,11,12
Four studies have attempted to defi ne the clinical and 
laboratory features that distinguish tuberculous meningitis 
from bacterial5,19,25,39 and other19 causes of meningitis. The 
diagnostic value of headache to diff erentiate bacterial 
meningitis from tuberculous meningitis showed 
discrepant results.5,39 In one adult study, cranial nerve 
palsies were more common in adult patients with 
tuberculous meningitis than in those with bacterial 
meningitis.39 Optic atrophy, extra-pyramidal movements, 
and focal defi cits were associated with tuberculous 
meningitis in one paediatric study,19 but optic atrophy is a 
late occurrence and abnormal extra-pyramidal movements 
are rare. None of these fi ndings have been validated in 
patients with HIV, and cryptococcal meningitis shares 
similar clinical features.42,43
The average duration between symptom onset and 
tuberculous meningitis presentation is 5–30 days1,4–6,10,19 and 
does not diff er between patients with and without HIV.12,44 
Symptom duration of more than 4 days,25 5 days,5,39 or 
6 days19 has been used to discriminate between tuberculous 
meningitis and bacterial meningitis in HIV-seronegative 
adults and paediatric patients, but cannot diff erentiate 
tuberculous meningitis from cryptococcal meningitis, 
which also presents as subacute meningitis.41,45
A history of recent close contact with a person with 
infectious tuberculosis (within the past 12 months) is an 
important clue to the diagnosis of tuberculous meningitis 
in children, aff ecting more than 50%.1,44,46,47 A positive 
tuberculin skin test also indicates probable M tuberculosis 
infection. However, the sensitivity of the tuberculin skin 
Figure 1: Categories for patients with suspected tuberculous meningitis
Patients suspected of tuberculous meningitis enter a study after lumbar puncture or brain imaging has been done 
in those meeting required criteria. Patients then move up or down the diagnostic pyramid as subsequent results 
become available and are classifi ed into defi nite, probable, possible, or not tuberculous meningitis according to 
diagnostic criteria.  Defi nite tuberculous meningitis: microbiological identifi cation or evidence from commercial 
nucleic acid amplifi cation tests of CNS Mycobacterium tuberculosis infection. Probable tuberculous meningitis: 
when imaging is available a diagnostic score of 12 or above is required, and when imaging is not available, a 
diagnostic score of 10 or above is required. Possible tuberculous meningitis: when imaging is available a diagnostic 
score of 6–11 is required, and when imaging is not available, a score of 6–9 is required.
Lumbar puncture Brain CT/MRI







Not tuberculous meningitis: alternative cause identified
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test is variable; reported sensitivities range from 17% to 
32% in mixed adult and paediatric populations6,7 and 30% 
to 77% in children.1,11,19,44,46 In infants, the sensitivity can be 
as high as 86%,48 but specifi city would be reduced in 
settings with universal BCG vaccination because of cross-
reacting immune responses, which tend to wane with 
time. An HIV infection in patients with tuberculosis49 or 
tuberculous meningitis44,50 reduces the likelihood of 
positive tuberculin skin test results. Additionally, a 
positive tuberculin skin test does not diff erentiate 
M tuberculosis infection (which is a common event in 
tuberculosis endemic areas) from active disease.51 
Peripheral blood interferon-gamma release assays are 
useful in the diagnosis of tuberculosis infection.52 
Generally, these tests have higher specifi city than do 
tuberculin skin tests,53 although sensitivities vary and 
interferon-gamma release assays do not make the crucial 
distinction between M tuberculosis infection and active 
disease. There is little data on the effi  ciency of the assays 
in severe disease such as tuberculous meningitis, and 
their role in the diagnosis of children or patients with 
HIV has not been established. In immunocompromised 
adults with extrapulmonary tuberculosis these assays 
have a sensitivity of 88% (95% CI 68–97%) and a 
specifi city of 71% (51–86%),54 and in adult patients with 
tuberculous meningitis they have a sensitivity of 69% 
(51–83%) and a specifi city of 57% (42–70%).55 However, 
further studies are needed to validate these fi ndings. The 
rate of false negatives in patients with HIV with active 
tuberculosis increases as the CD4 cell count declines,56 
which is of particular importance in such patients with 
tuberculous meningitis, many of whom present with 
profound immunosuppression. A systematic review 
of commercially available antibody detection tests 
concluded that such tests have no role in the diagnosis 
of extrapulmonary tuberculosis.57
Response to tuberculosis treatment is generally included 
in classifi cation systems8,22,24 but is an unreliable diagnostic 
aid. In practice, many patients presenting with clinical 
features of meningitis receive antimicrobial treatment for 
both tuberculous meningitis and bacterial meningitis. 
Improvement of the patient’s health after treatment will 
also not distinguish tuberculous meningitis from viral 
meningitis, which usually resolves spontaneously. 
Conversely, no response to treatment does not preclude 
the diagnosis of tuberculous meningitis; patients with 
multidrug-resistant tuberculous meningitis show little or 
no clinical improvement with standard tuberculosis 
treatment and their prognosis is poor.58,59 Furthermore, at 
least 10% of patients with tuberculous meningitis have 
paradoxical deterioration after treatment initiation.40,60 For 
these reasons, we have not included response to treatment 
in the consensus case defi nition. 
In summary, all patients with features suggestive of 
meningitis (one or more of the following: headache, 
irritability, vomiting, fever, neck stiff ness, convulsions, 
focal neurological defi cits, or altered consciousness) and 
without a defi nite tuberculous meningitis diagnosis, 
should, according to our consensus case defi nition, be 
classifi ed as probable, possible, or not tuberculous 
meningitis, depending on their total diagnostic score. 
Duration of neurological symptoms for more than 5 days 
is the most informative clinical criterion. A miliary picture 
on chest radiograph, the presence of lethargy, or other 
subtle signs in high-risk children (ie, children less than 
3 years of age with documented M tuberculosis exposure) 
might also justify CSF examination or imaging studies. 
The score required for classifi cation as probable 
tuberculous meningitis will vary according to the 
availability of cerebral imaging (≥12 when imaging is 
available or ≥10 when imaging is not available) to encourage 
a uniform approach and ensure diagnosis with the highest 
possible certainty, irrespective of the resources available. 
CSF criteria
Routine analysis of CSF in most patients with tuberculous 
meningitis shows clear appearance, pleocytosis 
(range=5–1000 cells per μL; median=50–450 cells per μL) 
with a lymphocyte predominance, a raised protein 
concentration (0·5–3 g/L), and a low glucose 
concentration (absolute value <2·2 mmol/L and a CSF to 
Panel 2: Consensus tuberculous meningitis diagnosis
Clinical entry criteria
• Symptoms and signs of meningitis including one or more of the following: headache, 
irritability, vomiting, fever, neck stiff ness, convulsions, focal neurological defi cits, 
altered consciousness, or lethargy.
Tuberculous meningitis classifi cation 
Defi nite tuberculous meningitis
• Patients should fulfi ll criterion A or B:
A) Clinical entry criteria plus one or more of the following: acid-fast bacilli seen in the 
CSF; Mycobacterium tuberculosis cultured from the CSF; or a CSF positive 
commercial nucleic acid amplifi cation test. 
B) Acid-fast bacilli seen in the context of histological changes consistent with 
tuberculosis in the brain or spinal cord with suggestive symptoms or signs and CSF 
changes, or visible meningitis (on autopsy).
Probable tuberculous meningitis 
• Clinical entry criteria plus a total diagnostic score of 10 or more points (when cerebral 
imaging is not available) or 12 or more points (when cerebral imaging is available) 
plus exclusion of alternative diagnoses. At least 2 points should either come from CSF 
or cerebral imaging criteria.
Possible tuberculous meningitis
• Clinical entry criteria plus a total diagnostic score of 6–9 points (when cerebral 
imaging is not available) or 6–11 points (when cerebral imaging is available) plus 
exclusion of alternative diagnoses. Possible tuberculosis cannot be diagnosed or 
excluded without doing a lumbar puncture or cerebral imaging. 
Not tuberculous meningitis
• Alternative diagnosis established, without a defi nitive diagnosis of tuberculous 
meningitis or other convincing signs of dual disease.
CSF=cerebrospinal fl uid.
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plasma ratio <50% [median=~27%]).1,5,6,13,17,19,61 Although 
lower CSF protein concentrations13,14 and white cell 
counts13,14,62 have been described in patients with HIV, 
most studies show similar fi ndings compared to patients 
without HIV.11,12,44,63–65 Atypical CSF fi ndings have been 
described in both groups, including normal CSF glucose, 
protein, cell count, or a neutrophil predominance.13,14,17,19,63–65 
Rare cases of culture-proven tuberculous meningitis with 
no other CSF abnormalities have also been reported.9 
CSF fi ndings that favour the diagnosis of tuberculosis 
over bacterial meningitis include clear appearance,5 a 
white-cell count less than or equal to 900–1000/μL,5,25,39 a 
neutrophil content less than 30–75%,5,19,25,39 and a protein 
concentration greater than 1 g/L.5 These studies did not, 
however, include patients with HIV and cryptococcal 
meningitis, many of whom have similar CSF fi ndings.45 
Although CSF adenosine deaminase activity 
determination can be of benefi t as a rule-in or rule-out 
test when values of less than 4 U/L and greater than 8 U/L 
are used, it cannot discriminate between tuberculous 
meningitis and bacterial meningitis.66 False-positive 
results can also be found in patients infected with 
HIV who have other HIV-associated neurological 
diseases, such as cryptococcal meningitis, lymphomatous 
meningitis, and cytomegalovirus disease.67
The specifi city of tuberculous meningitis diagnosis can 
be increased by molecular diagnostic tests. A systematic 
review and meta-analysis of commercial nucleic acid 
amplifi cation tests for the diagnosis of tuberculous 
meningitis showed a combined average sensitivity of 56% 
and specifi city of 98%.36 Because of its high specifi city, a 
positive commercial nucleic acid amplifi cation test is 
regarded as a defi nitive test in patients with suspected 
tuberculous meningitis, and off ers particular value in 
Diagnostic score
Clinical criteria                               (Maximum category score=6)
Symptom duration of more than 5 days 4
Systemic symptoms suggestive of tuberculosis (one or more of the following): weight loss (or poor weight gain in children), 
night sweats, or persistent cough for more than 2 weeks
2
History of recent (within past year) close contact with an individual with pulmonary tuberculosis or a positive TST or IGRA 
(only in children <10 years of age)
2
Focal neurological defi cit (excluding cranial nerve palsies) 1
Cranial nerve palsy 1
Altered consciousness 1
CSF criteria  (Maximum category score=4)
Clear appearance 1
Cells: 10–500 per  μl 1
Lymphocytic predominance (>50%) 1
Protein concentration greater than 1 g/L 1
CSF to plasma glucose ratio of less than 50% or an absolute CSF glucose concentration less than 2·2mmol/L 1
Cerebral imaging criteria             (Maximum category score=6)
Hydrocephalus 1
Basal meningeal enhancement 2
Tuberculoma 2
Infarct 1
Pre-contrast basal hyperdensity 2
Evidence of tuberculosis elsewhere        (Maximum category score=4)
Chest radiograph suggestive of active tuberculosis: signs of tuberculosis=2; miliary tuberculosis=4 2/4
CT/ MRI/ ultrasound evidence for tuberculosis outside the CNS 2
AFB identifi ed or Mycobacterium tuberculosis cultured from another source—ie, sputum, lymph node, gastric washing, urine, 
blood culture
4
Positive commercial  M tuberculosis NAAT from extra-neural specimen 4
Exclusion of alternative diagnoses
An alternative diagnosis must be confi rmed microbiologically (by stain, culture, or NAAT when appropriate), serologically 
(eg, syphilis), or histopathologically (eg, lymphoma). The list of alternative diagnoses that should be considered, dependent 
upon age, immune status, and geographical region, include: pyogenic bacterial meningitis, cryptococcal meningitis, syphilitic 
meningitis, viral meningo-encephalitis, cerebral malaria, parasitic or eosinophilic meningitis (Angiostrongylus cantonesis, 
Gnathostoma spinigerum, toxocariasis, cysticercosis), cerebral toxoplasmosis and bacterial brain abscess (space-occupying lesion 
on cerebral imaging)and malignancy (eg, lymphoma)  
TST=tuberculin skin test. IGRA=interferon-gamma release assay. NAAT=nucleic acid amplifi cation test. AFB=acid-fast bacilli. The individual points for each criterion (one, 
two, or four points) were determined by consensus and by considering their quantifi ed diagnostic value as defi ned in studies.
Table: Diagnostic criteria for classifi cation of defi nite, probable, possible, and not tuberculous meningitis
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patients who have previously received tuberculosis 
treatment.68 Detection of M tuberculosis antigens30,69,70 and 
antibodies35,70 in CSF, and CSF interferon-gamma release 
assays26,55,71 might be useful, but these results require 
verifi cation in large studies from various settings. 
In the consensus case defi nition, a maximum score of 
four points is assigned to CSF criteria that include: a 
clear CSF appearance; a leucocyte count of 10–500 cells 
per μL; a lymphocyte predominance (>50%); a protein 
concentration greater than 1 g/L; and a CSF to plasma 
glucose ratio of less than 50% or an absolute CSF 
glucose concentration of less than 2·2 mmol/L. A 
commercial M tuberculosis nucleic acid amplifi cation 
test is regarded as a defi nitive diagnostic test for 
tuberculosis. At present, insuffi  cient evidence exists for 
the inclusion of CSF antibody or interferon-gamma 
release assay tests.
Cerebral imaging criteria
The contribution of cerebral imaging to the diagnosis of 
tuberculous meningitis is well established, although its 
performance is not essential to establish a diagnosis of 
defi nite or probable disease. Abnormalities are most 
frequently detected in patients with severe disease.72 On 
CT, hydrocephalus and basal meningeal enhancement 
are the most common radiological features of tuberculous 
meningitis. About 80% of children have hydrocephalus3,72–74 
and 75% basal meningeal enhancement;1,3,75 whereas 
about 45% of adolescents and adults have hydrocephalus7,8,72 
and 8–34% basal meningeal enhancement.7,8,72 Infarcts 
(8–44% of cases)1,3,7,8,72–74 and tuberculoma (8–31%)1,3,7,8,73,74 
are also seen in many cases (fi gure 2). Andronikou76 
recorded the presence of a pre-contrast hyperdensity in 
the basal cisterns to be 100% specifi c of tuberculous 
meningitis in children, but this fi nding has not been 
validated in other studies. The combination of basal 
meningeal enhancement, infarcts, and hydrocephalus 
also had 100% specifi city; basal meningeal enhancement 
was the most sensitive feature (89%). Kumar74 reported 
similar results. MRI has higher sensitivity than CT for 
the detection of abnormalities such as meningeal 
enhancement, infarcts, and tuberculomas,77,78 especially 
of lesions involving the brainstem. Thwaites79 reported 
MRI fi ndings in adult patients with tuberculous 
meningitis; 82% had basal meningeal enhancement and 
hydrocephalus was seen in  77% of cases. In the same 
study, tuberculoma developed in 74% of patients during 
treatment, most of which were asymptomatic. Children11,44 
and adults14,27,63 with tuberculous meningitis and HIV 
show less hydrocephalus11,14 and basal meningeal 
enhancement,11,14 and a higher frequency of infarcts,27 
gyral enhancement,44 and mass lesions compared with 
patients who do not have HIV.63 Patients with HIV and 
tuberculous meningitis are also more likely to have 
cerebral atrophy,11,14 which can be diffi  cult to distinguish 
from communicating hydrocephalus. However, these 
fi ndings are not consistent and some authors recorded 
no diff erence on imaging between the adults with and 
without HIV.64 Alternative causes of meningitis, such as 
cryptococcal meningitis, cytomegalovirus encephalitis, 
toxoplasmosis, sarcoidosis, meningeal metastases, and 
lymphoma, which are more common in patients with 
HIV, can result in similar radiological fi ndings.61 
The consensus case defi nition recommends that, when 
possible, CT or MRI brain scans should be done as part 
of the assessment for tuberculous meningitis. 
Recommended supportive diagnostic criteria include: 
hydrocephalus, basal meningeal enhancement, infarcts, 
tuberculoma, and pre-contrast basal hyperdensity (on 
CT imaging).
Evidence of tuberculosis elsewhere
The presence of tuberculosis outside the CNS increases 
the likelihood of tuberculous meningitis. Suggestive chest 
radiograph abnormalities are seen in 33–60%1,6,7,27,65,72 of 
patients. A higher incidence of abnormal chest radiograph 
fi ndings,11 and extrapulmonary tuberculosis12 have been 
identifi ed in association with HIV infection. Additional 
imaging (ie, chest CT scan80 and abdominal ultrasound3,65) 
can be useful to identify involvement of other organs. 
Taking samples from sites of infection other than the 
CNS, such as lung, lymph node, liver, bone marrow, 
urine, ascitic fl uid, and gastric fl uid, further increases the 
chance of a positive diagnosis.7,47 Gastric aspiration or 
induced sputum are particularly useful in children; in 
one study,47 M tuberculosis was isolated in 68% of children 
with tuberculous meningitis. Positive M tuberculosis blood 
cultures seem very rare, even in immunocompromised 
patients with tuberculous meningitis.59 
The consensus case defi nition states that every eff ort 
should be made to identify tuberculosis outside of the 
CNS. To do so, and when appropriate, clinicians should 
use: radiological features of tuberculosis on chest 
radiography, CT, MRI, or ultrasound; isolation of 
M tuberculosis from sputum, gastric aspirates, lymph 
nodes, ascitic fl uid, urine, blood, bone marrow, or any 
other clinical specimen.
Figure 2: Cerebral imaging abnormalities observed in tuberculous meningitis
Non-contrast CT scan showing hyperdense material occupying the suprasellar and middle cerebral artery cisterns 
and hydrocephalus with periventricular lucency (A). Post-contrast CT scan showing basal meningeal enhancement 
and multiple right-sided suprasellar rim-enhancing lesions (B). MRI fl air sequence showing bilateral basal ganglia 
infarcts (C). Adapted from Reference 76 with permisson from Springer.
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Exclusion of alternative diagnosis
The provision of an exhaustive list of possible diff erential 
diagnoses for tuberculous meningitis is beyond the scope 
of this article, but alternative conditions with which the 
disease is commonly confused, and which should be 
actively considered, are listed in the table. The diagnosis 
of severely immunocompromised individuals (eg, patients 
with HIV/AIDS), in whom more than one infection could 
be present, can be diffi  cult. All patients should have a CSF 
Gram stain done (preferably with bacterial culture) to 
exclude pyogenic bacterial meningitis. In patients with 
HIV, India ink microscopy (preferably with cryptococcal 
antigen latex agglutination test or fungal culture) should 
also be done. Additional alternative diagnostic 
investigations that should be considered depending on 
age, immune status, and geographical region include 
neurosyphilis (venereal disease research laboratory or 
rapid plasma reagin assay with or without the fl uorescent 
treponemal antibody absorption assay, micro-
hemagglutination assay, or Treponema pallidum particle 
agglutination assay); viral meningoencephalitis (CSF viral 
PCR or culture); cerebral malaria (peripheral blood smears 
for malarial parasites); parasitic or eosinophilic meningitis 
(CSF serology for Angiostrongylus cantonensis, Gnathostoma 
spinigerum, toxocariasis, and cysticercosis); cerebral 
toxoplasmosis (cerebral imaging and positive serum 
serology for Toxoplasma gondii or histopathology); pyogenic 
bacterial brain abscess (cerebral imaging or histopathology); 
and malignancy (cytology or histopathology).
The consensus case defi nition recommends that an 
alternative diagnosis should be confi rmed 
microbiologically (by stain, culture, or nucleic acid 
amplifi cation tests when appropriate), serologically (eg, 
syphilis), or histopathologically (eg, lymphoma). 
Conclusion
In view of the limitations of available diagnostic 
techniques and the urgent need for comparable 
tuberculous meningitis data from various settings, the 
consensus clinical case defi nition presented here, 
provides a robust and pragmatic case defi nition for use 
in future clinical research. Despite its limitations, we 
believe that ubiquitous application of this case defi nition, 
or at least meticulous reporting of the key variables listed, 
will improve methodological rigour, allow comparison of 
data, promote scientifi c communication, and encourage 
research collaboration. Strengthening the evidence base 
is essential if we are to improve the standard of care, and, 
ultimately, the clinical outcome for patients with 
tuberculous meningitis.
Contributors
All authors contributed equally to the preparation and writing of this 
Personal View.
Confl icts of interest
We declare that we have no confl icts of interest.
Acknowledgments
This Personal View arose from a tuberculous meningitis workshop hosted 
by the Institute of Infectious Diseases and Molecular Medicine (IIDMM) 
in Cape Town, South Africa. The meeting was funded by the Clinical 
Infectious Diseases Research Initiative, IIDMM. SM receives funding 
from the Perinatal HIV Research Unit from the United States Agency for 
International Development (USAID) and PEPFAR. RJW receives funding 
from The Wellcome Trust (084323) and the Medical Research Council. We 
thank Savvas Andronikou for providing the CT image showing 
pre-contrast basal hyperdensity. The following people attended the 
meeting: Tasnim Bana, Roland Eastman, Brian Eley, Graham Fieggen, 
Anthony Figaji, Jeanine Heckmann, Gregory Hussey, Gary Maartens, 
Suzaan Marais, Helen McIlleron, Graeme Meintjes, Marc Mendelson, 
Alvin Ndondo, Mark Nicol, Dominique J Pepper, Jonathan Peter, 
Helen Van der Plas, Jo Wilmshurst, Kathryn Wood (University of Cape 
Town, Cape Town, South Africa); Kathleen Bateman, Peter R Donald, 
Franclo Henning, Richard Hewlett, Pieter Janse van Rensburg, 
Ben J Marais, Johan F Schoeman, Priscilla Springer, Ronald Van Toorn 
(University of Stellenbosch, Cape Town, South Africa); Ahmed Bhigjee 
(University of KwaZulu-Natal, Durban, South Africa); Maxine Caws, 
Anna D Heemskerk (Oxford University Clinical Research Unit, Ho Chi 
Minh City, Vietnam); Macaya Douoguih, Lisa Beth Ferstenberg 
(AERAS Global TB Vaccine Foundation, USA); Robert Heyderman 
(Malawi- Liverpool-Wellcome Trust Clinical Research Programme, 
Blantyre, Malawi); Usha K Misra (Sanjay Gandhi Postgraduate Institute 
of Medical Sciences, Lucknow, India); Kameshwar Prasad (All India 
Institute of Medical Sciences, New Delhi, India); Ahmad Rizal 
(Padjadjaran University, Bandung, Indonesia); Guy Thwaites, 
Robert J Wilkinson (Imperial College, London, UK); Estee Torok 
(Cambridge University, Cambridge, UK), Reinout Van Crevel (Radboud 
University Nijmegen Medical Center, Nijmegen, Netherlands).
References
1 van Well GT, Paes BF, Terwee CB, et al. Twenty years of pediatric 
tuberculous meningitis: a retrospective cohort study in the western 
cape of South Africa. Pediatrics 2009; 123: e1–8.
2 Farinha NJ, Razali KA, Holzel H, Morgan G, Novelli VM. 
Tuberculosis of the central nervous system in children: a 20-year 
survey. J Infect 2000; 41: 61–68.
3 Karande S, Gupta V, Kulkarni M, Joshi A. Prognostic clinical 
variables in childhood tuberculous meningitis: an experience from 
Mumbai, India. Neurol India 2005; 53: 191–95.
4 Saitoh A, Pong A, Waecker NJ Jr, Leake JA, Nespeca MP, Bradley JS. 
Prediction of neurologic sequelae in childhood tuberculous 
meningitis: a review of 20 cases and proposal of a novel scoring 
system. Pediatr Infect Dis J 2005; 24: 207–12.
5 Youssef FG, Afi fi  SA, Azab AM, et al. Diff erentiation of tuberculous 
meningitis from acute bacterial meningitis using simple clinical 
and laboratory parameters. Diagn Microbiol Infect Dis 2006; 
55: 275–78.
6 Girgis NI, Sultan Y, Farid Z, et al. Tuberculosis meningitis, Abbassia 
Fever Hospital-Naval Medical Research Unit No 3-Cairo, Egypt, 
from 1976 to 1996. Am J Trop Med Hyg 1998; 58: 28–34.
7 Hosoglu S, Geyik MF, Balik I, et al. Predictors of outcome in patients 
with tuberculous meningitis. Int J Tuberc Lung Dis 2002; 6: 64–70.
8 Kalita J, Misra UK, Ranjan P. Predictors of long-term neurological 
sequelae of tuberculous meningitis: a multivariate analysis. 
Eur J Neurol 2007; 14: 33–37.
Search strategy and selection criteria
We searched PubMed for papers published from Jan 1, 1990, 
up to May 4, 2010. Search terms used included 
combinations of the following: “tuberculous meningitis”, 
“Mycobacterium tuberculosis”, “extra-pulmonary 
tuberculosis”, “tuberculosis”, ‘central nervous system”, 
“neurotuberculosis”, “diagnosis”, and “diagnostic criteria”. 
We also searched the reference lists of articles retrieved. 
Relevant papers available in English were reviewed.
www.thelancet.com/infection   Published online September 6, 2010   DOI:10.1016/S1473-3099(10)70138-9 9
Personal View
9 Karstaedt AS, Valtchanova S, Barriere R, Crewe-Brown HH. 
Tuberculous meningitis in South African urban adults. Q JM 1998; 
91: 743–47.
10 Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for 
the treatment of tuberculous meningitis in adolescents and adults. 
N Engl J Med 2004; 351: 1741–51.
11 van der Weert EM, Hartgers NM, Schaaf HS, et al. Comparison of 
diagnostic criteria of tuberculous meningitis in human 
immunodefi ciency virus-infected and uninfected children. 
Pediatr Infect Dis J 2006; 25: 65–69.
12 Thwaites GE, Duc Bang N, Huy Dung N, et al. The infl uence of 
HIV infection on clinical presentation, response to treatment, and 
outcome in adults with Tuberculous meningitis. J Infect Dis 2005; 
192: 2134–41.
13 Cecchini D, Ambrosioni J, Brezzo C, et al. Tuberculous meningitis 
in HIV-infected and non-infected patients: comparison of 
cerebrospinal fl uid fi ndings. Int J Tuberc Lung Dis 2009; 13: 269–71.
14 Katrak SM, Shembalkar PK, Bijwe SR, Bhandarkar LD. The clinical, 
radiological and pathological profi le of tuberculous meningitis in 
patients with and without human immunodefi ciency virus 
infection. J Neurol Sci 2000; 181: 118–26.
15 Thwaites GE, Tran TH. Tuberculous meningitis: many questions, 
too few answers. Lancet Neurol 2005; 4: 160–70.
16 Thwaites GE, Chau TT, Farrar JJ. Improving the bacteriological 
diagnosis of tuberculous meningitis. J Clin Microbiol 2004; 
42: 378–79.
17 Torok ME, Chau TT, Mai PP, et al. Clinical and microbiological 
features of HIV-associated tuberculous meningitis in Vietnamese 
adults. PLoS One 2008; 3: e1772.
18 Bhigjee AI, Padayachee R, Paruk H, Hallwirth-Pillay KD, Marais S, 
Connoly C. Diagnosis of tuberculous meningitis: clinical and 
laboratory parameters. Int J Infect Dis 2007; 11: 348–54.
19 Kumar R, Singh SN, Kohli N. A diagnostic rule for tuberculous 
meningitis. Arch Dis Child 1999; 81: 221–24.
20 Andronikou S, Wilmshurst J, Hatherill M, VanToorn R. 
Distribution of brain infarction in children with tuberculous 
meningitis and correlation with outcome score at 6 months. 
Pediatr Radiol 2006; 36: 1289–94.
21 Nagesh Babu G, Kumar A, Kalita J, Misra UK. Proinfl ammatory 
cytokine levels in the serum and cerebrospinal  fl uid of tuberculous 
meningitis patients. Neurosci Lett 2008; 436: 48–51.
22 Quan C, Lu CZ, Qiao J, Xiao BG, Li X. Comparative evaluation of 
early diagnosis of tuberculous meningitis by diff erent assays. 
J Clin Microbiol 2006;  44: 3160–66.
23 Rafi  W, Venkataswamy MM, Nagarathna S, Satishchandra P, 
Chandramuki A. Role of IS6110 uniplex PCR in the diagnosis of 
tuberculous meningitis: experience at a tertiary neurocentre. 
Int J Tuberc Lung Dis 2007; 11: 209–14.
24 Juan RS, Sanchez-Suarez C, Rebollo MJ, et al. Interferon gamma 
quantifi cation in cerebrospinal fl uid compared with PCR for the 
diagnosis of tuberculous meningitis. J Neurol 2006; 253: 1323–30.
25 Moghtaderi A, Alavi-Naini R, Izadi S, Cuevas LE. Diagnostic risk 
factors to diff erentiate tuberculous and acute bacterial meningitis. 
Scand J Infect Dis 2009; 41: 188–94.
26 Patel VB, Singh R, Connolly C, et al. Cerebrospinal T cell responses 
aid the diagnosis of tuberculous meningitis in a HIV and TB 
endemic population. Am J Respir Crit Care Med 2010; published 
online May 4. DOI:10.1164/rccm.200912-1931OC.
27 Schutte CM. Clinical, cerebrospinal fl uid and pathological fi ndings 
and outcomes in HIV-positive and HIV-negative patients with 
tuberculous meningitis. Infection 2001; 29: 213–17.
28 Kennedy DH, Fallon RJ. Tuberculous meningitis. JAMA 1979; 
241: 264–68.
29 Marais BJ, Brittle W, Painczyk K, et al. Use of light-emitting diode 
fl uorescence microscopy to detect acid-fast bacilli in sputum. 
Clin Infect Dis 2008; 47: 203–37.
30 Naidu AK, Gogate A. Early detection of tuberculous meningitis 
using one step competitive ELISA. Indian J Pathol Microbiol 1997; 
40: 531–38.
31 Caviedes L, Lee TS, Gilman RH, et al. Rapid, effi  cient detection and 
drug susceptibility testing of Mycobacterium tuberculosis in 
sputum by microscopic observation of broth cultures—the 
tuberculosis working group in Peru. J Clin Microbiol 2000; 
38: 1203–08.
32 Caws M, Dang TM, Torok E, et al. Evaluation of the MODS culture 
technique for the diagnosis of tuberculous meningitis. PLoS One 
2007; 2: e1173.
33 Shankar P, Manjunath N, Mohan KK, et al. Rapid diagnosis of 
tuberculous meningitis by polymerase chain reaction. Lancet 1991; 
337: 5–7.
34 Ghoshal U, Kishore J, Kumar B, Ayyagari A. Serodiagnosis of smear 
and culture-negative neurotuberculosis with enzyme linked 
immunosorbent assay for anti A-60 immunoglobulins. 
Indian J Pathol Microbiol 2003; 46: 530–34.
35 Kashyap RS, Kainthla RP, Satpute RM, et al. Demonstration of IgG 
antibodies to 30 Kd protein antigen in CSF for diagnosis of 
tuberculous meningitis by antibody-capturing ELISA. Neurol India 
2004; 52: 359–62.
36 Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM Jr. 
Diagnostic accuracy of nucleic acid amplifi cation tests for 
tuberculous meningitis: a systematic review and meta-analysis. 
Lancet Infect Dis 2003; 3: 633–43.
37 van Kampen SC, Anthony RM, Klatser PR. The realistic 
performance achievable with mycobacterial automated culture 
systems in high and low prevalence settings. BMC Infect Dis 2010; 
published online April 12. DOI:10.1186/1471-2334-10-93.
38 Helb D, Jones M, Story E, et al. Rapid detection of 
Mycobacterium tuberculosis and rifampin resistance by use of on-
demand, near-patient technology. J Clin Microbiol 2010; 48: 229–37.
39 Thwaites GE, Chau TT, Stepniewska K, et al. Diagnosis of adult 
tuberculous meningitis by use of clinical and laboratory features. 
Lancet 2002; 360: 1287–92.
40 Wang JT, Hung CC, Sheng WH, Wang JY, Chang SC, Luh KT. 
Prognosis of tuberculous meningitis in adults in the era of modern 
antituberculous chemotherapy. J Microbiol Immunol Infect 2002; 
35: 215–22.
41 Satishchandra P, Mathew T, Gadre G, et al. Cryptococcal meningitis: 
clinical, diagnostic and therapeutic overviews. Neurol India 2007; 
55: 226–32.
42 Lan SH, Chang WN, Lu CH, Lui CC, Chang HW. Cerebral 
infarction in chronic meningitis: a comparison of tuberculous 
meningitis and cryptococcal meningitis. Q JM 2001; 94: 247–53.
43 Sanchez-Portocarrero J, Perez-Cecilia E, Jimenez-Escrig A, et al. 
Tuberculous meningitis: clinical characteristics and comparison 
with cryptococcal meningitis in patients with human 
immunodefi ciency virus infection. Arch Neurol 1996; 53: 671–76.
44 Topley JM, Bamber S, Coovadia HM, Corr PD. Tuberculous 
meningitis and co-infection with HIV. Ann Trop Paediatr 1998; 
18: 261–66.
45 Heyderman RS, Gangaidzo IT, Hakim JG, et al. Cryptococcal 
meningitis in human immunodefi ciency virus-infected patients in 
Harare, Zimbabwe. Clin Infect Dis 1998; 26: 284–89.
46 Yaramis A, Gurkan F, Elevli M, et al. Central nervous system 
tuberculosis in children: a review of 214 cases. Pediatrics 1998; 
102: e49.
47 Doerr CA, Starke JR, Ong LT. Clinical and public health aspects of 
tuberculous meningitis in children. J Pediatr 1995; 127: 27–33.
48 Tung YR, Lai MC, Lui CC, et al. Tuberculous meningitis in infancy. 
Pediatr Neurol 2002; 27: 262–66.
49 Dodd PJ, Millington KA, Ghani AC, et al. Interpreting tuberculin 
skin tests in a population with a high prevalence of HIV, 
tuberculosis, and nonspecifi c tuberculin sensitivity. 
Am J Epidemiol 2010; published online April 9. DOI:10.1093/aje/
kwq017 
50 Azuaje C, Fernandez Hidalgo N, Almirante B, et al. Tuberculous 
meningitis: a comparative study in relation to concurrent human 
immunodefi ciency virus infection. Enferm Infecc Microbiol Clin 
2006; 24: 245–50.
51 McConkey SJ, Youssef FG, Azem E, Frenck RW, Weil GJ. Evaluation 
of a rapid-format antibody test and the tuberculin skin test for 
diagnosis of tuberculosis in two contrasting endemic settings. 
Int J Tuberc Lung Dis 2002; 6: 246–52.
52 Mutsvangwa J, Millington KA, Chaka K, et al. Identifying recent 
Mycobacterium tuberculosis transmission in the setting of high HIV 
and TB burden. Thorax 2010; 65: 315–20.
53 Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based 
assays for the diagnosis of latent tuberculosis infection: an update. 
Ann Intern Med 2008; 149: 177–84.
10 www.thelancet.com/infection   Published online September 6, 2010   DOI:10.1016/S1473-3099(10)70138-9
Personal View
54 Kim SH, Song KH, Choi SJ, et al. Diagnostic usefulness of a 
T-cell-based assay for extrapulmonary tuberculosis in 
immunocompromised patients. Am J Med 2009; 122: 189–95.
55 Kim SH, Cho OH, Park SJ, et al. Rapid diagnosis of tuberculous 
meningitis by T cell-based ssays on peripheral blood and 
cerebrospinal fl uid mononuclear cells. Clin Infect Dis 2010; 
50: 1349–58.
56 Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and 
prediction of active tuberculosis disease by a whole-blood 
interferon-gamma release assay in HIV-1-infected individuals. 
Clin Infect Dis 2009; 48: 954–62.
57 Steingart KR, Henry M, Laal S, et al. A systematic review of 
commercial serological antibody detection tests for the diagnosis of 
extrapulmonary tuberculosis. Postgrad Med J 2007; 83: 705–12.
58 Thwaites GE, Lan NT, Dung NH, et al. Eff ect of antituberculosis 
drug resistance on response to treatment and outcome in adults 
with tuberculous meningitis. J Infect Dis 2005; 192: 79–88.
59 Cecchini D, Ambrosioni J, Brezzo C, et al. Tuberculous meningitis 
in HIV-infected patients: drug susceptibility and clinical outcome. 
AIDS 2007; 21: 373–74.
60 Sutlas PN, Unal A, Forta H, Senol S, Kirbas D. Tuberculous 
meningitis in adults: review of 61 cases. Infection 2003; 31: 387–91.
61 Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J. 
British Infection Society guidelines for the diagnosis and treatment 
of tuberculosis of the central nervous system in adults and children. 
J Infect 2009; 59: 167–87.
62 Thwaites GE, Chau TT, Caws M, et al. Isoniazid resistance, 
mycobacterial genotype and outcome in Vietnamese adults with 
tuberculous meningitis. Int J Tuberc Lung Dis 2002; 6: 865–71.
63 Dube MP, Holtom PD, Larsen RA. Tuberculous meningitis in 
patients with and without human immunodefi ciency virus 
infection. Am J Med 1992; 93: 520–24.
64 Yechoor VK, Shandera WX, Rodriguez P, Cate TR. Tuberculous 
meningitis among adults with and without HIV infection. 
Experience in an urban public hospital. Arch Intern Med 1996; 
156: 1710–16.
65 Berenguer J, Moreno S, Laguna F, et al. Tuberculous meningitis in 
patients infected with the human immunodefi ciency virus. 
N Engl J Med 1992; 326: 668–72.
66 Tuon FF, Higashino HR, Lopes MI, et al. Adenosine deaminase and 
tuberculous meningitis—a systematic review with meta-analysis. 
Scand J Infect Dis 2010; 42: 198–207.
67 Corral I, Quereda C, Navas E, et al. Adenosine deaminase activity in 
cerebrospinal fl uid of HIV-infected patients: limited value for 
diagnosis of tuberculous meningitis. Eur J Clin Microbiol Infect Dis 
2004; 23: 471–76.
68 Thwaites GE, Caws M, Chau TT, et al. Comparison of conventional 
bacteriology with nucleic acid amplifi cation (amplifi ed 
mycobacterium direct test) for diagnosis of tuberculous meningitis 
before and after inception of antituberculosis chemotherapy. 
J Clin Microbiol 2004; 42: 996–1002.
69 Kashyap RS, Dobos KM, Belisle JT, et al. Demonstration of 
components of antigen 85 complex in cerebrospinal fl uid of 
tuberculous meningitis patients. Clin Diagn Lab Immunol 2005; 
12: 752–58.
70 Bera S, Shende N, Kumar S, Harinath BC. Detection of antigen and 
antibody in childhood tuberculous meningitis. Indian J Pediatr 
2006; 73: 675–79.
71 Thomas MM, Hinks TS, Raghuraman S, et al. Rapid diagnosis of 
Mycobacterium tuberculosis meningitis by enumeration of 
cerebrospinal fl uid antigen-specifi c T-cells. Int J Tuberc Lung Dis 
2008; 12: 651–57.
72 Ozates M, Kemaloglu S, Gurkan F, Ozkan U, Hosoglu S, 
Simsek MM. CT of the brain in tuberculous meningitis. A review of 
289 patients. Acta Radiol 2000; 41: 13–17.
73 Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. Serial CT 
scanning in childhood tuberculous meningitis: prognostic features 
in 198 cases. J Child Neurol 1995; 10: 320–29.
74 Kumar R, Kohli N, Thavnani H, Kumar A, Sharma B. Value of CT 
scan in the diagnosis of meningitis. Indian Pediatr 1996; 33: 465–68.
75 Theron S, Andronikou S, Grobbelaar M, Steyn F, Mapukata A, 
du Plessis J. Localized basal meningeal enhancement in 
tuberculous meningitis. Pediatr Radiol 2006; 36: 1182–85.
76 Andronikou S, Smith B, Hatherhill M, Douis H, Wilmshurst J. 
Defi nitive neuroradiological diagnostic features of tuberculous 
meningitis in children. Pediatr Radiol 2004; 34: 876–85.
77 Wasay M, Kheleani BA, Moolani MK, et al. Brain CT and MRI 
fi ndings in 100 consecutive patients with intracranial tuberculoma. 
J Neuroimaging 2003; 13: 240–47.
78 Abdelmalek R, Kanoun F, Kilani B, et al. Tuberculous meningitis in 
adults: MRI contribution to the diagnosis in 29 patients. 
Int J Infect Dis 2006; 10: 372–77.
79 Thwaites GE, Macmullen-Price J, Tran TH, et al. Serial MRI to 
determine the eff ect of dexamethasone on the cerebral pathology of 
tuberculous meningitis: an observational study. Lancet Neurol 2007; 
6: 230–36.
80 Yaramis A, Bukte Y, Katar S, Ozbek MN. Chest computerized 
tomography scan fi ndings in 74 children with tuberculous 





Chapter 4: Part 1

Presentation and Outcome of Tuberculous Meningitis in
a High HIV Prevalence Setting
Suzaan Marais1,2,3*, Dominique J. Pepper1,4, Charlotte Schutz1,2,3, Robert J Wilkinson1,2,3,5,6, Graeme
Meintjes1,2,3,5
1 Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa, 2 Infectious Diseases Unit, GF Jooste Hospital, Cape Town,
South Africa, 3Department of Medicine, University of Cape Town, Cape Town, South Africa, 4Department of Internal Medicine, University of Mississippi Medical Center,
Jackson, Mississippi, United States of America, 5Division of Medicine, Imperial College London, London, United Kingdom, 6Division of Mycobacterial Research, MRC
National Institute for Medical Research, London, United Kingdom
Abstract
Background: Mycobacterium tuberculosis is a common, devastating cause of meningitis in HIV-infected persons. Due to
international rollout programs, access to antiretroviral therapy (ART) is increasing globally. Starting patients with HIV-
associated tuberculous meningitis (TBM) on ART during tuberculosis (TB) treatment may increase survival in these patients.
We undertook this study to describe causes of meningitis at a secondary-level hospital in a high HIV/TB co-infection setting
and to determine predictors of mortality in patients with TBM.
Methods: A retrospective review of cerebrospinal fluid findings and clinical records over a six-month period (March 2009–
August 2009). Definite, probable and possible TBM were diagnosed according to published case definitions.
Results: TBM was diagnosed in 120/211 patients (57%) with meningitis. In 106 HIV-infected patients with TBM, six-month
all-cause mortality was lower in those who received antiretroviral therapy (ART) during TB treatment; hazard ratio = 0.30
(95% CI = 0.08–0.82). Factors associated with inpatient mortality in HIV-infected patients were 1) low CD4+ count at
presentation; adjusted odds ratio (AOR) = 1.4 (95% confidence interval [CI] = 1.03–1.96) per 50 cells/mL drop in CD4+
count and, 2) higher British Medical Research Council TBM disease grade (2 or 3 versus 1); AOR = 4.8 (95% CI = 1.45–
15.87).
Interpretation: Starting ART prior to or during TB treatment may be associated with lower mortality in patients with HIV-
associated TBM. Advanced HIV and worse stage of TBM disease predict in-hospital mortality in patients presenting with
TBM.
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Introduction
Meningitis causes significant mortality and morbidity in HIV-
infected persons [1–4]. Tuberculous meningitis (TBM) accounts
for a substantial proportion of cases, particularly in high
tuberculosis (TB) prevalence areas [3]. Globally, access to
antiretroviral therapy (ART) is rapidly increasing due to ART
rollout programs [5]. Starting ART during TB treatment is
associated with reduced mortality in HIV/TB co-infected patients
[6,7]. However, few studies have reported the influence of ART on
the outcome of patients with HIV-associated TBM [8–10]. In this
study, we report the causes of meningitis at a secondary-level
hospital in a high HIV/TB prevalence setting in the era of
increasing availability of ART. We also describe the presentation
and outcome of patients with TBM and investigate the predictors
of mortality (including ART) in these patients.
Methods
Ethics statement
The ethics committee of the University of Cape Town (UCT)
approved the study (REC REF 223/2010). As this was a
retrospective folder review, and data were analysed anonymously
outside of the clinical setting, the ethics committee of UCT waived
the requirement for informed consent and informed consent was
not obtained.
Setting and population
We conducted a retrospective study at GF Jooste Hospital, a
200-bed public sector referral hospital that serves adult patients
from a community of approximately 1.3 million people. This
predominantly low-income, high-density population is at the
epicenter of the TB/HIV pandemic; in some parts of the referral
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area the reported TB case notification rate exceeds 1500 cases per
100 000 people per year and the HIV seroprevalence at antenatal
clinics reaches 30% [11]. All patients accessing public sector care
with suspected meningitis are referred to GF Jooste Hospital for
investigations, including a lumbar puncture (LP). Adult patients
($18 years) who had a LP performed over a six-month period (1
March 2009–31 August 2009) were identified from laboratory logs
and included in the study.
Procedure
As per standard protocol at the hospital laboratory [3],
cerebrospinal fluid (CSF) samples underwent macroscopic exam-
ination, protein and glucose quantification, cell count, Gram stain,
and bacterial and fungal culture. India ink staining and/or
Crytococcus Latex Antigen Testing (CLAT) were also performed.
If the clinical presentation or initial CSF findings were suggestive
of TBM (as determined by the attending clinician), Ziehl-Neelsen
(ZN) staining of sediment and/or Mycobacterium tuberculosis (M.
tuberculosis) culture was performed. If acid-fast bacilli (AFB) were
cultured from CSF, TB polymerase chain reaction (PCR)
[Genotype MTBDRplus, Hain Lifesciences]) tests were performed
to further identify mycobacteria species, and to determine first-line
drug susceptibility (to rifampicin and isoniazid). In cases where
rifampicin-resistant organisms were identified, additional drug
susceptibility testing was performed by conventional methods.
Syphilis serology (venereal disease research laboratory and/or
Treponema pallidum hemagglutination assay), cytology and viral
PCR examination were performed at attending clinician’s
discretion.
All CSF findings were reviewed. Microbiological diagnoses (i.e.
where CSF analysis identified a specific etiological cause) were
documented. Clinical records of patients with ‘markedly abnor-
mal’ CSF who did not have a microbiological diagnosis were
reviewed. In line with a previous study [3], CSF was considered to
be ‘markedly abnormal’ when one or more of the following were
present: 1) neutrophils .5 cells6106/L, 2) lymphocytes.20
cells6106/L, 3) protein .1 g/L, and 4) glucose ,2.2 mmol/L.
Patients who did not present with symptoms and/or signs of
meningitis such as headache, photophobia, seizure, vomiting,
altered mental state, neck stiffness or focal neurological deficit (e.g.
patients with peripheral neuropathy) and those in whom an
alternative diagnosis was made (e.g. subarachnoid hemorrhage),
were excluded from the analysis. Data recorded for patients with
TBM included medical and treatment history prior to admission,
history of the presenting complaint (s), clinical examination, results
of investigations, inpatient management and admission outcome.
Additional information such as date of starting ART, was obtained
from primary care clinic records. We used hospital medical notes,
the National Health Laboratories Service database and the
electronic hospital and primary care clinic (TB and ART)
attendance registers to trace patients, in order to determine
outcome (alive, dead or lost to follow-up) six months after LP was
performed.
Patients received standardized TB treatment according to
national treatment guidelines using Directly Observed Therapy
Short-course (DOTS) either at the primary care TB clinic, or
delivered to home by lay health care workers [12]. The duration of
TB treatment (at least six to nine months) depended on the
attending clinician’s discretion. Patients with a new diagnosis of
tuberculosis received isoniazid, rifampin, pyrazinamide, and
ethambutol for two months (dosing schedules detailed in Table
S1). This was followed by rifampicin and isoniazid for at least four
months. The retreatment regimen included rifampicin, isoniazid,
pyrazinamide, ethambutol and intramuscular streptomycin during
the initial two months of treatment, followed by rifampicin,
isoniazid, pyrazinamide and ethambutol for one month, followed
by rifampicin, isoniazid and ethambutol for at least five months
(dosing schedules detailed in Table S2). At the time of the study,
national guidelines advised ART for all patients with a CD4+
count of less than 200 cells/mL or World Health Organization
(WHO) stage 4 disease [13]. First-line ART during this study was
stavudine, lamivudine, and either nevirapine or efavirenz.
Efavirenz was preferred for patients who were receiving
rifampicin-based antituberculosis treatment.
Definitions
Definite TBM was diagnosed when 1) AFB were seen in CSF,
2) AFB or M. tuberculosis was cultured from CSF or 3) M. tuberculosis
was detected by PCR from CSF. Probable and possible TBM were
diagnosed according to modified published case definitions
[10,14]. Probable TBM was diagnosed when: 1) a patient
presented with clinical features of meningitis and 2) suggestive
CSF findings of TBM (total white cell count .5 cells6106/L,
protein .0.45 g/L and glucose ,2.2 mmol/L), plus 3) one or
more of the following i) chest radiograph findings consistent with
pulmonary TB, ii) an extra-meningeal specimen positive for AFB,
iii) other evidence of extra-meningeal TB (e.g. abdominal
ultrasound features) or iv) brain computed tomography (CT)
evidence of TBM including one or more of the following: basal
meningeal enhancement, hydrocephalus or infarctions. Possible
TBM was diagnosed when: 1) a patient presented with clinical
features of meningitis and either 2) four or more of the following
were present i) a history of TB ii) a predominance of CSF
lymphocytes (.50%), iii) illness duration of more than five days iv)
CSF glucose ,2.2 mmol/L, v) altered consciousness, vi) clear or
yellow CSF with protein.1 g/L, vii) focal neurological signs, or 3)
‘markedly abnormal’ CSF (excluding isolated hypoglycemia) with
evidence of TB elsewhere.
Patients were excluded from the probable and possible TBM
groups if an alternative cause of meningitis was found, or if they
improved with no treatment or alternative treatment in the
absence of TB treatment. Cryptococcal meningitis (CM) was
diagnosed when CSF India ink stain, CLAT or Cryptococcus
neoformans culture was positive. Bacterial meningitis was
diagnosed when: 1) bacteria were isolated from CSF or 2) a
patient presented with clinical features of meningitis and i) a CSF
polymorphonuclear cell predominance and showed a good
response to antibacterial treatment in the absence of TB
treatment, or ii) a CSF polymorphonuclear cell count .1000
cells6106/L, regardless of outcome. Viral meningitis was
diagnosed when a patient presented with clinical meningitis and:
1) a virus was identified from CSF, or 2) a CSF lymphocytic
predominance and had symptom resolution in the absence of
antimicrobial treatment. Loss to follow-up was defined as being
unable to trace a patient six months after LP, using the methods
described above.
Statistical analysis
Univariate analysis was performed to 1) identify significant
differences between patients who did, and did not die during
hospitalization and at six months follow-up and 2) identify
significant differences between patients with definite and those
with probable/possible TBM. Continuous variables were com-
pared using the Student t-test or Mann-Whitney U test, and
categorical variables were compared by Fisher’s exact test.
Variables associated with inpatient mortality (p,0.2) were
evaluated using multivariate analysis. Stepwise logistic regression
was used to identify variables predictive of inpatient mortality in all
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TBM patients (regardless of HIV status) and subsequently, in
HIV-infected patients only. A Cox proportional hazard model was
used to assess the association of ART started before or during TB
treatment with six-month mortality in HIV-infected patients who
survived hospitalization. The validity of the model’s assumptions
was tested with Schoenfeld residuals.
A p-value,0.05 was considered statistically significant. Time to
death was summarized by use of Kaplan-Meier estimates. The
statistical analyses were performed with GraphPad Prism version 5
and STATA version 10.1 software.
Results
Causes of ‘markedly abnormal’ CSF
During the study period, 812 LPs were performed in 698
patients. CSF analysis was ‘markedly abnormal’ (n = 146), and/or
identified a cause of meningitis (n = 107) in 253 patients. Figure 1
shows the reasons for exclusion (n= 42) and diagnoses in 211
patients who were diagnosed with meningitis. The most frequent
microbiological diagnoses were CM, and TBM, which accounted
for 45% (48/107), and 44% (47/107), of cases respectively. Fifty-
seven percent (120/211) of patients with meningitis were
diagnosed with definite (n = 47), probable (n = 35) or possible
(n = 38) TBM.
Findings in patients with TBM
The demographic, clinical and investigative findings for patients
with definite, probable and possible TBM are detailed in Tables 1
and 2. Eighty-eight percent of patients with TBM were HIV-
infected with a median CD4+ count of 79 cells/uL (interquartile
range [IQR]= 39–137); 20 (19%) of these patients were receiving
ART at the time of presentation. The majority of TBM cases
(68%) presented with advanced TBM disease (British Medical
Research Council [BMRC] disease grade 2 or 3) [15] 7 days
(median, IQR=3–15 days) after symptom onset. 26/115 (23%) of
patients for whom this information was available were receiving
TB treatment at time of presentation for a median duration of 106
days (IQR=50–178). Disseminated TB was common; 87/114
Figure 1. Flow diagram of differential diagnoses in patients with ‘markedly abnormal’ CSF and/or microbiological-confirmed
meningitis. 1 Common alternative diagnoses include: hypoglycemia (n = 9), intracranial bleed (n = 7) and peripheral nerve disorders (n = 6).
2 Including 5 patients with CSF culture-confirmed bacterial meningitis. Organisms isolated include: Streptococcus pneumonia (n = 3), beta-hemolytic
Streptococcus (n = 1), Neisseria meningitides (n = 1). 3 Including 1 patient with positive CSF polymerase chain reaction for both cytomegalovirus and
herpes simplex-1 virus. 4 Other causes of meningitis include: Acute HIV infection (n = 1), Toxoplasma gondiimeningoencephalitis (n = 1), disseminated
Burkitt’s lymphoma (n= 1), disseminated large B-cell lymphoma (n= 1), chronic resolving TBM immune reconstitution inflammatory syndrome (n = 1).
5 Including patients with the following differential diagnoses: 1) TBM with tuberculoma or toxoplasmosis (n = 1); 2) partially treated bacterial
meningitis, viral meningitis or TBM (n= 3); and 3) viral meningitis or TBM (n = 3). CSF, cerebrospinal fluid.
doi:10.1371/journal.pone.0020077.g001
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(76%) of patients presented with features of extra-meningeal TB.
Chest radiograph abnormalities consistent with TB were observed
in 74% (76/103) of patients. Abdominal ultrasound was performed
in 27 patients, of which 25 (93%) showed features of TB. In
addition, AFB were seen on microscopy, or M. tuberculosis was
cultured, from one or more extra-meningeal specimens from 26
patients; specimens included sputum (n= 21), lymph node fine
needle aspiration biopsy (n = 6), pleural fluid (n = 1), blood (n= 5)
and urine (n = 3).
Atypical CSF findings in patients with definite TBM (n= 47)
included a polymorphonuclear cell predominance (.50% of total
leucocyte count) in six (13%), a glucose level of more than
2.2 mmol/L in 13 (28%), a protein concentration of less or equal
to 0.45 g/L in three (6%) and a total leucocyte count of five or less
cells6106/L in two (4%). No patient with definite TBM had
completely normal CSF (both biochemistry and cell count). ZN
staining was requested for CSF specimens from 88 patients,
including 47 (100%) definite TBM, 24 (69%) probable TBM and
25 (66%) possible TBM cases. 76/88 of these specimens (86%)
were insufficient for TB microscopy. Of the 12 TBM cases who
had CSF direct smear examination performed, AFB were
visualized in one. Cerebrospinal fluid M. tuberculosis culture was
requested for 106 patients including 47 [100%] definite TBM, 31
[89%] probable TBM, and 28 [74%] possible TBM cases.
Significantly less patients with probable and possible TBM had
M. tuberculosis culture performed, compared to those with definite
TBM, who by definition required a positive culture (p = 0.02, and
p= 0.0009, respectively). Drug susceptibility testing for first-line
TB drugs (rifampicin and isoniazid) was performed on 40/47
(85%) of isolates; 35 were susceptible to rifampicin and isoniazid,
three were resistant to isoniazid, one was resistant to rifampicin,
and one was resistant to both rifampicin and isoniazid (multidrug-
Table 1. Demographic and clinical characteristics of patients with definite, probable and possible tuberculous meningitis (TBM).
Definite TBM (n=47) Probable TBM (n=35) Possible TBM (n=38)
Age, median (IQR) 35 (28–42) 36 (29–51) 38 (28–42)
Female, n/N (%) 22/47 (47) 16/35 (46) 22/38 (58)
HIV status, n/N (%)
Infected 43/47 (91) 27/35 (77) 36/38 (95)
Uninfected 2/47 (4) 5/35 (14) 1/38 (3)
Unknown 2/47 (4) 3/35 (9) 1/38 (3)
CD4+ cell count, median (IQR)1 63 (35–115) 79 (36–150) 109 (33–201)
On ART at presentation, n/N (%)2 9/41 (22) 6/27 (22) 5/35 (14)
Previous TB, n/N (%) 15/43 (35) 7/34 (21) 12/38 (32)
On TB treatment at time of LP, n/N (%) 9/43 (21) 8/34 (24) 9/38 (24)
Symptom onset to LP, median (IQR) 7 (4–15) 6 (3–21) 3 (2–11)
Neurological symptoms, n/N (%)
Headache 26/42 (62) 18/34 (53) 17/38 (45)
Confusion3 23/42 (55) 21/34 (62) 17/38 (45)
Neck pain/stiffness3 12/42 (29) 8/34 (24) 5/38 (13)
Nausea/vomiting 15/42 (36) 11/34 (32) 12/38 (32)
Photophobia/blurred vision/diplopia 11/42 (26) 8/34 (24) 6/38 (16)
Seizures 7/42 (17) 2/34 (6) 6/38 (16)
Neurological signs, n/N (%)
BMRC TBM Disease Grade4
1 10/42 (24) 7/34 (21) 16/38 (42)
2 29/42 (69) 23/34 (68) 20/38 (53)
3 3/42 (7) 4/34 (12) 2/38 (5)
Confusion5 29/42 (69) 22/34 (65) 23/38 (61)
Neck stiffness5 31/42 (74) 23/34 (68) 19/38 (50)*
Focal neurological signs 9/42 (21) 17/34 (50)* 2/38 (5)**
IQR, interquartile range; n, number of patients; N, total number of patients for whom results were available; HIV, human immunodeficiency virus; ART, antiretroviral
therapy; TB, tuberculosis; LP, lumbar puncture; D4T, stavudine 30 mg twice daily; 3TC, lamivudine 150 mg twice daily or 300 mg daily; EFV, efavirenz 600 mg nightly;
AZT, zidovudine 300 mg twice daily; NEV, nevirapine 200 mg twice daily; ddI, didanosine 400 mg daily; LPV/rtv, lopinavir/ritonavir 800/200 mg twice daily.
*Significantly different (p,0.05) from patients with definite TBM;
**p,0.01.
1Only performed in HIV-infected patients.
2N includes HIV-infected patients only. Treatment regimens included: 1) D4T, 3TC, EFV (n = 11), 2) AZT, 3TC, NEV (n = 3), 3) D4T, 3TC, NEV (n = 3), 4) AZT, 3TC, EFV (n = 1),
5) AZT, 3TC, LPV/rtv (n = 1), 6) AZT, ddI, LPV/rtv (n = 1).
3Refers to symptoms reported by patient or family only.
4British Medical Research Council TBM disease grades: 1- Glasgow coma scale (GCS) 15 with no neurological deficit; 2- GCS 11–14 without neurological deficit, or GCS 15
with focal neurological deficit; 3- GCS#10.15
5Refers to clinical findings on physical examination only.
doi:10.1371/journal.pone.0020077.t001
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resistant [MDR] organisms). The latter two patients both died
during hospitalization after starting regimen 2 TB treatment (prior
to the availability of M. tuberculosis drug susceptibility testing
results). In two additional patients MDRM. tuberculosis strains were
cultured from extra-meningeal specimens prior to admission. One
of these patients presented on a MDR TB drug regimen (i.e.
ethambutol, pyrazinamide, ethionamide, ofloxacin and kanamy-
cin) and was alive at 6-months follow-up. The M. tuberculosis drug
resistance profile was unknown for the other patient at TBM
presentation; the patient died during hospitalization after starting
regimen 2 TB treatment.
Table 3 describes the management and outcome in patients
with TBM. Five of 89 patients not receiving TB treatment at the
time of presentation, failed to initiate TB treatment after LP; all
five subsequently died. In one patient with definite TBM who did
not commence TB treatment, the diagnosis was not considered
initially as routine CSF investigations was mildly abnormal (only
abnormality: lymphocyte count = 66106/L) and there were no
features of extra-pulmonary TB on chest radiograph. The
remaining four patients (2-probable TBM, 2-possible TBM) died
shortly after admission (within 24 hours), prior to TB drug
initiation. The exact time of TB treatment initiation at
presentation was known for 82/84 remaining patients: 11 patients
started TB treatment 1–4 days prior to LP, but after symptom
onset; 63 patients started TB treatment within 24 hours of LP; and
8 patients started TB treatment more than 24 hours after LP at a
median time of three days (range, 2–8 days). Adjunctive
corticosteroid treatment was started in 64/113 (57%) of patients
during admission; significantly more patients with definite TBM
received corticosteroids compared to those with possible TBM
(71% versus 32%, p= 0.0007). The proportion of patients with
probable TBM who received corticosteroids (70%) was similar to
that of the definite TBM group. No patient received any other
adjunctive therapy e.g. acetazolamide, or surgery. Overall
inpatient mortality during hospitalization was 38% (45/120
patients), four days (median, IQR: 3–9 days) after LP (Figure 2).
Among those discharged from hospital, 57% (31/54 patients) of
HIV-infected patients (not on ART at time of presentation)
initiated ART during six months of TB treatment. ART regimens
for these patients are detailed in tables 1 and 3. At six-month
follow-up, 48% of all TBM patients had died and 10% were lost to
follow-up. Baseline characteristics did not differ significantly
between patients who were retained in care and those who were
lost to follow-up (data not shown). However, there was a trend to
higher CD4+ counts in HIV-infected patients lost to follow-up
compared to those who were not (median [IQR], 164 [71–250]
cells/mL compared to 68 [35–144] cells/mL, p= 0.06).
Table 4 shows factors analyzed for association with inpatient
mortality for all patients [n= 120] in univariate analysis. A higher
BMRC TBM disease grade (2 or 3 versus 1: AOR [95% CI] = 3.0
[1.08–8.40], p = 0.04) remained predictive of mortality in
multivariate analysis (logistic regression model p= 0.007,
R2= 0.12). Table 5 shows factors analyzed for association with
inpatient mortality for HIV-infected patients [n= 106] only. CD4+
count (for every 50 cells/mL drop in CD4+ count: AOR [95%
confidence interval [CI]] = 1.4 [1.03–1.96], p = 0.03) and a higher
BMRC TBM disease grade (2 or 3 versus 1: AOR [95% CI] =
4.8 [1.45–15.87], p = 0.01) remained predictive of mortality
Table 2. Laboratory and radiological investigation findings of patients with definite, probable and possible tuberculous meningitis
(TBM).
Definite TBM (n=47) Probable TBM (n=35) Possible TBM (n=38)
Blood results, median (IQR)
Hemoglobin (g/dL) 10.5 (9.1–13) 12 (10.7–13.2)* 10 (8–11.4)
White cell count (cells6109/L) 5.9 (4.3–8.5) 5.6 (4.5–7.7) 7.7 (5.4–10)
Sodium (mmol/L) 126 (123–130) 129 (127–133)** 130 (126–135)**
Cerebrospinal fluid results, median, (IQR)
Protein (g/L) 2.6 (1.6–4.8) 2.4 (1.3–5.2) 1.2 (0.8–1.9)**
Glucose (mmol/L) 1.6 (0.9–2.4) 1.9 (1.3–2.8) 2.7 (2.1–3.2)**
Lymphocytes (cells6106/L) 77 (23–199) 59 (23–143) 12 (0–31)**
Polymorphonuclear cells (cells6106/L) 7 (0–39) 12 (0–12) 0 (0–3)**
Features of TB elsewhere, n/N (%) 35/42 (83) 21/34 (62)* 31/38 (82)
Chest radiograph abnormalities 34/38 (89) 18/27 (67)* 24/38 (63)
Abdominal ultrasound abnormalities1 6/6 (100) 11/11 (100) 8/10 (80)
Extra-meningeal AFB on microscopy/M.tb cultured 9/47 (19) 5/35 (14) 12/38 (32)
CT brain abnormalities,
(excluding cerebral atrophy), n/N (%)1 11/16 (69) 21/23 (91)2 4/5 (80)3
Hydrocephalus 4/16 (25) 6/23 (26) 0/5 (0)
Meningeal enhancement 3/16 (19) 9/23 (39) 0/5 (0)
Infarct 5/16 (31) 12/23 (52) 1/5 (20)
IQR, interquartile range; n, number of patients; N, total number of patients for whom results were available; TB, tuberculosis; AFB, acid-fast bacilli; M.tb, Mycobacterium
tuberculosis; CT, computed tomography.
*Significantly different (p,0.05) from patients with definite TBM,
**p,0.01.
1N includes total number of patients who underwent procedure.
2Significantly more patients with probable TBM had CT brain performed compared to patients with definite TBM, p = 0.007.
3Significantly less patients with possible TBM had CT brain performed compared to patients with definite TBM, p = 0.04.
doi:10.1371/journal.pone.0020077.t002
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Figure 2. Kaplan-Meier survival curves of patients with definite, probable and possible tuberculous meningitis (TBM). Survival
probability at 6-months was similar between patients with definite TBM and those with probable TBM (log-rank test p = 0.69), and possible TBM (log-
rank test p = 0.15).
doi:10.1371/journal.pone.0020077.g002
Table 3. Management and outcome of patients with definite, probable and possible tuberculous meningitis (n = 120).
TB treatment
On treatment at time of presentation, n/N (%) 26/115 (23)
Treatment started, n/N (%)1 84/89 (94)
Duration between symptom onset and starting treatment in days, median (IQR) 7 (3–13)
Corticosteroids started, n/N (%) ** 64/113 (57)
ART
Treatment started #6 months after starting TB treatment, n/N (%)2 31/54 (57)
Duration between diagnostic LP and starting ART in days, median (IQR) 42 (17–81)
Outcome3
Inpatient mortality, n (%) 45 (38)
Duration from LP to death in days4, median (IQR) 4 (3–9)
Six months, n (%)
Alive 50 (42)
Dead 58 (48)
Lost to follow-up 12 (10)
Nine months, n (%)
Alive 47 (39)
Dead 59 (49)
Lost to follow-up 14 (12)
TB, tuberculosis; n, number of patients; N, number of patients for whom results were available; IQR, interquartile range; LP, lumbar puncture; ART, antiretroviral therapy;
TBM, tuberculous meningitis; D4T, stavudine 30 mg twice daily; 3TC, lamivudine 150 mg twice daily or 300 mg daily; EFV, efavirenz 600 mg nightly; AZT, zidovudine
300 mg twice daily; tenofovir 300 mg daily.
**Significantly more patients with definite TBM (71%) received corticosteroid treatment compared to patients with possible TBM (32%, p,0.01).
1N includes patients not on TB treatment at presentation.
2N includes HIV-infected patients not on ART at presentation who survived admission. Treatment regimens included: 1) D4T, 3TC, EFV (n = 14) 2) AZT, 3TC, EFV (n = 7) 3)
3TC, TDF, EFV (n = 3). Treatment regimes were not known for 7 patients.
3Outcomes reported for all patients (n = 120) with TBM.
4Only including patients who died during hospitalization.
doi:10.1371/journal.pone.0020077.t003
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Table 4. Univariate analysis of variables associated with inpatient mortality in all patients with definite, probable and possible
tuberculous meningitis (n = 120).
Died (n=45) Survived (n =75) P-value OR1 (95% CI)
Age, median years (IQR) (N = 120) 37 (28–41) 35 (28–44) 0.97 - -
Female, n (%) (N = 120) 24 (55) 36 (48) 0.71 1.2 (0.59–2.60)
History of previous TB, n (%) (N = 115) 13 (30) 21 (29) 1.00 1.1 (0.46–2.40)
On TB treatment at time of LP, n (%) (N = 115) 9 (21) 18 (25) 0.66 0.79 (0.32–1.97)
HIV-infected, N (%) (N = 114) 39 (98) 67 (91) 0.26 4.1 (0.48–34.38)
BMRC TBM disease grade 2 or 3, n (%)(N = 114) 36 (84) 45 (63) 0.03* 3.0 (1.16–7.63)
Definite TBM, n (%) (N = 120) 18 (40) 29 (39) 1.00 1.1 (0.50–2.25)
WCC, median cells6109/L (IQR) 6.2 (4.5–8.9) 6.0 (4.6–9) 0.83 - -
Hemoglobin, median g/dL (IQR) 10.3 (8.8–12.3) 11 (9.6–12.8) 0.16 - -
Serum sodium, median mmol/L (IQR) 127 (124–133) 129 (125–134) 0.48 - -
CSF polymorphs, median cells6106 (IQR) 0 (0–14) 0 (0–14) 0.61 - -
CSF lymphocytes, median cells6106 (IQR) 39 (8–144) 46 (16–125) 0.78 - -
CSF protein, median g/L (IQR) 2.28 (1.51–4.87) 1.76 (1.05–3.08) 0.11 - -
CSF glucose, median mmol/L (IQR) 1.8 (1–2.8) 2.2 (1.5–2.9) 0.19 - -
Symptoms to TB treatment, median days (IQR) 7 (2–12) 6 (4–14) 0.37 - -
Corticosteroids started, n (%)(N = 113) 21 (50) 43 (61) 0.33 0.7 (0.30–1.41)
n, number of patients; N, total number of patients for whom analysis was performed; IQR, interquartile range; TB, tuberculosis; LP, lumbar puncture; BMRC, British
Medical Research Council; WCC, total blood white cell count ; CSF, cerebrospinal fluid.
p-value statistically significant (,0.05).
1Odds ratios (OR) and 95% confidence intervals (95%CI) reported for categorical variables.
doi:10.1371/journal.pone.0020077.t004
Table 5. Univariate analysis of variables associated with inpatient mortality in HIV-infected patients with definite, probable and
possible tuberculous meningitis (n = 106).
Died (n =39) Survived (n=67) P-value OR1 (95% CI)
Age, median years (IQR) (N = 106) 37 (28–41) 34 (28–44) 0.88 - -
Female, n (%) (N = 106) 19 (49) 38 (57) 0.54 0.7 (0.33–1.60)
History of previous TB, n (%) (N = 102) 13 (35) 19 (29) 0.66 1.3 (0.55–3.10)
On TB treatment at time of LP, n (%)(N = 101) 9 (24) 17 (27) 1.00 0.88 (0.35–2.26)
On ART at time of LP, n (% of HIV-infected) (N = 103) 8 (22) 12 (18) 0.80 1.2 (0.46–3.38)
CD4 at presentation, median cells/mL (IQR) 54 (23–143) 109 (40–170) 0.03* - -
BMRC TBM disease grade 2 or 3, n (%) (N = 100) 30 (81) 39 (62) 0.07 2.64 (1.002–6.94)
Definite TBM, n (%) (N = 106) 16 (41) 27 (40) 1.00 1.03 (0.46–2.30)
WCC, median cells6109/L (IQR) 6.2 (4.4–8.9) 5.6 (4.4–8.9) 0.60 - -
Hemoglobin, median g/dL (IQR) 9.9 (8.5–11.5) 10.9 (9.4–12.6) 0.09 - -
Serum sodium, median mmol/L (IQR) 127 (124–134) 129 (125–134) 0.96 - -
CSF polymorphs, median cells6106 (IQR) 0 (0–16) 0 (0–12) 0.92 - -
CSF lymphocytes, median cells6106 (IQR) 42 (7–135) 46 (10–130) 0.80 - -
CSF protein, median g/L (IQR) 2.01 (1.26–3.00) 1.72 (1.04–3.09) 0.48 - -
CSF glucose, median mmol/L (IQR) 1.93 (0.9–2.8) 2.2 (1.6–2.9) 0.22 - -
Symptoms to TB treatment, median days (IQR) 7 (2–14) 6 (4–14) 0.40 - -
Corticosteroids started, n (%)(N = 99) 19 (53) 36 (57) 0.68 0.84 (0.36–1.91)
n, number of patients; N, total number of patients for whom analysis was performed; IQR, interquartile range; TB, tuberculosis; LP, lumbar puncture; ART, antiretroviral
therapy; BMRC, British Medical Research Council; CD4, CD4+ cell count; WCC, total blood white cell count ; CSF, cerebrospinal fluid.
*p-value statistically significant (,0.05).
1Odds ratios (OR) and 95% confidence intervals (95%CI) reported for categorical variables.
doi:10.1371/journal.pone.0020077.t005
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in multivariate analysis (logistic regression model p= 0.01, R2=
0.14).
Analysis of factors associated with six-month mortality is
reported only for HIV-infected hospital survivors for whom
outcome was known at six-months follow-up (n= 56, Table 6).
Being either on ART at presentation, or having started ART
during TB treatment, was negatively associated with six-month
mortality (OR=0.2, 95% CI= 0.05–0.81, p = 0.03). This associ-
ation was confirmed in a Cox proportional hazard model (n = 66),
which included 10 HIV-infected patients who were lost to follow-
up after discharge (Figure 3, hazard ratio = 0.30, 95% CI= 0.08–
0.82, p = 0.03). No additional factors were associated with six-
months mortality when all patients (regardless of HIV-status) with
a known outcome at six-month follow-up were included in analysis
(data not shown).
Discussion
Several studies have reported CM as the most frequent cause of
meningitis in HIV-infected patients [1–3,16,17]. In our study,
TBM was the most common cause of meningitis (57%) when both
microbiological-confirmed cases and cases diagnosed on clinical
grounds were included. An earlier study conducted at our hospital
(2006–2008) reported CM and TBM as the cause of microbio-
logical-confirmed meningitis in 63%, and 28% of cases, respec-
tively [3]. By comparison, we found TBM (44%) and CM (45%) to
account for similar proportions of microbiological-confirmed
cases. This change may reflect increasing ART access in the
referral area (during 2009, 23 449 patients were commenced on
ART in the Western Cape public health sector, compared to
19 527 patients during 2008 [Catherine White, Western Cape ART
Monitoring and Evaluation Programme- personal communication]) and
therefore fewer HIV-infected patients reaching the severity of
immunosuppression associated with CM.
A higher BMRC TBM disease grade was predictive of death
during hospitalization when all patients (regardless of HIV status)
were included in the analysis. When the analysis was restricted to
HIV-infected patients only, both a lower CD4+ and a higher
BMRC TBM disease grade were associated with death. The
predictive value of worse TBM disease on the mortality of both
HIV-infected [18,19] and uninfected [20,21] patients is well
documented. Two previous studies also found an association
between low CD4+ count (less than 50 cells/mL [18] and less than
200 cells/mL [22]) and inpatient mortality in HIV-infected TBM
patients. However, this finding has not always been reproduced
[19,23]. Other factors previously reported associated with reduced
hospital survival in HIV-associated TBM include disease duration
of more than 14 days [22] and infection with MDR-TB strains
[18]. In our study, prolonged symptom duration was not
associated with inpatient mortality. Due to the low prevalence of
MDR-TB (MDR-TB isolates identified in 3 patients; 1 from CSF
and 2 from extra-meningeal specimens), its influence on mortality
could not be assessed.
In this study, six-month mortality in HIV-infected TBM
patients was significantly lower in patients who received ART
during TB treatment. As most studies in HIV-infected TBM
patients thus far were conducted in patients not receiving ART
[24], few have assessed the influence of ART on outcome. Torok
et al. [10] reported lack of ART prior to or during TB treatment to
Table 6. Univariate analysis of variables associated with six-month mortality in HIV infected patients with definite, probable and
possible tuberculous meningitis (n = 56).1
Died (n =12) Survived (n =44) P-value OR2 (95% CI)
Age, median years (IQR) (N = 56) 36 (29–49) 34 (28–44) 0.58 - -
Female, n (%) (N = 56) 3 (25) 19 (43) 0.33 0.4 (0.10–1.85)
History of previous TB, n (%) (N = 55) 5 (42) 13 (30) 0.50 1.6 (0.44–6.17)
On TB treatment at time of LP, n (%) (N = 54) 4 (33) 11 (26) 0.72 1.4 (0.36–5.62)
On ART at time of LP, n (% of HIV-infected) (N = 56) 1 (8) 10 (23) 0.42 0.3 (0.35–2.70)
CD4 at presentation, median cells/mL (IQR) 98 (18–160) 104 (46–159) 0.46 - -
BMRC TBM disease grade 2 or 3, n (%)(N = 54) 6 (50) 26 (62) 0.52 0.6 (0.17–2.24)
Definite TBM, n (%) (N = 56) 3 (25) 20 (45) 0.32 0.4 (0.10–1.68)
WCC, median cells6109/L (IQR) 6.8 (4.8–9.4) 5.6 (4.1–9.4) 0.56 - -
Hemoglobin, median g/dL (IQR) 9.7 (8.4–12.2) 10.6 (8.9–12.2) 0.60 - -
Serum sodium, median mmol/L (IQR) 134 (126–135) 128 (123–131) 0.09 - -
CSF polymorphs, median cells6106 (IQR) 0 (0–22) 2 (0–12) 0.42 - -
CSF lymphocytes, median cells6106 (IQR) 17 (0–67) 79 (19–172) 0.06 - -
CSF protein, median g/L (IQR) 1.28 (0.80–2.42) 1.91 (1.08–4.09) 0.12 - -
CSF glucose, median mmol/L (IQR) 2.2 (1.5–2.9) 2.3 (1.7–3.2) 0.97 - -
Symptoms to TB treatment, median days (IQR) 8 (4–48) 7 (4–17) 0.74 - -
Corticosteroids started, n (%)(N = 54) 5 (42) 25 (60) 0.33 0.5 (0.13–1.79)
ART started prior to LP/during TB treatment, n (%) (N = 56) 5 (42) 34 (77) 0.03* 0.2 (0.05–0.81)
n, number of patients; N, total number of patients for whom analysis was performed; IQR, interquartile range; TB, tuberculosis; LP, lumbar puncture; ART, antiretroviral
therapy; BMRC, British Medical Research Council; CD4, CD4+ cell count; WCC, total blood white cell count ; CSF, cerebrospinal fluid.
*p-value statistically significant (,0.05).
1Analysis performed for HIV-infected patients who survived hospitalization for whom outcome was known at 6-month follow-up. One HIV-infected hospital survivor for
whom ART treatment at TBM presentation was unknown excluded from analysis.
2Odds ratios (OR) and 95% confidence intervals (95%CI) reported for categorical variables.
doi:10.1371/journal.pone.0020077.t006
Tuberculous Meningitis in a HIV Prevalent Setting
PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e20077
be associated with earlier time to death by univariate, but not
multivariate, analysis in adult TBM patients. However, a
subsequent randomised trial conducted at the same site found
no significant difference in nine-month mortality between HIV-
infected TBM patients who started ART before or at two months
of TB treatment (58% mortality), compared to the historical
comparator group most of whom were not exposed to ART (67%
mortality) [9,10]. Croda et al. [8] found a history of ART prior to
TBM presentation to be predictive of death at nine-months follow-
up. The authors postulate that this surprising finding most likely
related to non-compliance to ART.
Contrary to inpatient mortality rates which are generally similar
between HIV-infected and uninfected patients with TBM
[22,23,25,26], six to nine-month outcome is substantially worse in
HIV-infected patients [14,27–29]. HIV-related illnesses (other than
TBM) probably account for a substantial proportion of deaths after
hospital discharge in HIV-infected TBM patients, particularly those
not on ART. As previous studies in HIV-associated TB have shown
a clear survival benefit in patients receiving ART [6,7], it is intuitive
to infer a causal relationship between ART and improved survival
in our patient cohort. However, survival-bias might also have
contributed to the association of ART and reduced mortality at six-
month follow-up that we observed: those who survived were able to
initiate ART.
Our study has several important limitations, which may have
resulted in bias. Firstly, due to its retrospective nature, not all
information was available in all cases. Specifically, a substantial
proportion of chest radiographs (14%) were not available for
review. This might have resulted in an underestimate of patients
with probable TBM. The reasons for a substantial proportion of
HIV-infected patients (43% of ART naı̈ve patients who survived
admission) failing to start ART after discharge could not be
determined. Patients are not routinely followed-up at our facility
after discharge from hospital; eligible patients are referred to their
local ART clinics to start ART. Alternatively, patients who require
prolonged admission may commence ART during admission to a
step-down facility. Limited access to primary care clinic and step-
down facility clinical records precluded the systematic collection of
data regarding reasons for failing to start ART, drug toxicities and
interactions, as well as co-morbidities after starting TB treatment
and ART. Also, adherence to ART and the proportion of patients
receiving directly observed TB treatment could not be assessed,
and causes of death were not determined. Although similar to
studies of TB patients previously conducted in our setting [30,31],
the loss to follow-up rate (10%) was not insubstantial. No factors
predictive of loss to follow-up could be confirmed by analysis of
baseline characteristics of these patients compared to those
retained in care. However, a trend to a lower CD4+ count was
observed in the latter group. Secondly, as study entry relied on
CSF findings, patients with TBM who died prior to LP, and those
who had a contraindication to LP based on brain CT, were not
included in the analysis.
Thirdly, HIV itself often results in mild CSF abnormalities [32].
For this reason, we did not include patients with mildly abnormal
CSF if a specific cause of meningitis was not found. However, it is
well documented that a minority of patients with TBM may
present with mildly abnormal, or completely normal CSF,
especially in the context of HIV co-infection [8,22,23,33]. This
group of patients would have been excluded from our study if CSF
TB microscopy and culture were negative. Furthermore, the
decision to perform CSF TB microscopy and culture was not
uniform, being based on the attending clinician’ s discretion.
Significantly less patients with possible and probable TBM
compared to definite TBM had CSF M. tuberculosis culture
performed; this could have resulted in the misclassification of
some patients with definite TBM who might have had M.
tuberculosis cultured had culture been performed.
Fourthly, CSF findings and neurological signs, most notably
focal neurological deficits (21% definite TBM versus 5% possible
TBM [p,0.01]), differed significantly between patients with
definite and possible TBM. This might reflect the inclusion of
some patients with alternative diagnoses such as viral meningitis as
possible TBM or, alternatively, be indicative of more severe
disease in patients with definite TBM. Patients with possible TBM
were also less likely, whilst those with probable TBM were more
likely, to undergo brain CT compared to patients with definite
Figure 3. Cox proportional hazard model survival curves. ART: HIV-infected tuberculous meningitis (TBM) patients either on antiretroviral
therapy (ART) at TBM presentation or started on ART during subsequent 6 months of antituberculosis (TB) treatment (n = 43). No ART: HIV-infected
TBM patients not on ART at presentation nor started on ART during subsequent 6 months of TB treatment (n = 23). The model only included patients
who survived hospitalization (n = 66). Hazard ratio for patients on ART= 0.30 (95% confidence interval 0.08–0.82, p-value= 0.03).
doi:10.1371/journal.pone.0020077.g003
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TBM (p=0.04 and p= 0.007, respectively). This reflects the
limited resources in our setting: brain imaging in the context of
meningitis is usually prioritized to patients with severe disease or in
whom an intracerebral space occupying lesion is suspected i.e.
those with focal neurological deficits, severe depressed level of
consciousness or seizures. Both the differences in CSF findings and
the differences in the proportions of patients who underwent brain
imaging between the definite and possible TBM groups could have
resulted in bias, resulting in different corticosteroid prescription
practices between the 2 groups (71% definite TBM compared to
32% possible TBM, [p= 0.0007]) and possibly differentially
influencing outcomes. In our setting, corticosteroids are prescribed
at the treating clinician’s discretion.
Conclusions
In our setting where most patients with TBM are HIV co-
infected, advanced HIV and worse stage of TBM disease are poor
prognostic factors. Starting ART prior to or during TB treatment
may be associated with lower mortality in TBM patients co-
infected with HIV.
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CONCISE COMMUNICATION
Central nervous system disorders after starting
antiretroviral therapy in South Africa
Valerie Asselmana, Friedrich Thienemannb,c, Dominique J. Pepperd,e,
Andrew Boullef, Robert J. Wilkinsona,b,d,g,h, Graeme Meintjesa,b,d,g and
Suzaan Maraisa,b,d
Objective: To describe the spectrum of central nervous system (CNS) disease during the
first year of antiretroviral therapy (ART) and to determine the contribution of neuro-
logical immune reconstitution inflammatory syndrome (IRIS).
Design: A prospective observational cohort study conducted over a 12-month period at
a public sector referral hospital in South Africa.
Methods: HIV-seropositive patients who developed new or recurrent neurological or
psychiatric symptom(s) or sign(s) within the first year of starting ART were enrolled. We
used the number of patients starting ART in the referral area in the preceding year as the
denominator to calculate the incidence of referral for neurological deterioration.
Patients with delirium and peripheral neuropathy were excluded. Outcome at 6 months
was recorded.
Results: Seventy-five patients were enrolled. The median nadir CD4þ cell counts was
64cells/ml. Fifty-nine percent of the patients were receiving antituberculosis treatment.
The incidence of referral for CNS deterioration in the first year of ART was 23.3 cases
[95% confidence interval (CI), 18.3–29.2] per 1000 patient-years at risk. CNS tuber-
culosis (n¼27, 36%), cryptococcal meningitis (n¼18, 24%), intracerebral space
occupying lesions (other than tuberculoma) (n¼10, 13%) and psychosis (n¼9,
12%) were the most frequent diagnoses. Paradoxical neurological IRIS was diagnosed
in 21 patients (28%), related to tuberculosis in 16 and cryptococcosis in five. At 6
months, 23% of the patients had died and 20% were lost to follow-up.
Conclusion: Opportunistic infections, notably tuberculosis and cryptococcosis, were
the most frequent causes for neurological deterioration after starting ART. Neurological
IRIS occurred in over a quarter of patients.
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Introduction
Neurological disorders are important causes of morbidity
and mortality in HIV-infected patients [1,2]. The use of
combination antiretroviral therapy (ART) has signifi-
cantly reduced the incidence and progression of HIV-
associated dementia, as well as the incidence of
opportunistic infections affecting the central nervous
system (CNS) [3]. However, an early complication of
ART is the immune reconstitution inflammatory
syndrome (IRIS), which may affect the CNS [4,5]. IRIS
occurs due to an exuberant inflammatory response
directed toward opportunistic pathogens [6]. This results
in the paradoxical worsening of a patient’s condition
despite adequate antimicrobial therapy (paradoxical IRIS)
or the unmasking of an occult opportunistic infection
with an unusually inflammatory presentation (unmasking
IRIS) [7]. Neurological IRIS is described in several
HIV-related CNS disorders such as tuberculosis (TB),
cryptococcal meningitis, cytomegalovirus infection and
progressive multifocal leukoencephalopathy [4,5].
Efavirenz (EFV) may cause CNS adverse events in more
than 50% of the patients [8,9]. Furthermore, a Thai study
reported an increased rate of primary CNS lymphoma
and ischemic/hemorrhagic strokes in HIV-infected
patients within the first 2 years of ARTwhen compared
with HIV-infected patients from the same setting in the
pre-ART era [2].
In this study, we describe the spectrum of CNS disease
during the first year of ARTamong patients presenting to
a referral hospital in South Africa.
Participants and methods
A prospective observational study at GF Jooste Hospital, a
secondary-level, public sector referral hospital in Cape
Town, South Africa. GF Jooste Hospital serves adults
from a population of approximately 1.3 million people
who reside in high-density, low-income communities.
The incidence of TB in these communities exceeds 1000
cases per 100 000 of the population per annum and the
antenatal HIV seroprevalence can be 30% [10]. Eleven
primary-level ART clinics are situated in the referral area.
Most patients attending these clinics do not have health
insurance. Thus, the public sector referral hospital serves
most patients with significant clinical deterioration
following ART initiation.
Between 1 November 2007 and 31 October 2008
(12 months), we enrolled adult (18 years of age) HIV-
seropositive patients who were referred to our facility
with new or recurrent neurological or psychiatric
symptom(s) or sign(s) within the first year of starting
ART. Patients with neurological deterioration due to
peripheral neuropathy or ‘delirium secondary to a general
medical condition’ were excluded. Doctors in the
infectious diseases outpatient clinic and the admitting
medical doctors were informed about the study and they
screened all patients who presented to GF Jooste hospital
with a medical illness. Patients who met the inclusion
criteria were referred to a study physician. The study
physicians also actively sort out referrals in the outpatient
clinic and medical wards each day of the week (Monday–
Friday). Data obtained by the study physician included
demographic information, CD4þ cell counts prior to
ART initiation, ART regimen, previous/concurrent
illnesses affecting the CNS, details of TB disease if present,
medication use and details of neurological presentation.
Thereafter, a neurological examination was performed by
the study physician and investigations requested as
determined by presentation. We subsequently used
primary clinic and hospital medical notes, as well as the
National Health Laboratories Service database to trace
specimens, and the electronic hospital and primary clinic
attendance registers to trace patients in order to determine
the outcome 6 months after presentation. Data obtained
prospectively (i.e. details regarding presentation and initial
management), aswell as retrospectively (i.e. outcomedata),
were recorded on a standardized data collection sheet. Data
analysis was performed using Microsoft Excel. The
incidence of referral for CNS deterioration was calculated
with 95%Poisson confidence intervals (CIs) on the basis of
the total number of patients initiating ART in the year
preceding each study month at the 11 referring ART
clinics, reduced by 10.9% to allow for losses to care. The
data were obtained from monthly reports of total patients
started on ART in each referring clinic and provincial
cohort data on retention in care at 6 months on ART [11].
TheResearch EthicsCommittee of theUniversityof Cape
Town approved this study.
Definitions
We defined paradoxical tuberculosis-associated immune
reconstitution inflammatory syndrome (TB-IRIS) and
cryptococcal meningitis immune reconstitution inflam-
matory syndrome (CM-IRIS) using consensus clinical
case definitions [7,12,13]. The diagnosis of paradoxical
TB-IRIS required diagnosis of active TB prior to ART
initiation, response to antitubercular treatment and
development of recurrent, new or worsening symp-
toms/signs of neurological TB within 3 months of
starting ART. Paradoxical TB-IRIS was also diagnosed in
patients who were diagnosed with TB after initiation of
ART and subsequently developed a neurological para-
doxical reaction after starting antitubercular therapy that
did not have an alternative explanation. The diagnosis of
paradoxical CM-IRIS required diagnosis of cryptococcal
meningitis prior to ART, initial response to antifungal
treatment with improvement of symptoms/signs and
presentation with cryptococcal meningitis recurrence
that was culture negative within 12 months of ART
initiation. If there was a cryptococcal meningitis
recurrence on ART and the cerebrospinal fluid (CSF)
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cultured Cryptococcus neoformans, the onset of the event
had to be within 3 months of initiation of antifungal
therapy to be defined as CM-IRIS. The diagnosis of a
culture-positive cryptococcal meningitis relapse on ART
required re-presentation with CSF fungal culture-
positive cryptococcal meningitis and occurrence more
than 3 months after start of antifungal therapy.
The diagnosis of ‘delirium secondary to a general medical
condition’ required acute confusion secondary to sepsis
owing to a nonneurological infection or metabolic
abnormality (e.g. hypoxia, hypoglycemia, renal or hepatic
failure).
Results
Seventy-five patients presented with neurological
deterioration within 1 year of starting ART. Between
1 November 2006 and 31 October 2007, the estimated
person time at risk in the first year of ART was 3222
patient-years, accounting for losses to care. The incidence
rate of referred patients with CNS deterioration in the
first year on ART was, therefore, 23.3 cases (95% CI,
18.3–29.2) per 1000 patient-years at risk.
Table 1 summarizes the 75 patients’ clinical and
demographic characteristics. Forty-four patients (59%)
were receiving antitubercular treatment at the time of
neurological deterioration, 30 of whom had culture-
confirmed disease. Drug susceptibility testing for
rifampicin and isoniazid (INH) was performed on 18
isolates, which revealed drug susceptibility in 15 patients
and multidrug-resistance (resistant to rifampicin and
INH) in three patients. The four most frequent reasons
for neurological deterioration were CNS TB, crypto-
coccal meningitis, intracerebral space occupying lesions
(SOLs) and psychosis (Table 2).
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Table 1. Characteristics and outcomes of 75 HIV-seropositive patients presenting with neurological deterioration within 1 year of initiating
antiretroviral therapy.
Female, n (%) 40 (53)
Age in years, median (range) 33 (18–68)
Nadir CD4þ cell counts (cells/ml), median (IQR) 64 (23–114)
WHO Staging, n (%)
Stage II 2 (3)
Stage III 28 (37)
Stage IV 45 (60)






Current TB, n (%)a 44 (59)
Pulmonary/extrapulmonary diseaseb, n/n 27/22
Time from antitubercular treatment initiation to starting ART in days, median (IQR)c 56 (34–100)
Previous TB, n (%) 31 (41)
Previous CM, n (%) 11 (15)
Time from ART initiation to symptom onset in days, median (IQR) 23 (9–89)
Paradoxical TB-IRIS, n¼16 16 (11–30)
Paradoxical CM-IRIS, n¼5 58 (27–88)
Time from symptom onset to presentation in days, median (IQR) 4 (3–14)
Paradoxical TB-IRIS, n¼16 4 (3–16)
Paradoxical CM-IRIS, n¼5 3 (2–4)
Outcome at 6 months, n (%)
Alive 43 (57)
Deadd 17 (23)
Lost to follow-upe 15 (20)
3TC, lamivudine; ART, antiretroviral therapy; CM, cryptococcal meningitis; CM-IRIS, cryptococcal meningitis immune reconstitution inflam-
matory syndrome; d4T, stavudine; EFV, efavirenz; IQR, interquartile range; NVP, nevirapine; TB, tuberculosis; TB-IRIS, tuberculosis-associated
immune reconstitution inflammatory syndrome; TDF, tenofovir; ZDV, zidovudine.
aIncludes all patients on antitubercular treatment at the time of neurological deterioration [those who started prior to ART initiation (n¼40) and
those who started after ART initiation (n¼4)].
bExtrapulmonary disease sites include nodal (n¼11), central nervous system (n¼5), abdominal (n¼4), pleural (n¼4) and pericardial (n¼2). In
five patients, both pulmonary and extrapulmonary diseasewere present. In three patientsmore than one extrapulmonary site of diseasewas present.
cFor 40 patients who started antitubercular treatment prior to ART.
dDeaths occurred in the following patient categories: intracerebral space occupying lesion (other than tuberculoma) (n¼6), new diagnosis of
neurological TB (n¼2), poor adherence to antitubercular treatment (n¼2), multidrug-resistant TB (n¼1), new diagnosis of CM (n¼3),
cytomegalovirus encephalitis (n¼1) and HIV encephalopathy (n¼2).
eLost to follow-up occurred in the following patient categories: paradoxical TB-IRIS (n¼1), multidrug-resistant TB (n¼2), poor adherence to
antitubercular treatment (n¼1), paradoxical CM-IRIS (n¼1), culture-positive CM relapse on ART (n¼1), new diagnosis of CM (n¼1), cerebral
toxoplasmosis (n¼1), intracerebral space occupying lesion of uncertain cause (n¼1), EFV-induced psychosis (n¼2), reactive psychosis (n¼1),
isolated abducens nerve palsy (n¼1), varicella zoster virus radiculopathy (n¼1) and bacterial meningitis (n¼1).
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Central nervous system tuberculosis
Twenty-seven patients (36%) presented with neurological
deterioration related to TB. Paradoxical TB-IRIS was
diagnosed in 16/75 patients (21%). Thirteen out of 16 of
these patients received corticosteroids. At 6-months
follow-up, 15/16 patients were alive and one was lost to
follow-up. All patients diagnosed with tuberculoma
either had a negative-serum immunoglobulin G (IgG)
serological analysis for toxoplasma species or showed a
good response to antitubercular treatment in the absence
of treatment for toxoplasmosis.
Cryptococcal meningitis
Eighteen patients (24%) presented with deterioration
related to cryptococcal meningitis. Five patients (7%)
presented with paradoxical CM-IRIS, of whom one
received corticosteroids. At 6-months follow-up, four of
these five patients were alive and one was lost to follow-
up.
Space occupying lesions (other than
tuberculoma)
Ten patients (13%) presented with SOL due to
toxoplasmosis (n¼ 1) or of uncertain cause (n¼ 9).
The diagnosis of cerebral toxoplasmosis was on the basis
of a response to antitoxoplasma treatment in the absence
of antitubercular treatment. In the other nine patients, it
could not be ascertained whether the SOL was related to
TB or toxoplasmosis: four were already receiving
antitubercular treatment and had antitoxoplasma treat-
ment added, three were started on treatment for both TB
and toxoplasmosis, one was treated only for toxoplas-
mosis, but died and one was only treated for TB, but
died.
Psychosis
Nine patients (12%) presented with psychosis. An EFV-
induced psychosis was the most likely cause in five. One
patient was diagnosed with INH-induced psychosis and
another was diagnosed with a reactive psychosis
secondary to social stressors. A diagnosis of HIV-induced
psychosis was presumed for two patients in whom no
other cause could be identified.
Outcomes
At 6-months follow-up, 43 (57%) patients were alive, 17
(23%) were dead and 15 (20%) were lost to follow-up
from the healthcare system (Table 1). The median interval
from ART initiation, and presentation, to death was 67
days [interquartile range (IQR) 47–164 days] and 23 days
(IQR 10–39 days), respectively.
Discussion
This is, to our knowledge, the first prospective study
describing the spectrum of neurological disorders
occurring within the first year of ART. TB and
cryptococcal meningitis together accounted for at least
60% of cases. This is likely owing to the high incidence of
TB in our setting, and profound immunosuppression at
ART initiation; in 2007, 19% of adults starting ART in
the Western Cape province had CD4þ cell counts below
50 cells/ml, whereas the median CD4þ cell counts of
patients starting ART in two of the referring clinics were
131 cells/ml [14].
Paradoxical IRIS, which was associated with TB (n¼ 16)
and cryptococcal meningitis (n¼ 5), accounted for 28%
of cases. Paradoxical CM-IRIS may occur in up to 30% of
patients following ART initiation [15–17]. We pre-
viously reported neurological TB-IRIS in 12% of patients
who presented with TB-IRIS [12]. The median interval
from starting ART to symptom onset in our patients with
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Table 2. Causes of neurological deterioration within one year of
antiretroviral therapy initiation in 75 HIV-seropositive patients.
n (%)
CNS TB 27 (36)




TB spinal epidural abscess (n¼1)




Deterioration due to poor adherence 5 (7)
Cryptococcal meningitis (CSF culture positive2) 18 [12] (24)
Paradoxical CM-IRIS3 5 [1] (7)
Culture-positive relapse on ART4 4 [4] (5)
New diagnosis of CM 9 [7] (12)
Intracerebral space occupying lesion5 10 (13)
Cerebral toxoplasmosis 1 (1)





Reactive psychosis 1 (1)
Other 11 (15)
Seizure 3 (4)
CMV encephalitis 2 (3)
HIV encephalopathy 2 (3)
Isolated abducens nerve palsy 1 (1)
VZV radiculopathy 1 (1)
Bacterial meningitis 1 (1)
RIND 1 (1)
ART, antiretroviral therapy; CM, cryptococcal meningitis; CM-IRIS,
cryptococcal meningitis immune reconstitution inflammatory syn-
drome; CMV, cytomegalovirus; CNS, central nervous system; CSF,
cerebrospinal fluid; EFV, efavirenz; INH, isoniazid; MDR-TB, multi-
drug-resistant tuberculosis; RIND, reversible ischemic neurological
deficit; TB, tuberculosis; TB-IRIS, tuberculosis-associated immune
reconstitution inflammatory syndrome; VZV, varicella zoster virus.
1,3,4See definitions in the text.
2CSF culture positive for Cryptococcus neoformans at time of
deterioration.
5Space occupying lesions other than tuberculoma.
6The most likely differential diagnoses included tuberculoma and
toxoplasmosis.
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TB-IRIS and CM-IRIS was 16 and 58 days, respectively.
These findings are similar to previous reports [12,15].
The management of neurological IRIS is problematic; no
diagnostic test exists and treatment strategies are based on
anecdotal case reports [18]. Eighty-one percent of
patients with TB-IRIS and 20% of patients with CM-
IRIS in our cohort received corticosteroid therapy, which
may be of benefit in patients with neurological TB-IRIS
[12,18]. High mortality rates have been associated
with both CM-IRIS (up to 66%) [17] and neurological
TB-IRIS (at least 13%, at 6-months follow-up) [12]. No
patients in our cohort who presented with IRIS died
during 6-months follow-up and only one patient with
TB-IRIS and one with CM-IRIS were lost to follow-up
at 6 months.
New or expanding SOL developed in 21% of patients
(n¼ 16). Confirming the cause of SOL is difficult in our
setting in which access to stereotactic brain biopsy is
limited. Similar to previous studies [12], we relied on
available evidence to make the diagnosis. The major
differential diagnoses of SOL are cerebral toxoplasmosis
(diagnosed in one patient) and tuberculoma (diagnosed in
six patients) [19]. In more that half of our patients (9/16),
the diagnosis was uncertain. The lack of definitive
diagnosis in most patients, and the associated high
mortality in these patients (6/9), emphasize the challenge
of managing patients with SOL.
Neurological deterioration is an important cause of
clinical deterioration and death after starting ART. The
referral rate of 23.3 cases per 1000 patient-years at risk is
most likely an underestimate of the true incidence of
neurological deterioration. Although significant neuro-
logical presentation related to a CNS cause results in
referral to our facility, patients with mild symptoms or
signs are not always referred; patients who are too
confused or otherwise unwell to seek medical help may
die at home; and patients may attend other hospitals or
move out of the referral area. Furthermore, new or
worsening peripheral neuropathy is a common cause for
neurological deterioration after starting ART [20].
However, as most peripheral neuropathies are managed
at primary care level, we did not include these patients in
our study. In this study, the challenges posed by the
management of patients with neurological deterioration
are reflected in poor outcome (23% died), and high rate of
loss to follow-up (20%), at 6 months. In comparison,
among all patients starting ART in our setting, mortality
and loss to follow-up is considerably lower. The
cumulative mortality rate during the first year of ART
(from 2004 to 2007 in the largest ART clinics in our
referral area) was 8%, and 3–5% of patients were lost to
follow-up during the first year of ART [21]. In a busy
ART program, clinic attendance and adherence to ART
require patient mobility, insight and motivation. Neuro-
logical deterioration makes this difficult, especially if
there is inadequate treatment support from family or
friends. Patients with psychosis or confusionmay not have
the insight to seek medical help and may default ARTand
other medical therapies. Furthermore, patients with
weakness or other neurological impairment may be
physically incapable of seeking medical care indepen-
dently. This may contribute to the high loss to follow-up
rate we observed.
Conclusion
In our setting, opportunistic infections, notably TB and
cryptococcosis, were the most important causes for
neurological deterioration during the first year of ART.
Over a quarter of patients were related to paradoxical
IRIS. Our study has particular relevance to ART
programs in high TB prevalence regions. We highlight
the challenges associated with the management of these in
patients in resource-constrained settings.
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Background. Tuberculosis immune reconstitution inflammatory syndrome (IRIS) is a common cause of dete-
rioration in human immunodeficiency virus (HIV)–infected patients receiving tuberculosis treatment after starting
antiretroviral therapy (ART). Potentially life-threatening neurological involvement occurs frequently and has been
suggested as a reason to defer ART.
Methods. We conducted a prospective study of HIV-infected, ART-naive patients with tuberculous meningitis
(TBM). At presentation, patients started tuberculosis treatment and prednisone; ART was initiated 2 weeks later.
Clinical and laboratory findings were compared between patients who developed TBM-IRIS (TBM-IRIS patients)
and those who did not (non-TBM-IRIS patients). A logistic regression model was developed to predict TBM-IRIS.
Results. Forty-seven percent (16/34) of TBM patients developed TBM-IRIS, which manifested with severe
features of inflammation. At TBM diagnosis, TBM-IRIS patients had higher cerebrospinal fluid (CSF) neutrophil
counts compared with non-TBM-IRIS patients (median, 50 vs 3 cells ×106/L, P = .02). Mycobacterium tuberculosis
was cultured from CSF of 15 TBM-IRIS patients (94%) compared with 6 non-TBM-IRIS patients (33%) at time of
TBM diagnosis; relative risk of developing TBM-IRIS if CSF was Mycobacterium tuberculosis culture positive = 9.3
(95% confidence interval [CI], 1.4–62.2). The combination of high CSF tumor necrosis factor (TNF)-α and low
interferon (IFN)-γ at TBM diagnosis predicted TBM-IRIS (area under the curve = 0.91 [95% CI, .53–.99]).
Conclusions. TBM-IRIS is a frequent, severe complication of ART in HIV-associated TBM and is character-
ized by high CSF neutrophil counts and Mycobacterium tuberculosis culture positivity at TBM presentation. The
combination of CSF IFN-γ and TNF-α concentrations may predict TBM-IRIS and thereby be a means to individ-
ualize patients to early or deferred ART.
Keywords. meningitis; tuberculosis; neutrophils; pathogenesis.
Paradoxical tuberculosis immune reconstitution in-
flammatory syndrome (IRIS) occurs in 8%–43% of
human immunodeficiency virus (HIV)–infected pa-
tients receiving tuberculosis treatment after starting
antiretroviral therapy (ART) [1–4]. Tuberculosis IRIS
results from rapid restoration of Mycobacterium
tuberculosis–specific immune responses, but its patho-
genesis remains poorly understood [1, 5, 6].
Neurological tuberculosis IRIS occurs in a substan-
tial proportion (12%) of tuberculosis IRIS cases and is
the commonest cause of central nervous system (CNS)
deterioration during the first year of ART in settings
of high tuberculosis/HIV prevalence [7, 8]. Mortality is
high (up to 30%) in those affected [8]. Manifestations
of neurological tuberculosis IRIS include meningitis
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[7–11], intracranial tuberculomata [7, 8, 12–14], brain abscess-
es [12, 15], radiculomyelitis [7, 8, 11], and spinal epidural ab-
scesses [7]. There are no prospective studies describing
tuberculous meningitis (TBM) IRIS; only isolated cases [9–15]
and 1 case series of neurological tuberculosis IRIS [8, 16] have
been published. Although consensus now exists that ART
should be started early (around 2 weeks) in HIV/tuberculosis-
coinfected patients with severe immunosuppression, a poten-
tial exception is TBM because of the perceived risk of TBM-
IRIS [17, 18]. However, the frequency and severity of this
complication are not well documented and no means exist to
predict the syndrome.
We therefore investigated clinical and laboratory findings in
ART-naive HIV-infected patients who presented with TBM.
We undertook serial cerebrospinal fluid (CSF) sampling in pa-
tients who did and did not develop TBM-IRIS.
MATERIALS AND METHODS
Setting
This prospective, observational study was performed at GF
Jooste Hospital, a public sector referral hospital in Cape
Town.Thehospital servesa low-income,high-densitypopulation
in which the tuberculosis notification rate exceeds 1.5% per
year with 70% of tuberculosis cases coinfected with HIV [19].
Participants
ART-naive HIV-infected patients aged ≥18 years presenting
with meningitis from March 2009 through October 2010 were
screened for study inclusion. HIV infection was diagnosed using
2 rapid HIV antibody tests and confirmed by HIV load. Definite
TBM was diagnosed when acid-fast bacilli were seen, or when
M. tuberculosis was cultured from CSF. Probable TBM was diag-
nosed when a patient showed clinical, laboratory, and radiologi-
cal features of TBM in the absence of other infective causes for
presentation [20]. Paradoxical TBM-IRIS was diagnosed accord-
ing to a published definition for tuberculosis IRIS modified for
meningitis [7, 8]. The definition had 3 components: (1) TBM
diagnosis before starting ART and improvement on tuberculosis
treatment prior to ART initiation; (2) onset of TBM-IRIS mani-
festations (ie, new, recurrent, or worsening clinical features of
TBM) within 3 months of ART initiation; and (3) exclusion of
alternative causes for clinical deterioration.
Patients were ineligible if they had a contraindication to
lumbar puncture, including unequal pressures between individ-
ual brain compartments on brain imaging, or severe TBM (ie,
modified British Medical Research Council [BMRC] grade III
disease severity) [21]. The University of Cape Town Research
Ethics Committee approved the study and written informed
consent was obtained from all patients or their relatives.
Procedures
Demographic data and history of tuberculosis disease, HIV
infection, and other systemic illnesses and medications were
recorded. Patients underwent general physical and
neurological examination. Chest radiography, phlebotomy, and
lumbar puncture were performed. In patients with suspected
raised intracranial pressure or focal neurological deficits, brain
computed tomography scanning was performed prior to
lumbar puncture. CSF analysis included biochemistry, cytolo-
gy, microbiology (including microscopy and culture for fungi
and pyogenic bacteria), syphilis serology, HIV load, and Cryp-
tococcus latex agglutination titer. Ziehl-Neelsen staining of
sediment and M. tuberculosis culture was performed. If myco-
bacteria were cultured from CSF, tuberculosis polymerase
chain reaction (PCR; Genotype MTBDRplus, Hain Lifesciences)
was performed to determine susceptibility to rifampicin and
isoniazid. CSF varicella zoster virus PCR was performed if the
etiology was suspected. CSF was also stored at −80°C and
analyzed for a range of inflammatory markers on the Bio-Plex
platform (Bio-Rad Laboratories, Hercules, CA) using custom-
ized Milliplex kits (Millipore, St Charles, MO) according to the
manufacturer’s instructions.
At TBM diagnosis, patients started tuberculosis treatment
according to national guidelines [22] and prednisone (1.5 mg/
kg/day). After 2 weeks of treatment and prior to initiation of
ART, patients were assessed for improvement on tuberculosis
treatment. The initial ART regimen was stavudine, lamivu-
dine, and efavirenz. Later during the study, tenofovir replaced
stavudine according to revised national guidelines. CSF inves-
tigations performed at TBM diagnosis were repeated at the
time of ART initiation, 2 weeks later, and at time of TBM-
IRIS presentation and 2 weeks thereafter. Prednisone was
reduced to 0.75 mg/kg/day 4 weeks after starting ART and dis-
continued 2 weeks thereafter, unless the patient developed
TBM-IRIS. At TBM-IRIS presentation, investigations were
performed to exclude alternative causes of deterioration. Pred-
nisone was either recommenced or the dose increased. Pa-
tients were followed for the duration of tuberculosis treatment
(9 months); routine visits were at 2 weeks, 4 weeks, 6 weeks,
12 weeks, 6 months, and 9 months after TBM diagnosis. Pa-
tients were seen more frequently during deterioration.
Statistical Analysis
Statistical analysis was performed using the GraphPad Prism
version 5, R version 2.14.1, and StatXact version 9 software
packages. Categorical variables were compared using χ2 or
Fisher exact test. Continuous variables were compared between
groups and time points within groups, using the Wilcoxon
rank sum and Wilcoxon matched pairs tests, respectively.
Adjusted relative risks (RRs) were evaluated using Cochran-
Mantel-Haenszel tests and tests of homogeneity when










considering categorical risk factors. Log-binomial models were
fitted to continuous risk factors. Significance testing was done
using 2-sided P values with P < .05 taken as significant.
The predictive accuracy of CSF neutrophil counts at TBM
diagnosis for TBM-IRIS was assessed using nonparametric area
under the receiver operating characteristic curve (AUC). Addi-
tionally, a model to predict TBM-IRIS risk was developed from
5 prespecified cytokines measured in CSF at time of TBM diag-
nosis. Interleukin 6 (IL-6), interleukin 10, interleukin 12p40,
interferon gamma (IFN-γ), and tumor necrosis factor alpha
(TNF-α) were selected as candidate markers of TBM-IRIS
based on previous studies [23, 24]. We prespecified the analysis
for evaluating the multivariate cytokine model as follows. Sig-
nificant cytokines comparing TBM-IRIS and non-TBM-IRIS
using Wilcoxon rank sum tests were selected for a logistic
regression model. Nonsignificant cytokines were dropped,
resulting in a final model. The entire model building process
was evaluated using leave-one-out cross-validation, the boot-
strap method [25], and the permutation test to provide a cross-
validated (nonparametric) estimate of the AUC, P values, and
95% confidence intervals (CIs). As a secondary analysis, we ex-
amined whether the addition of CSF neutrophils and/or lym-
phocyte counts would improve the model’s predictive ability.
RESULTS
TBM Presentation
The final diagnoses and reasons for exclusion of patients with
meningitis are shown in Figure 1. Thirty-four patients were
included in the final analysis; 15 (44%) were female and the
median age was 33 years (interquartile range [IQR], 29–44).
Sixteen patients (47%) developed TBM-IRIS (TBM-IRIS
Figure 1. Flow diagram of patients with features of meningitis (eg, headache, confusion, vomiting, and/or neck stiffness) screened for study inclusion.
aPatients defaulted within 3 months of starting antiretroviral therapy (ART). bTime points of lumbar punctures include tuberculous meningitis (TBM)
diagnosis, ART initiation, and 2 weeks after starting ART. cCerebrospinal fluid varicella-zoster virus polymerase chain reaction was performed in 1
patient with who had shingles at time of TBM presentation, which was positive. Abbreviations: ART; antiretroviral therapy, IRIS; immune reconstitution
inflammatory syndrome; TB; tuberculosis; TBM, tuberculous meningitis.










patients) whereas 18 did not (non-TBM-IRIS patients).
Tables 1 and 2 show the demographic and baseline character-
istics of these 2 groups. Baseline characteristics were similar
between groups, although patients who developed TBM-IRIS
had a longer duration of symptoms (median, 19 vs 9 days)
and more frequent features of extrameningeal tuberculosis,
such as chest symptoms (81% vs 44%) and chest radiographic
abnormalities (81% vs 50%). Five TBM-IRIS patients (31%)
and 3 non-TBM-IRIS patients (17%) developed features of
extrameningeal tuberculosis IRIS.
TBM-IRIS Presentation
Features of TBM-IRIS developed a median of 14 days (IQR,
4–20) after starting ART. Symptoms and signs included new
or worsening headache (n = 12), confusion (n = 6), neck pain/
stiffness (n = 11), generalized tonic-clonic seizures (n = 4),
Table 1. Demographic and Baseline Characteristics of Patients Who Developed Tuberculous Meningitis Immune Reconstitution In-
flammatory Syndrome and Those Who Did Not
TBM-IRIS Non-TBM-IRIS
No. (%) No. (%)
Female 9 (56) 6 (33)
Age, y, median (IQR) 33 (30–46) 31 (25–41)
Duration between tuberculosis treatment and ART, d, median (IQR)a 15 (14–16) 15 (14–20)
Previous tuberculosis 5 (31) 6 (33)
Neurological symptoms
Duration of neurological symptoms, d, median (IQR) 19 (6–31) 9 (6–21)
Nausea/vomiting 13 (81) 8 (44)
Headache 16 (100) 14 (78)
Visual disturbances 6 (38) 5 (28)
Confusion 7 (44) 6 (33)
Neck pain/stiffness 13 (81) 14 (78)
Systemic symptoms
Chest symptoms 13 (81) 8 (44)
Night sweats 12 (75) 8 (44)
Abdominal symptoms 9 (56) 5 (28)
Weight loss 14 (88) 12 (67)
Clinical findings
Body mass index, median (IQR) 18.4 (17.2–23.3) 20.7 (19.0–23.3)
BMRC disease grade 1b 7 (44) 11 (61)
Focal neurological signsc 4 (25) 3 (17)
Blood investigations
Sodium, mmol/L, median (IQR) 123 (121–129) 130 (128–134)
Hemoglobin, g/dL, median (IQR) 10.2 (8.5–11.7) 12.4 (9.3–13.4)
Other investigations
CXR abnormalities 13 (81) 9 (50)
Features of extra CNS tuberculosisd 14 (88) 12 (67)
Abdominal ultrasound, abnormal/number performed 5/5 (100) 6/8 (75)
Brain CT abnormal/number performede 4/5 (80) 5/9 (56)
Data are presented as No. (%) unless otherwise specified. Definitions for TBM-IRIS and non-TBM-IRIS are taken from [16] and [18], respectively.
Abbreviations: ART, antiretroviral therapy; BMRC, British Medical Research Council; CNS, central nervous system; CT, computed tomography; CXR, chest
radiograph; IQR, interquartile range; TBM-IRIS, tuberculous meningitis immune reconstitution inflammatory syndrome.
a ART regimens included stavudine (D4T), lamivudine (3TC), and efavirenz (EFV; n = 19); tenofovir, 3TC, and EFV (n = 9); zidovudine, 3TC, and EFV (n = 5); and
D4T, 3TC, and lopinavir/ritonavir (n = 1).
b BMRC grade I: Glasgow Coma Scale (GCS) score of 15 with no focal neurologic signs; grade II: GCS score of 11–14 or GCS of 15 with focal neurologic signs;
grade III: GCS score of ≤10 [21].
c Including cranial nerve palsies (n = 4), hemiparesis (n = 1), cerebellar signs (n = 2).
d Including number of patients with 1 or more of the following: chest radiograph or abdominal ultrasound features of tuberculosis and acid-fast bacilli seen or
M. tuberculosis cultured from specimen other than cerebrospinal fluid.
e Including features compatible with TBM: hydrocephalus, meningeal enhancement, tuberculoma, and infarct.










Table 2. Serial Blood and Cerebrospinal Fluid Findings in Patients Who Developed Tuberculous Meningitis Immune Reconstitution
Inflammatory Syndrome (TBM-IRIS) and Those Who Did Not (non-TBM-IRIS)
TBM-IRIS Non-TBM-IRIS
Median (IQR) Median (IQR) P Valuec
Blood
C-reactive protein, mg/L
TBM diagnosis 45 (13–98) 25 (1–71) .22
ART start 6 (4–15) 8 (1–20) .64
2 wk after ART start 56 (20–105) 14 (6–63) .07
CD4 count, cells/μL
TBM diagnosis 131 (52–169) 102 (69–278) .79
ART start 93 (65–158) 145 (64–231) .40
2 wk after ART start 158 (139–193) 178 (103–261) .68
HIV load, log10
TBM diagnosis 5.39 (4.75–6.16) 5.60 (4.76–5.72) .83
ART start 5.61 (5.26–6.26) 5.30 (4.90–6.04) .13
2 wk after ART start 3.15 (2.50–3.36) 2.71 (2.43–2.98) .13
Cerebrospinal fluid
Protein, g/L
TBM diagnosis 2.70 (1.80–5.11) 1.88 (1.28–3.31) .24
ART start 1.63 (1.22–2.67) 0.94 (0.82–1.63) .03
2 wk after ART start/IRIS presentationa 3.11 (1.99–22.83) 0.61 (0.37–1.76) <.001
2 wk after IRIS presentationb 2.62 (2.24–12.74) … …
Glucose (CSF blood ratio)
TBM diagnosis 0.24 (0.15–0.31) 0.47 (0.28–0.57) .01
ART start 0.51 (0.43–0.55) 0.48 (0.38–0.57) .63
2 wk after ART start/IRIS presentationa 0.39 (0.33–0.43) 0.53 (0.37–0.59) .05
2 wk after IRIS presentationb 0.38 (0.34–0.48) … …
Neutrophil counts, ×106/L
TBM diagnosis 50 (15–86) 3 (0–44) .02
ART start 1 (0–4) 0 (0–5) .32
2 wk after ART start/IRIS presentationa 42 (17–244) 0 (0–3) <.001
2 wk after IRIS presentationb 3 (0–12) … …
Neutrophil proportion, % of cells per sample
TBM diagnosis 36 (6–53) 0 (0–12) .009
ART start 1 (1–11) 0 (0–18) .61
2 wk after ART start/IRIS presentationa 9 (4–22) 1 (0–33) .35
Lymphocyte counts, ×106/L
TBM diagnosis 218 (63–366) 93 (24–274) .36
ART start 110 (44–225) 41 (18–79) .02
2 wk after ART start/IRIS presentationa 177 (69–363) 25 (6–52) <.001
2 wk after IRIS presentationb 147 (98–405) … …
HIV load, log10
TBM diagnosis 6.35 (5.80–6.73) 5.60 (4.81–6.54) .05
ART start 5.56 (5.16–5.95) 5.40 (4.93–5.82) .27
2 wk after ART start 3.00 (2.24–3.67) 2.55 (2.42–2.80) .21
Definitions for TBM-IRIS and non-TBM-IRIS are taken from [16] and [18], respectively.
Abbreviations: ART, antiretroviral therapy; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; IQR, interquartile range; IRIS, immune reconstitution
inflammatory syndrome; TBM, tuberculous meningitis.
a For TBM-IRIS patients, results are reported for lumbar puncture performed at TBM-IRIS presentation, which occurred a median of 14 days after ART initiation.
b In 5 TBM-IRIS patients, lumbar puncture was not performed 2 weeks after TBM-IRIS because of death (n = 1), contraindication to lumbar puncture (n = 3), and
patient admitted to alternative facility (n = 1).
c P < .05 was considered statistically significant.










vomiting (n = 5), paraparesis (n = 3), myoclonic jerks (n = 1),
dysconjugate eye movements (n = 1), and aphasia (n = 1). At
time of TBM-IRIS presentation, 15 patients underwent brain
imaging, including computed tomography (n = 14) or magnet-
ic resonance imaging (n = 1). Imaging showed features of
TBM in 14 of these patients. Magnetic resonance imaging of
the spine was performed in 2 patients with paraparesis; both
had features of radiculomyelitis (Supplementary Figure 1).
Serial Blood and CSF Findings
Baseline blood investigations were similar between TBM-IRIS
and non-TBM-IRIS patients with the exception of serum
sodium concentrations, which were lower in TBM-IRIS pa-
tients (median, 123 vs 130 mmol/L, P = .01, Table 1). Table 2
and Figure 2 show serial blood and CSF findings. There was a
significant rise in CD4 counts between starting ART and 2
weeks later in both TBM-IRIS (median, 93–158 cells/μL,
P = .009) and non-TBM-IRIS (median, 145–178 cells/μL,
P = .04) patients. Between these time points, blood and CSF
HIV loads decreased significantly (P < .001) in both groups.
At TBM diagnosis, TBM-IRIS patients had higher CSF cell
counts, in particular neutrophils (median, 50 vs 3 cells ×106/L,
P = .02, Table 2). Similarly, neutrophil percentages from indi-
vidual samples were higher in TBM-IRIS patients compared
with non-TBM-IRIS patients (median, 36% vs 0%, P = .009).
CSF to blood glucose ratios were lower in TBM-IRIS patients
(median, 0.24 vs 0.47, P = .005). In both groups, CSF parame-
ters initially improved on tuberculosis treatment (Table 2 and
Figure 2). However, at TBM-IRIS presentation, TBM-IRIS pa-
tients showed findings of recurrent inflammation. In this
group, lymphocyte and neutrophil counts at TBM-IRIS pre-
sentation were similar, and protein concentrations higher,
compared with the same parameters at TBM diagnosis
(median protein, 3.11 g/L at TBM-IRIS vs 2.70 g/L at TBM
diagnosis, P = .007).
Mycobacterium tuberculosis was cultured from the CSF of
15 TBM-IRIS patients (94%) and 6 non-TBM-IRIS patients
(33%) at TBM diagnosis; the risk of developing TBM-IRIS if
CSF M. tuberculosis culture was positive at this time point was
71.4% (15/21), compared with a risk of 7.7% (1/13), corre-
sponding to an RR of 9.3 (95% CI, 1.4–62.2, P = .004). Addi-
tional analyses considered the RRs of culture positivity
adjusting for the following known or potential risk factors for
tuberculosis IRIS: baseline viral load (median, ≥330 000
copies/mL, equivalent to log10 = 5.52, vs <330 000), CD4
count (median, ≤137 cells/μL vs >137), evidence of dissemi-
nated disease in the form of an abnormal chest radiograph
suggesting miliary disease, and duration of illness (median du-
ration, ≥2 weeks vs <2 weeks). Mycobacterium tuberculosis
culture positivity remained a significant risk factor after ad-
justing for these factors (Supplementary Table 1). There was
no evidence of differences in the RRs according to these
factors after considering culture status. Some TBM-IRIS pa-
tients remained culture positive after 2 weeks (n = 7) and 4
weeks (n = 2) of tuberculosis treatment. No non-TBM-IRIS
patients were culture positive after starting tuberculosis treat-
ment. All cultures were fully drug sensitive with the exception
of one, which was monoresistant to isoniazid.
Analysis of Baseline CSF Neutrophil Count and Cytokine
Concentrations to Predict TBM-IRIS
Concentrations of the prespecified cytokines from which the
model to predict TBM-IRIS was developed are shown in Sup-
plementary Table 2 and Supplementary Figure 2. The final
multivariate logistic regression model included IFN-γ and
TNF-α and produced a cross-validated AUC of 0.91 (95% CI,
.53–.99, P = .02), indicating high diagnostic accuracy when
jointly considering these 2 cytokines to differentiate TBM-
IRIS from non-TBM-IRIS at time of TBM diagnosis. The
odds ratio (OR) for TNF-α was 1.85 (per 10 pg/mL, P = .006),
indicating an 85% increase in the odds of IRIS for every 10
pg/mL increase in TNF-α (after adjusting for IFN-γ). The OR
for IFN-γ was 0.64 (per 100 pg/mL, P = .01), indicating de-
creased odds of IRIS with increasing IFN-γ (after adjusting for
TNF-α). Figure 3 provides a heatmap representation of the
predicted probabilities of the resulting model with the ob-
served values overlaid. Neutrophil counts produced an AUC
of 0.72 (95% CI, .54–.90, P = .03), indicating modest discrimi-
natory accuracy for TBM-IRIS. However, including CSF neu-
trophil and lymphocyte counts in the model did not improve
its ability to predict TBM-IRIS.
Management and Outcome
In 13 patients prescribed prednisone (0.75–1.5 mg/kg/day),
the dose was increased at TBM-IRIS diagnosis. Prednisone
was restarted at a dose of 1.5 mg/kg/day in the other 3 TBM-
IRIS patients. The median total duration of corticosteroid
treatment in TBM-IRIS patients was 109 days (IQR, 69–141)
compared with 35 days (IQR, 20–43) in non-TBM-IRIS pa-
tients. ART was interrupted during TBM-IRIS in 1 patient
because of brainstem involvement. This patient made a full
recovery and had no recurrent symptoms after recommence-
ment of ART under prednisone cover. At 9 months’ follow-
up, all non-TBM-IRIS patients were alive (including 1 who
had defaulted study follow-up but continued tuberculosis
treatment from a primary care tuberculosis clinic), 2 had
marked cognitive impairment (international HIV dementia
scale <10) [26], and 1 patient had marked cognitive impair-
ment with residual hemiparesis. Twelve IRIS patients (75%)
were alive at 9 months’ follow-up, 2 patients showed marked
cognitive impairment, 1 patient defaulted study follow-up but
was alive, and 1 had marked cognitive impairment, residual










Figure 2. Serial cerebrospinal fluid (CSF) findings in patients who developed tuberculous meningitis immune reconstitution inflammatory syndrome
(left), and those who did not (right), including protein concentrations (A), CSF to blood glucose ratios (B ), neutrophil counts (C ), and lymphocyte counts
(D ). Significant differences (P < .05) between time points within groups are indicated. Abbreviations: ART; antiretroviral therapy, CSF cerebrospinal fluid;
IRIS; immune reconstitution inflammatory syndrome; TBM, tuberculous meningitis.










hemiparesis, and hearing impairment. Death occurred in 4
(25%) TBM-IRIS patients at 33, 53, 60, and 118 days after
TBM diagnosis and was related to TBM-IRIS in 2 patients.
The 2 other deaths were due to a road traffic accident (n = 1)
and unknown cause (n = 1). Kaplan-Meier survival analysis by
TBM-IRIS vs non-IRIS (with a log-rank hypothesis test of the
difference in survival between these 2) was nonsignificant.
DISCUSSION
This is the first prospective study of TBM-IRIS. In our cohort,
tuberculosis IRIS presenting as TBM-IRIS (47%), as well as
tuberculosis IRIS involving any organ system (56%), was more
frequent than in previous studies [2–4, 27]. Extrapulmonary
tuberculosis is a risk factor for tuberculosis IRIS [14, 28], and
our cohort included only patients with TBM. A shorter inter-
val between starting tuberculosis treatment and ART (which
was 2 weeks in our study) similarly increases the risk of tuber-
culosis IRIS [2–4]. The high TBM-IRIS incidence we observed
is striking considering that all TBM-IRIS patients were taking
prednisone (1.5 mg/kg/day) at time of ART initiation and 13
of these patients (81%) were taking prednisone (0.75–1.5 mg/
kg/day) at the time of developing TBM-IRIS. Adjunctive corti-
costeroids have been shown to reduce mortality in TBM and
tuberculosis pericarditis, presumably by reducing pathological
host immune responses [21, 29]. In paradoxical tuberculosis
IRIS, the symptomatic benefit of corticosteroids was demon-
strated in a randomized trial in which prednisone was com-
pared to placebo [30]. For these reasons, we anticipated that
prednisone would decrease the risk of tuberculosis IRIS.
TBM-IRIS was associated with a poor outcome; 2 patients
(13%) died as a result of TBM-IRIS, all-cause mortality at 9
months was 25%, and 3 of 11 (27%) survivors examined at 9
months’ follow-up were severely disabled, compared with no
deaths and 3 of 17 (18%) patients with severe morbidity in the
non-TBM-IRIS group. Our findings are similar to a previous
study performed in neurological tuberculosis IRIS [8]. The
poor outcome in at least 44% of TBM-IRIS cases emphasizes
Figure 3. Predictive model for tuberculous meningitis immune reconstitution inflammatory syndrome (TBM-IRIS; patients depicted by gray triangles)
and non-TBM-IRIS (patients depicted by black circles). Tumor necrosis factor–α and interferon-γ concentrations (pg/mL) are reported. Darker gray
indicates greater probability of TBM-IRIS, while lighter gray indicates greater probability of not developing TBM-IRIS. Probabilities associated with
shading are indicated by the legend. The middle line indicates 50% chance of TBM-IRIS, while the upper and lower gray lines indicate probabilities of
90% and 10%, respectively. Observe that when using the median line to classify patients as TBM-IRIS or non-TBM-IRIS, all but 2 TBM-IRIS and 1 non-
TBM-IRIS patients are correctly classified. Several points in the lower left were moved marginally to the right so that all subjects are clearly identifiable.
Abbreviations: IFN, interferon; TNF, tumor necrosis factor.










the need to predict and prevent, and improve the treatment of,
TBM-IRIS.
Low serum sodium concentration is associated with death
in HIV-associated TBM [31]. In our study, serum sodium
concentration was lower in TBM-IRIS patients compared with
non-TBM-IRIS patients at the time of TBM diagnosis. This
may reflect the higher degree of tuberculosis dissemination
observed in TBM-IRIS patients, which could have contributed
to their risk of developing TBM-IRIS.
Our finding of an association between higher CSF neutro-
phils at TBM presentation and subsequent development of
TBM-IRIS provides important and novel insight into the path-
ogenesis of tuberculosis IRIS. Not only were neutrophil counts
higher in TBM-IRIS patients compared with non-TBM-IRIS
patients, but neutrophil percentages for individual patients
were similarly raised in TBM-IRIS. The neutrophil counts
showed dynamic fluctuations over time in TBM-IRIS patients
with a marked decrease on tuberculosis treatment, and a strik-
ing increase at TBM-IRIS onset. Similar changes in lympho-
cyte counts were not observed. Studies of tuberculosis IRIS
have hitherto focused on the contribution of helper T-cell
type 1 lymphocyte responses [32, 33]. However, a role for
myeloid cells in tuberculosis IRIS is suggested by a case report
of a patient who died from unmasking pulmonary tuberculosis
IRIS; postmortem histological examination of diseased lung
showed a marked macrophage infiltrate [34]. We have found
cytokines of predominantly myeloid origin (IL-6 and TNF-α)
to be consistently elevated in patients with tuberculosis IRIS,
compared with those who did not develop IRIS [23]. Oliver
et al [6] also reported an association between plasma cytokines
(interleukin 18) and chemokines (CXCL-10) of the innate
immune system and tuberculosis IRIS. In an animal model,
immune reconstitution following transfer of mycobacteria-
specific CD4 T cells to T-cell–deficient mice infected with
Mycobacterium avium was associated with marked increases
of both blood and lung CD11b cells (likely representing in-
flammatory monocytes and neutrophils) [35]. Our results
suggest that neutrophils contribute to tuberculosis IRIS patho-
genesis. The combination of high CSF TNF-α and low IFN-γ
concentrations at the time of TBM diagnosis predicted TBM-
IRIS in this cohort. Simmons et al [36] reported a negative
correlation between CSF IFN-γ and mortality in HIV-infected
patients with TBM. Conversely, a positive correlation was
found between CSF IFN-γ and TNF-α concentrations and
TBM disease severity by others [37].
Several studies have shown an association between dissemi-
nated and extrapulmonary tuberculosis and subsequent tuber-
culosis IRIS [14, 28, 38, 39]. At TBM diagnosis, CSF M.
tuberculosis culture positivity, which reflects mycobacterial
antigen load, was a major risk factor for developing TBM-IRIS
(RR = 9.3). Furthermore, 7 TBM-IRIS patients (44%) were
persistently CSF M. tuberculosis culture positive after 2 weeks
of tuberculosis treatment and 2 patients (13%) remained
culture positive after 4 weeks of tuberculosis treatment. This
strongly supports the inference that a high M. tuberculosis ba-
cillary load at time of starting ART is a risk factor for tubercu-
losis IRIS [40]. The findings suggest it important to optimize
tuberculosis treatment prior to starting ART in patients at
high risk of developing TBM-IRIS.
We acknowledge several limitations. Because of the relative-
ly small sample size, the study may not have been powered to
detect further differences between IRIS and non-TBM-IRIS
patients. Only patients with less severe disease (BMRC TBM
grade 1 and 2) and those without contraindications to lumbar
puncture were enrolled, resulting in the exclusion of a signifi-
cant proportion of TBM patients presenting in our setting
[41]; our results may therefore not be generalizable to ART-
naive patients presenting with severe HIV-associated TBM.
The model to predict TBM-IRIS needs further validation and
exploration with independent data.
In conclusion TBM-IRIS complicated the course of treat-
ment of HIV-associated TBM in nearly half our patients,
despite the use of adjunctive corticosteroid therapy. The mani-
festations were severe, fatal in 2 cases. The occurrence of
TBM-IRIS associated with CSF M. tuberculosis culture positiv-
ity and a high neutrophil count at both baseline and at the
time of TBM-IRIS. The baseline relationship between CSF
TNF-α and IFN-γ predicted TBM-IRIS. These observations
provide novel insight into the pathogenesis of this condition
and provide rationale to individualize ART beyond 2 weeks in
this devastating, partly iatrogenic, condition.
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Neutrophil-associated central nervous system 
inflammation in tuberculous meningitis immune 
reconstitution inflammatory syndrome: A 
prospective observational study
Introduction 
As a consequence of rapid scale-up of antiretroviral therapy (ART) 
programs, tuberculosis-associated immune reconstitution inflammatory 
syndrome (TB-IRIS) is a significant contributor to the health-care burden 
in high TB/HIV co-infection settings.1-3 Paradoxical TB-IRIS presents as 
clinical deterioration after starting ART in TB patients who have improved 
or stabilized on TB treatment prior to ART initiation.4 This deterioration 
occurs in the context of a rapid restoration of Mycobacterium tuberculosis-
specific immune responses. The central nervous system (CNS) is 
commonly affected by TB-IRIS with 12-31% of TB-IRIS cases experiencing 
neurological deterioration.5-7 Neurological TB-IRIS is the most severe form 
of TB-IRIS, with an associated mortality of 13-75%,3, 5-7 as opposed to the 
3.2% estimate for all forms of paradoxical TB-IRIS combined.8 
Although recent studies have advanced our understanding of TB-IRIS 
through the identification of several cellular, immunological and genetic 
factors that associate with the syndrome, the immunopathogenesis 
remains incompletely defined and no diagnostic test exists.9 Thus far 
explorations of the immune response in TB-IRIS pathogenesis have been 
of those measured in the blood compartment, which is likely an incomplete 
representation of the immune response in affected tissues, e.g. lungs or 
CNS. The objective of this study was to better understand the pathogenesis 
of tuberculous meningitis (TBM)-IRIS. We hypothesised that cerebrospinal 
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fluid (CSF) inflammatory mediator concentrations will be increased in TBM 
patients who develop TBM-IRIS, compared to patients who do not develop 
TBM-IRIS.
Methods
Study design, setting and participants
We conducted a prospective, observational study at a public sector referral 
hospital in Cape Town, South Africa. ART-naïve HIV-infected adults who 
presented with TBM were recruited over a 20-month period. A detailed 
description of the clinical methods has previously been published.3 
Tuberculous meningitis was diagnosed according to a published case 
definition.10 ART-naïve HIV-infected adults without meningitis who presented 
with symptoms and/or signs necessitating a lumbar puncture (LP) were 
enrolled as control participants. The University of Cape Town Human 
Research Ethics Committee approved the study (232/2008). Additional 
details on participants are available in the appendix.
Procedure
We investigated serial inflammatory mediators in CSF (40 mediators) and 
blood (33 mediators) from HIV-associated TBM patients who started ART 
while on TB treatment. Paired samples were collected from patients who 
presented with TBM at three to five timepoints shown in Figure 1. Samples 
were collected at one timepoint in control participants. Samples were 
stored at -80°C and analyzed in batches as detailed below. 
The primary outcome measure was CSF mediator concentrations in TBM 
patients who did and did not develop TBM-IRIS at time of TBM-IRIS (TBM-
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IRIS patients) and two weeks after ART initiation (TBM-non-IRIS patients). 
The two weeks after ART initiation timepoint in TBM-non-IRIS patients was 
informed by the median time (14 days after ART initiation) reported for TB-
IRIS development.4 Secondary analyses of CSF and blood results were 
as follows: i) Baseline results were compared between TBM patients and 
control patients; ii) Within the TBM group, results were compared between 
TBM-IRIS and TBM-non-IRIS patients at TBM diagnosis and 2 weeks later 
(i.e. day of starting ART); Within the TBM-IRIS and TBM-non-IRIS groups, 
results were compared longitudinally between all timepoints; Within all 
groups (i.e. TBM, control, TBM-IRIS and TBM-non-IRIS) blood results were 
compared to CSF results at all timepoints.
Mediators analysed in CSF and serum by Luminex multiplex included: 
tumor necrosis factor (TNF), interferon (IFN)-γ, interleukin (IL)-2, IL-4, IL-
10, IL-13, IL-1β, IL-6, IL-12p40, IL-17, IFN-α2, C-C chemokine 2 ligand 
(CCL2), CCL3, CCL4, C-X-C chemokine ligand 1-3 (CXCL1-3), CXCL8, 
granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage 
(GM)-CSF. Matrix metalloproteinases (MMP)-1, -2, -3, -7, -9, -10, -12, and 
-13, and tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2 
were measured in CSF and plasma by Luminex multiplex. Luminex assays 
were performed in 96-well filter plates on the Bio-Plex platform (Bio-Rad 
Laboratories, Hercules, CA, USA) using customized MilliplexTM kits (Millipore, 
St Charles, MO, USA). Mediators measured by ELISA in CSF and serum 
included:  CXCL10, IL-22 and IL-23 (R & D Systems, Minneapolis, USA); IL-
21 (BioLegend, San Diego, USA); and IL-12p70 and IL-17A (high sensitivity 
assay) (eBioscience, Inc., San Diego, USA). CSF was also analysed 
by ELISA for IL-18  (Medical and Biological Laboratories Co, Naka-ku 
Nagoya, Japan) and neutrophil-associated mediators: cathepsin G (DRG 
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Diagnostics, Marburg, Germany); lipocalin-2 (RayBiotech inc. Norcross, 
USA); and LL-37, human neutrophil peptides (HNP) 1-3, complement (C) 
5a, and S100A8/A9 (Hycult Biotech inc., Uden, The Netherlands). See 
appendix for supplementary methods.
Statistical analysis
As no TBM-IRIS pilot data were available for statistical powering at study 
inception, we based our power calculations on previous TBM studies that 
determined CSF cytokine concentrations at TBM diagnosis11 and fold 
reductions in CSF cytokine concentrations on TB treatment.12 We estimated 
that for the primary analysis, a sample size of 15 patients in each group 
(TBM-IRIS and TBM-non-IRIS) was needed to detect a 2·1 fold difference 
in mediator concentrations, with β=0·8 and α=0·05. Statistical analysis was 
performed using GraphPad Prism version 5 (Graphpad software, inc.) and 
R version 3·0.13 Variables were compared between groups using Wilcoxon 
rank-sum tests. Variables between timepoints, and between blood and 
CSF compartments, within groups were compared using Wilcoxon 
matched-pairs tests. Correlations were estimated by Kendall’s tau (τ). 
Unsupervised agglomerative hierarchical clustering using complete 
linkage and Euclidean distance measure on all included mediators in CSF 
and individuals was performed. Clusterwise stability was assessed by two 
resampling schemes (bootstrap and subsetting; 100 resampling runs) and 
the Jaccard similarities computed.14, 15 Throughout, an unadjusted p-value 
of less than 0·05 was used as a nominal threshold for statistical significance, 
except for the correlation analysis which reports false discovery rate-
adjusted (Benjamini and Hochberg) p-values.16 Due to the large number of 
statistical tests the p-value should be used for guidance in interpretation 
rather than finality. See appendix for details on multivariate analysis.
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Role of the funding source
The sponsors had no role in study design; data collection, analysis 
and interpretation; writing of the manuscript or the decision to submit 
for publication and accept no liability whatsoever in this regard. The 
corresponding author had full access to all the data in the study and had 
the final responsibility for the decision to submit for publication.
Results
Details of recruitment, clinical characteristics and follow-up were previously 
reported for the TBM group.3 Eighteen patients with no meningitis were 
enrolled as controls. These patients were seen once (at presentation) only. 
Due to limited space on mediator analysis plates, 4/18 control patients were 
excluded from the analysis. To match the CD4 counts of TBM patients, 
the 14 controls with the lowest CD4 counts were selected for analysis. 
The demographic characteristics and baseline blood results of TBM (n=34) 
and control (n=14) patients are presented in Table 1. Sixteen TBM patients 
developed TBM-IRIS, a median of 14 days (IQR, 4-20) after starting ART, 
whilst 18 did not.3 Of note, 15/16 TBM-IRIS and 6/18 TBM-non-IRIS patients 
cultured M. tuberculosis from CSF at TBM diagnosis. 
IL-2, IL-4, IL-12p70, IL-13, IL-21, IL-23, MMP-12, and MMP-13 were 
excluded from all analyses due to minimal or no detection in CSF and blood 
at all timepoints (see appendix for further details). When comparing TBM 
patients (i.e. TBM-IRIS and TBM-non-IRIS combined) to patients with no 
meningitis at presentation, TBM patients had significantly higher (p<0·05) 
CSF concentrations of 28/32 mediators; only CCL2 and IL-17 were similar, 
and IL-18 and C5a had medians equal to zero in both groups (appendix 
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Table S2). Conversely, only 6/25 mediators in blood were different between 
groups; IFN-γ, IL-6, CXCL8, CXCL10, and MMP-3 concentrations were 
higher in TBM patients (p<0·05), whilst CCL2 was higher in controls 
(p=0·045). 
Within the TBM group at the time of TBM diagnosis, cytokine and 
chemokine concentrations were significantly higher in CSF than in blood 
with the exception of IL-12p40, which showed comparable levels in blood 
and CSF, and CXCL1-3, which showed a higher trend (p=0·056) in blood 
(appendix Table S2). Conversely, of the MMP, MMP-1, -2 -3, -7 and -10 
levels were significantly higher in blood compared to CSF, and only MMP-
9 as well as its inhibitor TIMP-1, were increased in CSF relative to blood 
(p<0·001). Within the control group, blood cytokine, chemokine, MMP, 
and TIMP concentrations were either similar to, or increased compared to 
CSF concentrations, with the exceptions of G-CSF, IFN-α2, CCL2, CCL3, 
and CXCL8 that were higher in CSF. Consistent with the combined TBM 
group, a highly compartmentalized inflammatory response was seen in 
both subgroups when dividing the TBM group into those who did and did 
not subsequently develop TBM-IRIS (Figure 2 and appendix Tables S3, S4 
and S5). 
At the time of TBM diagnosis the group who subsequently developed TBM-
IRIS showed significantly increased CSF Th1 (IFN-γ, IL-18) and other pro-
inflammatory cytokines (TNF, IL-6, IL-1β, G-CSF and GM-CSF), IFN-α2, 
chemokines (CCL2, -3, -4 and CXCL1-3, -8, -10), neutrophil-associated 
mediators (HNP1-3, lipocalin-2, C5a and S100A8/A9), MMP-1, -7 and 
-10, and TIMP-1 and -2, compared to TBM patients who did not develop 
TBM-IRIS (Figure 2 and appendix Table S3). Figure 3 and appendix Table 
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S6 show the changes in CSF mediator concentrations over time for TBM-
IRIS and TBM-non-IRIS patients. In both groups there was a significant 
decrease of the majority of mediators tested in CSF during TB treatment 
prior to starting ART. However, IL-12p40 and IL-17A showed a significant 
increase from baseline in TBM-IRIS, but not in TBM-non-IRIS patients, 
prior to starting ART. 
At TBM-IRIS presentation (compared to two weeks after ART initiation in 
TBM-non-IRIS patients), TBM-IRIS patients showed significantly higher 
CSF concentrations for all mediators (31/32) except IFN-α2 (Figure 2 
and appendix Table S5). ART was associated with marked rises in CSF 
inflammatory mediator concentrations in TBM-IRIS patients, despite 
adjunctive corticosteroid therapy (13/16 patients were still receiving 
prednisone), such that concentrations reached similar or higher levels 
at TBM-IRIS presentation, approximately two weeks after ART initiation, 
compared to those at TBM presentation  (appendix Table S6A). Conversely, 
in TBM-non-IRIS there were no significant CSF changes observed between 
starting ART and two weeks thereafter (appendix Table S6B). Moreover, 
when comparing findings between samples taken two weeks after starting 
ART to those from TBM diagnosis in TBM-non-IRIS, a significant decrease 
in CSF concentrations of G-CSF, GM-CSF, CCL3, CCL4, TNF, IFN-γ, IL-
6, CXCL8, CXCL10, lipocalin-2, S100A8/A9, MMP-10, and TIMP-1 was 
noted. This suggests that the rise in CSF mediators observed in TBM-
IRIS two weeks following ART reflected IRIS development, not simply ART 
prescription. 
Samples taken two weeks after TBM-IRIS presentation were available for 
analysis in 10/16 TBM-IRIS patients as death (n=1) and contra-indication 
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to LP (n=5) precluded CSF sampling in the others. Compared to mediator 
concentrations at TBM-IRIS presentation (when prednisone was restarted 
or the dose increased), the only significant changes in CSF mediators were 
decreased concentrations of G-CSF (p=0·039) and LL-37 (p=0·016), two 
weeks post TBM-IRIS.
At TBM diagnosis, blood concentrations were similar between TBM-
IRIS and TBM-non-IRIS with the exception of IFN-α2 (p=0·030), CXCL8 
(p=0·0049), and MMP-1 (p=0·037), which were higher in TBM-IRIS patients 
(Figure 2 and appendix Table S3). CXCL8 remained elevated in TBM-IRIS at 
time of starting ART (p=0·017; Figure 2 and appendix Table S4). Two weeks 
after starting ART, CCL4, TNF, IFN-γ, MMP-7 (p-value for all<0·05, >0·01), 
and CXCL8 and CXCL10 (p-value for both <0·01, >0·001) were elevated 
in blood of TBM-IRIS compared to TBM-non-IRIS patients, whilst TIMP-2 
was higher in TBM-non-IRIS (p=0·046, Figure 2 and appendix Table S5). 
Unsupervised hierarchical clustering of TBM patients by CSF mediators 
showed that TBM-non-IRIS patients who were culture positive for M. 
tuberculosis from CSF at TBM diagnosis tended to cluster with TBM-IRIS 
patients at all timepoints (Figure 4 and Jaccard similarity indexes are shown 
in appendix Table S7).  TBM-non-IRIS patients who were culture-positive 
showed mediator profiles more similar to TBM-IRIS patients than to culture-
negative TBM-non-IRIS patients, at TBM diagnosis (appendix Table S8), 
and further had increasing concentrations of a number of mediators after 
starting ART (Figure 3). Appendix Table S9 shows the similarities between 
CSF findings in CSF culture-positive TBM-non-IRIS patients and TBM-
IRIS patients, and the differences between culture-positive and culture-
negative TBM-non-IRIS patients, two weeks after starting ART. Of note, 
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neutrophil counts and S100A8/A9 distinguished culture-positive TBM-non-
IRIS patients from TBM-IRIS patients: neutrophils differentiated them at 
baseline (median [IQR], 3 [0-14] vs 38 [11-117] cells x 106/L, p=0·020) and 
at two weeks after ART initiation  (2 [0-11] vs 52 [17-244] cells x 106/L, 
p=0·0027), while S100A8/A9 differentiated them two weeks after ART 
(15346 [0-19152] vs 33500 [27000-48000] pg/ml, p=0·001). 
Correlation analyses showed no biologically significant correlations 
between neutrophil and lymphocyte counts and mediator concentrations in 
CSF of TBM-IRIS and TBM-non-IRIS patients over time (appendix Figures 
S1-3 and Table S10).
Discussion
This is the only comprehensive analysis to date of serial CSF and blood 
immune mediators in TBM-IRIS. Neutrophils, lymphocytes and total protein 
concentrations,3 as well as 31/32 analysed mediators (all except IFN-α2), 
were elevated in TBM-IRIS compared to TBM-non-IRIS patients two weeks 
after starting ART. This widespread upregulation of diverse mediators of 
diverse cellular functions suggests that both innate and adaptive immune 
responses are involved in TBM-IRIS pathogenesis. 
Adjunctive corticosteroid treatment is associated with reduced short-
term mortality in HIV-uninfected patients with TBM,17 and symptomatic 
improvement in TB-IRIS.1 In our study, an increased inflammatory response 
was observed after ART initiation in TBM-IRIS patients despite adjunctive 
corticosteroid therapy. Furthermore, a decrease of only two mediators was 
observed two weeks after corticosteroids were increased or restarted at 
TBM-IRIS presentation. Previous studies in TBM patients also found little 
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effect of corticosteroids on CSF cytokine or chemokine concentrations.12 
Cerebrospinal fluid concentrations of MMP-9 were shown to decrease in 
patients on dexamethasone compared to controls early during the treatment 
of TBM and it was postulated that this may represent a mechanism by which 
corticosteroids improve outcome in these patients.18 However, in our study 
MMP-9 did not change after TB treatment (plus corticosteroid) initiation 
in either TBM-IRIS or TBM-non-IRIS patients, and increased significantly 
after ART initiation in the TBM-IRIS group. These findings suggest that 
immunomodulatory treatment options more potent and specific than 
corticosteroids need to be derived for the prevention and/or management 
of TBM-IRIS.
As previously reported for extra-pulmonary TB, including TBM,11 pleural19 
and pericardial TB,20 a highly compartmentalized inflammatory response in 
CSF was seen in patients with TBM. Relatively fewer differences between 
TBM-IRIS and TBM-non-IRIS groups were observed for mediators in 
blood compared to the differences observed in CSF. Corticosteroids do 
modulate blood inflammatory responses in TB/HIV co-infected persons21, 22 
and likely further attenuated differences between these groups subsequent 
to TBM presentation once patients were started on TB treatment and 
corticosteroids. 
High baseline CSF mycobacterial load (reflected by M. tuberculosis culture 
positivity) is a risk factor for subsequent TBM-IRIS in TBM patients.3 
This is similar to cryptococcal meningitis (CM)-IRIS where high CSF 
fungal loads (reflected by quantitative culture) at time of CM diagnosis 
also predict subsequent IRIS.23 However, unlike the highly inflammatory 
baseline presentation being predictive of TBM-IRIS, paradoxical CM-IRIS 
Page | 113
is predicted by a paucity of inflammation at CM diagnosis as evidenced by 
a lack of CSF leukocytes and/or normal protein level 23,24 and lower serum 
levels of pro-inflammatory cytokines and chemokines (IL-6, CXCL8, TNF, 
and IFN-γ).24 These differing findings in TBM and CM suggest more than 
one pathogenic mechanism underlies neurological forms of IRIS. 
In this study TBM-non-IRIS patients who were culture-positive for M. 
tuberculosis from CSF at TBM diagnosis tended to have higher baseline 
mediator concentrations than culture-negative TBM-non-IRIS patients and 
showed a recurrent inflammatory response after ART initiation, reaching 
levels of magnitude comparable to those in TBM-IRIS two weeks after ART 
initiation. These increases in mediator concentrations were not seen in 
culture-negative TBM-non-IRIS patients. Drug choice, doses and the route 
of administration in TBM are based on the same principles as pulmonary 
TB, rather than being informed by randomized controlled trials in TBM.25 Our 
data supports increased research into antimicrobial regimens containing 
higher-than-normal dose rifampicin as well as a fluoroquinolone.26, 27 Given 
that mycobacterial load drives inflammation on ART it is plausible that 
improving early mycobacterial clearance from the CNS in HIV-associated 
TBM patients through a more potent TBM drug regimen may decrease the 
risk of TBM-IRIS. 
Although initial studies explored the role of lymphocytes in TB-IRIS 
pathogenesis, increasing evidence implicates the innate immune system 
as an important contributor,9 and it is proposed that neutrophils mediate 
TB pathology.28 Based on these results and the association we found 
between CSF neutrophils and TBM-IRIS,3 we investigated neutrophil-
associated mediators in the CSF of our cohort. S100A8/A9, HNP 1-3, 
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lipocalin-2 and C5a were increased at TBM diagnosis, and all measured 
neutrophil-associated mediators were increased two weeks after starting 
ART, in TBM-IRIS compared to TBM-non-IRIS patients. Unlike the other 
neutrophil-associated mediators but similar to neutrophils, S100A8/A9 
was also increased in TBM-IRIS compared to TBM-non-IRIS patients with 
baseline CSF culture-positivity two weeks after ART initiation, when TBM-
IRIS usually presents. Given these findings, we hypothesise that S100A8/
A9, through its interaction with neutrophils, contributes to the recurrent 
CSF inflammatory response that manifests as clinical deterioration in 
patients with TBM-IRIS. S100A8/A9 is a protein complex that appears 
to have prominent immune regulatory properties, such as neutrophil 
chemoattraction and stimulation.29 Several studies have shown that 
serum S100A8/A9 is increased in HIV-uninfected pulmonary TB patients 
compared to controls, and that concentrations correlated with radiographic 
severity.30, 31 In a murine model of TB, IL-17-induced S100A8/A9 was a 
key factor in neutrophil accumulation and exacerbated lung inflammation 
through inducing pro-inflammatory cytokines.31 Given that IL-17 may 
therefore be important in TBM-IRIS pathogenesis, but considering the 
low concentrations previously found during in vivo studies in blood20, 32 as 
well as site-of-disease samples (i.e. pericardial and pleural fluid)20 in TB 
patients, we measured IL-17A with a high sensitivity assay. Cerebrospinal 
fluid IL-17A concentrations increased significantly over time in the TBM-
IRIS group, reaching concentrations more than eight-fold that of TBM 
diagnosis at TBM-IRIS presentation; while an opposite trend was seen in 
TBM-non-IRIS patients. These findings support previous suggestions that 
IL-17 may be important in TB-IRIS pathogenesis.32
The role of MMP as key mediators of TB pathology has attracted interest 
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recently,33 and their association with TB-IRIS has been reported.34 MMP 
degrade extracellular matrix components,35  and their activity is regulated 
by synchronously expressed TIMP.36 In our study, MMP-1 and -9 and TIMP-
1 and -2 were persistently elevated in the CSF of TBM-IRIS compared to 
TBM-non-IRIS patients at all timepoints. Furthermore, all MMP as well as 
the MMP-9:TIMP-1 ratio showed a significant increase after starting ART in 
CSF of TBM-IRIS patients. In a previous study of TB-IRIS patients, MMP-
7 was elevated in serum from TB-IRIS patients in vivo.34 We hypothesize 
that MMP contribute to the excessive CSF inflammation observed in TBM-
IRIS patients; evidence suggests that MMP not only facilitate blood-brain-
barrier disruption, which results in leucocyte influx,37,38 but also upregulate 
microglial secretion of cytokines.39 Furthermore, elevated CSF MMP-940-42 
and MMP-240 concentrations and increased MMP-9:TIMP-1 ratios41 have 
been associated with poorer outcome, including death42 and neurological 
complications, in TBM patients.40, 41 
While this is the first comprehensive analysis hitherto of disease site 
coupled with blood immune mediators in TB-IRIS, we acknowledge certain 
limitations. We did not include HIV-uninfected patients with TBM as controls 
and we excluded patients with neurological deterioration prior to starting 
ART. We were therefore unable to compare the inflammatory response in 
TBM-IRIS to that of the “paradoxical reaction” characterized by neurological 
deterioration and which can occur in both HIV-infected and -uninfected 
patients with TBM after starting TB treatment.43 This is a descriptive study 
of mediators in TBM patients over time; cellular contributions to mediator 
production in CSF and blood compartment were not determined by 
functional experiments and will be the focus of future studies. 
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Our findings have several important implications. Firstly, adjunctive oral 
corticosteroid therapy during TBM treatment is insufficient to prevent, or to 
rapidly reduce, the marked inflammatory response that characterizes TBM-
IRIS; in addition to investigations of different corticosteroid doses and routes 
of administration in the management of severe TB-IRIS cases by randomized 
trials, alternative immunomodulatory therapies should be explored for the 
prevention and treatment of the disease. Secondly, although the adaptive 
immune system appears to be activated in TBM-IRIS, the sequence of 
immunological events in the CNS suggests a major contribution of the 
innate response in this condition. CSF neutrophils, which may be driven 
through a IL-17 and S100A8/A9-dependent pathway, associate with the 
most severe CNS inflammation manifesting as TBM-IRIS; these findings 
are likely to direct future research into TB-IRIS immunopathogenesis and 
management strategies.
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Panel: Research in context
Systematic review
We searched Pubmed up to Dec 2013, with no date limits set, with 
the terms “ tuberculosis and immune reconstitution inflammatory 
syndrome”,  “tuberculosis and immune restoration disease”, tuberculosis-
associated immune reconstitution syndrome”, “tuberculous meningitis”, 
and “neurological tuberculosis”. We also searched reference lists of 
identified papers. We included studies published in English that assessed 
tuberculosis-associated immune reconstitution inflammatory syndrome 
(TB-IRIS) disease and those that assessed immunopathogenic mechanisms 
of TB-IRIS and tuberculous meningitis (TBM). We only included studies 
for which we had access to the full text version. A systematic review 
of the immunopathogenesis of TB-IRIS performed by our group was 
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recently published.9 Systematic review of the literature further revealed 
that, although several studies have investigated blood immune markers 
in TB-IRIS, only one study of site-of-disease findings in TB-IRIS exists.3 
This study, performed on the same cohort of TBM patients presented in 
this manuscript, suggested an important role for neutrophils and baseline 
cerebrospinal fluid mycobacterial load in TBM-IRIS pathogenesis.
Interpretation
Aside from our previous publication,3 we know of no other study to 
investigate inflammatory markers from the site-of-disease in patients with 
TB-IRIS. Findings from this study contribute significantly to knowledge of 
the immunopathogenic process that occurs in the central nervous system 
of patients with TBM-IRIS; our results extend data from our previous 
study by providing additional evidence for a prominent role of the innate 
immune system in TB-IRIS pathogenesis. These results are likely to guide 
future immunopathogenic, and ultimately therapeutic studies in TB-IRIS, 
regardless of the disease site. 
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Figure legends and footnotes
Figure 1.  Flow diagram of timepoints when lumbar puncture and 
phlebotomy were performed in tuberculous meningitis (TBM) patients. 
Drug interventions are indicated at each timepoint (grey boxes)
Procedures were performed at a minimum of three timepoints: 1) TBM 
diagnosis; 2) antiretroviral treatment (ART) initiation; and 3) two weeks 
after ART initiation or TBM-IRIS presentation, which ever occurred first. 
Patients who developed TBM-IRIS after the “two weeks post ART initiation” 
timepoint underwent repeat procedures at TBM-IRIS presentation. Unless 
a lumbar puncture was contra-indicated, procedures were repeated in 
TBM-IRIS patients two weeks after TBM-IRIS presentation. 
Figure 2. Boxplots of mediator concentrations over time in A) 
cerebrospinal fluid and B) blood l† of patients who developed TBM-
IRIS (red)* and those who did not (blue).
Definitions of abbreviations: TBM, tuberculous meningitis; ART, antiretroviral 
therapy; wks; weeks 
The assays’ limits of detection have been substituted for zero values. Note 
the left y-axis is a log 10 scale. The right y-axis indicates timepoints of 
sample collection. Within graphs, boxes with horizontal lines represent 
interquartile ranges and medians. Raw data points are overlaid. See Tables 
E3, E4 and E5 for p-values of analyses between groups.
† Blood mediators with medians equal to zero at all timepoints in both 
groups are not shown.
* For patients who developed TBM-IRIS, the “2 weeks post ART” timepoint 
indicates findings at time of TBM-IRIS that developed at a median of 14 
days (interquartile range, 4-20) after starting ART.
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Concentrations of all mediators were measured as picograms per milliliter 
with the exception of Cathepsin G, which was measured in units per milliliter.
Figure 3. Representative examples of changes over time of 
cerebrospinal fluid (CSF) mediators in patients who developed TBM-
IRIS (n=16, red) and those who did not (n=18, blue). 
Definitions of abbreviations: TBM, tuberculous meningitis; ART, antiretroviral 
therapy
For patients who developed TBM-IRIS, the “2 weeks post ART” timepoint 
indicates findings at time of TBM-IRIS that developed at a median of 14 
days (interquartile range, 4-20) after starting ART.
Note that some TBM-non-IRIS patients showed an increase in mediator 
concentration and MMP-9:TIMP-1 ratio after starting ART; these patients 
were those who were culture positive for M. tuberculosis from CSF at time 
of TBM diagnosis.
Figure 4. Unsupervised hierarchical clustering of tuberculous 
meningitis (TBM) at A) TBM diagnosis, B) ART start and C) TBM-IRIS 
presentation or 2 weeks after ART (non-TBM-IRIS patients).
IRIS status: Indicates patients who developed TBM-IRIS in red and those 
who did not in blue.
TB Culture status: Black and green boxes indicate cerebrospinal fluid M. 
tuberculosis culture positivity and negativity, respectively at time of TBM 
diagnosis.
Results from cerebrospinal fluid analyses are reported.  Values plotted 
are natural log plus one. Corresponding concentrations in picograms per 
milliliter are indicated on the color key. Concentrations of all mediators 
were measured as picograms per milliliter with the exception of Cathepsin 
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G, which was measured in units per milliliter.  Neutrophils and lymphocytes 
were measured as cells x 106/L.
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Table 1. Baseline characteristics of patients presenting with 
tuberculous meningitis and controls without meningitis 
Tuberculous meningitis  (n=34) No meningitis * (n=14)
p-value
Age, years 33 (28-44) 34 (27-38) 0.95
Female, n (%) 15 (44) 9 (64) 0.34
Body mass index 20.0 (18.3-22.7) 20.5 (19.9-27.3) 0.17
Blood investigations
  Sodium (mmol/L) 129 (123-131) 135 (133-137) <0.0001
  Hemoglobin (g/dl) 11.4 (8.8-13.1) 12.4 (10.8-13.4) 0.10
  C-reactive protein (mg/L) 40 (6-78) 5 (1-8) 0.0052
  CD4 count (cells/mL) 113 (69-199) 129 (75-180) 0.91
  HIV viral load (log10) 5.46 (4.82-5.89) 4.87 (4.44-5.44) 0.061
Cerebrospinal fluid (CSF) investigations
  Lymphocyte count (x 106/L) 177 (87-339) 6 (2-13) <0.0001
  Neutrophil count (x 106/L) 20 (2-42) 0 (0-0) <0.0001
  Protein (g/L) 1.94 (1.29-3.06) 0.51 (0.38-0.87) <0.0001
  Glucose  (CSF:blood ratio) 0.30 (0.17-0.5) 0.53 (0.5-0.74) 0.0002
* Diagnoses include: HIV-associated psychosis (n=4), tension headache 
(n=4), generalized tonic-clonic seizures (n=2), meningioma (n=1), stroke 
(n=1), depression (n=1) and HIV-associated neurocognitive disorder (n=1).
Median and interquartile range is presented unless otherwise specified. 
P-values were calculated for comparisons between groups using 
Wilcoxon rank sum test for continuous variables and Fisher’s exact test 





Start TB treatment and prednisone (1.5 mg/kg/day)
2 weeks after TB treatment initiation 
Start antiretroviral therapy (ART)




2 weeks after TBM-IRIS diagnosis
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Figure 2
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ART-naïve HIV-infected adults (≥ 18 years) who presented with tuberculous 
meningitis (TBM) were recruited from March 2009 to October 2010. 
Lumbar puncture (LP) was repeated within 48 hours of TBM presentation 
in patients who had already a diagnostic LP performed. Definite TBM 
was retrospectively diagnosed when Mycobacterium tuberculosis was 
cultured from cerebrospinal fluid (CSF). Probable TBM was diagnosed 
when a patient showed clinical, laboratory or radiological features of 
TBM in the absence of other infective causes for presentation including 
bacteria, fungi, syphilis and if suspected, viruses.1 Paradoxical TBM-
immune reconstitution inflammatory syndrome (IRIS) was diagnosed 
according to a published definition for TB-IRIS modified for meningitis.2,3 
The definition had 3 components: (1) TBM diagnosis before starting 
ART and improvement on TB treatment prior to ART initiation; (2) onset 
of TBM-IRIS manifestations (ie, new, recurrent, or worsening clinical 
features of TBM) within 3 months of ART initiation; and (3) exclusion of 
alternative causes for clinical deterioration. As control participants, we 
enrolled HIV-infected ART-naïve adults (≥ 18 years) without a meningitis 
diagnosis who presented with symptoms and/or signs necessitating 
a lumbar puncture such as headache, cognitive decline or seizures. 
HIV infection itself is often associated with a mild to moderate CSF 
lymphocytic pleocytosis;4 we therefore did not exclude patients with a 
mild lymphocytosis (up to 25 cells x 106/L) as controls. Written informed 
consent was obtained from all patients or their relatives, if a patient was 
unable to provide informed consent.
Luminex multiplex and ELISA assays
All assays were performed according to manufacturer’s instructions. 
For Luminex multiplex experiments, all CSF and blood samples from 
an individual patient were assayed on the same plate.  Mediator 
concentrations were calculated with reference to a standard curve 
for each mediator derived from a range of concentrations of mediator 
standards assayed in the same manner as CSF and blood samples. 
Manufacturer supplied internal controls were used to validate standard 
curves. For ELISA experiments CSF and blood samples were assayed 





The median concentrations of IL-4, IL-12p70, IL-13, IL-21, IL-23 and 
MMP-12 were lower than the assay limit of detection in both blood and 
CSF in all subgroups (i.e. TBM-IRIS, TBM-non-IRIS and no meningitis 
patients) at all timepoints, whilst IL-2 (median <7pg/ml in TBM-IRIS 
patients at TBM diagnosis and starting ART) and MMP-13 (median=12pg/
ml in TBM-IRIS patients at TBM diagnosis) were minimally detected 
only in CSF of TBM-IRIS patients at the indicated timepoints. These 
mediators were therefore excluded from further analysis. 
Statistical analysis
A logistic multivariate model was developed (not shown) to predict 
TBM-IRIS from analytes measured in CSF at time of TBM diagnosis. 
The resulting model was extremely unstable due to a high degree of 
collinearity (as measured by variance inflation factor) and a small number 
of very high leverage individuals whereby removal resulted in instability 
in coefficient estimates. The variable selection process was flawed as 
standard methods (e.g. starting with those variables significant after a 
univariate test) would rest on a univariate test with low power (due to 
large proportion of values below the limit of detection). We therefore 
chose not to report the multivariate model as a supplement to univariate 
analyses.
Correlation between CSF mediators and white blood cell counts 
Figures S1, S2 and S3 show correlation between neutrophil and 
lymphocyte counts and mediator concentrations measured in CSF in 
TBM-IRIS and TBM-non-IRIS patients over time. Benjamini and Hochberg 
adjusted p-values are provided for correlation between cell types and 
mediators in Table S10.5 Notably, no significant correlation was observed 
between either cell type and any mediator in TBM-IRIS patients at any 
timepoint. A lack of significant correlation between mediators and 
cells was also observed in TBM-non-IRIS patients at TBM diagnosis. 
Although a statistically significant correlation between a minority of 
mediators and cell counts was observed at further timepoints in TBM-
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non-IRIS patients, these correlations were unlikely to be of biological 




Supplementary Table 1.  Sensitivities of Luminex multiplex and ELISA 
assays performed on mediators determined in cerebrospinal fluid (CSF) and 
blood
Units are picograms per milliliter except for Cathepsin G that is presented as units 
per milliliter
† For Luminex multiplex experiments, all CSF and blood samples from an individual 
patient were assayed on the same plate
* For ELISA experiments CSF and blood samples were assayed on separate plates
CSF Blood
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Tuberculous meningitis is a devastating disease in HIV-infected patients. 
Clinicians face numerous challenges in the management of HIV-associated 
TBM as diagnosing TBM is often difficult, the optimal treatment strategy 
for TBM is uncertain, and neurological TB-IRIS occurs in a substantial 
proportion of these patients. A better understanding of HIV-associated 
TBM is imperative to direct future local and international research with the 
ultimate aim of improving outcome in affected patients. South Africa is at 
the epicenter of the TB/HIV syndemic and in Cape Town, GF Jooste Hospital 
(until its temporary decommissioning in 2013) served those communities 
that are most affected by these diseases, providing an ideal setting to study 
HIV-associated TBM.
This thesis reports studies that investigated a continuum of pertinent 
aspects of HIV-associated TBM. In Chapter 3, a consensus case definition 
for use in TBM regardless of HIV-status is presented. Chapter 4 reports 
the disease burden and characteristics of HIV-associated TBM, and the 
contribution of neurological TB-IRIS to CNS deterioration during the first 
year of ART, in patients at a referral hospital in Cape Town. In Chapter 5 
the first prospective study of TBM-IRIS is described and finally, Chapter 6 
examines the immunopathogenesis of TBM-IRIS.
In the first study presented in Chapter 4 (Part 1 of Chapter 4), we report the 
clinical characteristics, frequency and outcome of definite, probable and 
possible TBM cases who presented to hospital over a 6-month period. We 
found that TBM accounted for more than 50% of adult meningitis cases 
and that 88% of affected patients were HIV-infected. The majority of HIV-
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infected TBM cases was severely immunosuppressed (median CD4 count: 
79 cells/mL), and was not receiving ART. We further found an increasing 
proportional contribution of TBM to meningitis cases over time; Jarvis et 
al. reported that during 2006-2008, CM was the most common cause of 
microbiologically confirmed meningitis (63%), compared to a minority of 
cases caused by M. tuberculosis (28%), at GF Jooste Hospital, whereas 
during our study period (March 2009-August 2009), TBM (44%) and CM 
(45%) contributed equally to this group. As discussed in Chapter 4, this 
proportional shift could be explained by the rapid increase in ART availability 
during this period, resulting in less patients reaching the severity of immune 
suppression that associates with CM. Our study emphasizes the poor 
outcome in TBM in spite of increased access to ART in the referral area; 
almost 50% of HIV-infected TBM patients were dead at 6-months follow-
up and the majority of deaths occurred during the first month of treatment. 
Risk factors identified for mortality in HIV-associated TBM included low 
CD4 count, more severe TBM disease (BMRC grade II and III versus I) 
and not receiving ART during TB treatment. These findings highlight the 
urgent need to identify and treat HIV infection prior to the development of 
severe immunosuppression, and the need for evidence-based treatment 
strategies in TBM. 
During the second study reported in Chapter 4 (Part 2 of Chapter 4) all 
patients who presented with CNS deterioration during the first year of 
ART over a 1-year period were enrolled, with the exception of those who 
presented with delirium secondary to a general medical condition. Seventy-
five patients met the inclusion criteria which provided an incidence of 
referral of 23.3 cases [95% CI; 18.3–29.2] per 1000 patient-years at risk. 
This high incidence rate emphasizes the significant morbidity caused by 
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CNS disorders in HIV-infected persons, in spite of them receiving ART. 
This study further provides a comprehensive description of the most 
common differential diagnoses to consider in patients who present with 
CNS deterioration after ART initiation in our and other high TB/HIV co-
infection settings. TB was the most frequent cause, accounting for 36% 
of cases, followed by CM that occurred in 24% of cases. Importantly, 
of patients who presented with CNS TB, the vast majority (16/27 cases) 
presented with paradoxical TB-IRIS. However, some other reasons for 
deterioration due to TB related to poor compliance to TB treatment in five, 
and MDR TB in two, patients respectively. These observations highlight the 
importance of obtaining a good history, and sending clinical specimens to 
rule out drug resistance, in neurological TB-IRIS suspects. Neurological 
TB-IRIS presented with diverse manifestations, including meningitis that 
was the most frequent manifestation, intracerebral tuberculoma (s), spinal 
arachnoiditis and a spinal epidural abscess. 15/16 TB-IRIS patients were 
alive, and outcome for one patient was unknown, at 6-months follow-up. 
Thirteen of these patients received corticosteroids during the IRIS episode, 
which might have contributed to their favorable outcome. However, a 
caveat is that a diagnosis could not be established in nine of 16 patients 
who presented with intracerebral space occupying lesions and of these 
nine, six were dead at 6-months follow-up. It is possible that some of these 
cases had TB-IRIS (manifesting as tuberculomas) and died as a result, and 
that we therefore underestimated the mortality associated with neurological 
TB-IRIS. 
The studies reported in Chapters 5 and 6 prospectively investigated 
paradoxical TBM-IRIS in TBM patients. Over a 20-month period, ART-
naïve HIV-infected patients who presented with TBM were enrolled. TBM 
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was diagnosed according to a published case definition and we excluded 
patients with the most severe TBM disease (i.e. BMRC disease grade III). 
Patients were started on TB treatment and prednisone and commenced ART 
two weeks later. We collected clinical specimens at these two timepoints 
as well as two weeks after ART initiation and at any time that a patient 
developed TBM-IRIS (which was diagnosed according to the INSHI case 
definition for paradoxical TB-IRIS modified for meningitis) as well as two 
weeks after IRIS presentation. Findings were compared between patients 
who developed TBM-IRIS and those who did not. 
As presented in Chapter 5, TBM-IRIS was a frequent complication of ART 
in TBM patients; 47% (16/34) of patients included in the final analysis 
developed TBM-IRIS, indicating the importance of anticipating this 
complication in TBM patients who start ART. A short interval between 
starting TB treatment and ART is a risk factor for TB-IRIS and our patients 
commenced ART two weeks after TB treatment initiation. Disseminated 
disease is a further risk factor for TB-IRIS and all our patients had 
meningitis. These two factors likely contributed to the high incidence of 
TBM-IRIS in our study. As discussed in Chapter 2, current South African 
Department of Health guidelines suggest delaying ART to 4-6 weeks after 
TB treatment initiation in all TBM patients because of the heightened 
risk of developing life-threatening neurological TB-IRIS with early ART 1. 
Low baseline CD4 count is a strong predictor of TB-IRIS 2, 3. However, we 
observed only a trend for lower CD4 counts at ART initiation in patients 
who developed TBM-IRIS, which could be explained by our small sample 
size. Of importance is the finding of an association between high baseline 
CSF neutrophil count and subsequent TBM-IRIS. Although there was a 
wide range of CSF neutrophil counts both in patients who developed TBM-
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IRIS and those who did not, clinicians should be aware of the increased risk 
of TBM-IRIS when neutrophils are present. Furthermore, the association 
between neutrophils and subsequent IRIS suggested a pivotal role for 
the innate system in TBM-IRIS pathogenesis, which directed our further 
studies presented in Chapter 6.  We also found that a high bacillary load 
predicted TBM-IRIS; M. tuberculosis was cultured from the CSF of 15/16 
TBM-IRIS patients, compared to 6/18 patients who did not develop TBM-
IRIS, at TBM diagnosis. Culture remained positive in seven and two TBM-
IRIS patients at two and four weeks on TB treatment, respectively, whereas 
none of the patients who did not develop TBM-IRIS were culture-positive 
at these subsequent timepoints. Given these observations, it is plausible 
that more rapid mycobacterial killing in the CNS early during TB treatment 
will decrease the probability of subsequent TBM-IRIS. 
Corticosteroids did not prevent TBM-IRIS (13/16 IRIS patients were receiving 
prednisone at TBM-IRIS presentation). Although a possible explanation is 
that the dose was suboptimal to suppress CNS inflammation adequately, this 
finding highlights the need for studies to explore other immunomodulatory 
therapies for the prevention of TBM-IRIS. TBM-IRIS presented with severe, 
often atypical, features of inflammation such as radiculomyelitis and 
pachymeningitis.    Corticosteroids were started or increased at TBM-IRIS 
presentation in all patients but regardless, two patients died due to TBM-
IRIS. These finding suggests that corticosteroids at a dose of 1.5-2 mg/kg/
day may be of benefit in some but not all TBM-IRIS cases. Although 15 of the 
16 TBM-IRIS patients experienced symptomatic improvement two weeks 
after prednisone was increased or restarted at TBM-IRIS presentation, only 
two of the inflammatory markers measured in CSF decreased significantly 
at the later timepoint, whilst the others remained unchanged between these 
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two timepoints. Several reasons could account for this lack of effect on 
immune mediators in the CNS; firstly, our sample size at two weeks after 
TBM-IRIS presentation was small (n=10) which may have been inadequate 
to detect statistically significant differences; secondly, the time between 
sampling may have been too short to observe changes in CSF which were 
occurring in the brain; and lastly, we may have failed to include mediators 
that respond rapidly to corticosteroids in the panel that we measured. 
Our patients were followed up closely and corticosteroids were increased 
or started within days of symptom development. In busy public sector 
facilities, it may happen that affected patients are not routinely advised 
of the urgency of returning to hospital should any CNS symptoms recur 
after ART initiation. Patients may further become confused and for that 
reason fail to seek medical help. The mortality associated with neurological 
TB-IRIS may therefore be higher in routine settings, compared to what we 
observed. A vital component of the management of HIV-associated TBM 
patients due to start ART is a comprehensive discussion with the patient, 
and preferably a family member, about the risk of developing TBM-IRIS, the 
typical symptoms that could be expected and the need to return to hospital 
should any of these develop or worsen.  
The immunopathogenesis of TB-IRIS is incompletely understood and we 
therefore analyzed mediators of diverse cellular origins and functions in 
the CSF and blood of TBM-IRIS and TBM-non-IRIS patients. Furthermore, 
considering our finding of the association between neutrophils and 
subsequent TB-IRIS, we included a panel of neutrophil-associated 
mediators in our CSF experiments. TBM-IRIS was associated with a broad 
inflammatory response compared to patients who did not develop TBM-
IRIS at TBM diagnosis. This finding is contrary to that found in CM-IRIS, 
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where an attenuated inflammatory response at CM presentation predicted 
those who subsequently developed CM-IRIS. These differences suggest 
that more than one mechanism underlies pathological immunity in IRIS. 
We further observed that after ART initiation, both TBM-IRIS as well as CSF M. 
tuberculosis culture-positive TBM-non-IRIS patients, developed recurrent 
CNS inflammation. These findings suggest that a high CSF bacillary load 
predisposes to a recurrent inflammatory response that manifests as IRIS in 
most, but not all patients. If not considered, this spectrum of inflammation 
observed after ART initiation may complicate the interpretation of findings 
of clinical studies investigating the immunopathogenesis of TB-IRIS. 
Importantly, neutrophils and their product S100A8/A9 were increased in 
TBM-IRIS patients compared to initially culture-positive TBM-non-IRIS 
patients at two weeks after ART initiation. This suggests a key-contributing 
role for neutrophils to the recurrent inflammatory response that manifests 
as clinical deterioration in patients with TBM-IRIS. 
With regards to predictive markers for TBM-IRIS, in Chapter 5 we report 
the predictive value of the combination of CSF TNF and IFN-γ for TBM-IRIS 
in TBM patients when five cytokines implicated in TB-IRIS pathogenesis 
were included in a multivariate model. However, subsequent statistical 
analysis that combined all mediators detected in CSF revealed that, due 
to high inter-individual variation and the high number of analytes included 
in analysis, further exploration by multivariate methods was flawed. 
Initial studies focused on the role of T-cells, whilst recent studies are 
increasingly investigating the role of the innate immune system, in TB-IRIS 
immunopathogenesis 4. Our findings of increased mediators of the innate 
as well as the adaptive immune system in TBM-IRIS patients imply that 
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both systems contribute to TB-IRIS pathogenesis. 
Impact of the studies in the field
In spite of promising recent advances in rapid diagnostic tests, currently 
available laboratory methods lack adequate sensitivity to allow their use as 
definitive diagnostic tools and the majority of TBM diagnoses are still based 
on supportive clinical findings 5. As discussed in Chapter 3, published clinical 
criteria for microbiologically unconfirmed TBM were not standardized prior 
to 2010 and this methodological heterogeneity complicated comparisons 
between research findings from different settings. The consensus clinical 
case definition for TBM presented in Chapter 3 is the first published case 
definition for use in clinical research that aims to be applicable to all TBM 
patients, regardless or age, HIV-status or resource availability.  Since its 
publication, several studies have applied the case definition in various 
settings. Haldar et al. describes the utility of ELISA and qPCR for the 
detection of selected M. tuberculosis proteins and DNA for the diagnosis 
of TBM 6. In their study, children (n=532) with TBM and unknown HIV status 
were classified as definite, probable, possible and not TBM cases according 
to the consensus case definition. A test combination of qPCR with two of 
the protein ELISAs (GlcB and HspX) accurately detected all TBM samples 
with a specificity of 90%. These results provide support for the utility of the 
consensus case definition in children with TBM. In a retrospective study, 
Hristea et al. classified children and adults (n=55) with definite TBM (i.e. 
either CSF culture or PCR positive for M. tuberculosis) according to the 
probable and possible TBM categories of the consensus case definition 
7. Four of these patients (7%) could not be classified as either probable or 
possible TBM cases. The authors suggest that the retrospective nature of 
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their study and the unavailability of some data required for the classification, 
might have contributed to some misclassifications. However, these results 
underscore the importance of further studies to validate the consensus 
case definition in diverse settings.
Neurological TB accounts for ~1 % of notified TB cases in resource-rich 
settings 8, 9, but due to poor epidemiological data the incidence in resource-
poor settings, such as South Africa, is uncertain. Knowledge of the magnitude 
of the disease burden in our setting and the outcome of those affected is 
a crucial first step to determine the need for local interventional trials that 
aim to improve outcome in TBM. Our findings of the major contribution of 
M. tuberculosis as a cause of meningitis, and the poor outcome of affected 
patients, in our high TB/HIV setting, underscore the feasibility in terms of 
patient numbers, and need for, randomized controlled trials to investigate 
optimal TBM treatment strategies in Cape Town.
Prior to 2010 only one case series that described paradoxical neurological 
TB-IRIS existed 10, 11. In these previous studies, we enrolled patients at 
neurological TB-IRIS presentation and their clinical and investigative findings 
and outcome were reported. The studies presented in Chapter 5 and 6 of this 
thesis are the only studies prior to and since 2010 to prospectively describe 
the clinical, laboratory and immunological characteristics of paradoxical 
TBM-IRIS from the time of TBM diagnosis. Furthermore, these are the first 
studies thus far to describe the immunological profiles of TB-IRIS at the 
site-of-disease. Our findings therefore not only contribute to knowledge in 
the field of TBM-IRIS per se, but also inform on TB-IRIS pathogenesis in 
general. 
Page | 178
Research priorities in HIV-associated TBM
The current mortality rate associated with HIV-associated TBM is 
unacceptably high, thus a pressing research priority in this field is the 
identification of better evidence-based treatment strategies. Improving 
outcome in HIV-associated TBM may require a multistep approach targeting 
several stages of management, including the initial phase of TBM treatment 
and the initial phase of ART.
As discussed in Chapter 2, drug regimens used in the treatment of TBM 
are based on the principals of pulmonary TB treatment rather than being 
informed by evidence from randomized controlled trials in TBM.  The 
majority of deaths in TBM occur within the first month of TB treatment 
and suboptimal CNS TB drug concentrations may contribute to this 
poor outcome. The first trial to compare two antimicrobial regimens 
in the treatment of TBM in which mortality is the primary endpoint, is 
ongoing in Vietnam 12. In this randomized controlled trial, standard TBM 
treatment is compared with standard treatment plus an increased dose 
of oral rifampicin (increased from 10mg/kg/day to 15 mg/kg/day) and the 
addition of oral levofloxacin (20 mg/kg/day) during the intensive phase of 
TB therapy. Levofloxacin has high early bactericidal activity 13, is safe and 
well tolerated 14 and shows good CSF penetration 15 and is therefore an 
attractive treatment option for TBM. Furthermore, as discussed in Chapter 
2, the standard dose of rifampicin may be inadequate in neurological 
TB patients. Results are awaited, but even if the intensified regimen is 
associated with improved outcome, administering drugs intravenously may 
provide an additional mortality benefit, particularly in HIV-infected patients. 
Malabsorption may contribute to decreased systemic drug bioavailability 
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in HIV-infected persons due to enteric infections such as cryptosporidiosis 
and HIV-associated enteropathy 16. TBM patients also often present critically 
ill, vomit and receive drugs through a nasogastric tube. All these factors 
may further associate with reduced TB drug concentrations if drugs are 
administered enterally. The randomized controlled trial by Ruslami et al. 17 
suggested a mortality benefit in patients who received higher-than-normal 
dose intravenous rifampicin during the early treatment of TBM, compared 
to oral standard dose rifampicin. However, the study design was not 
sufficiently robust (considering that mortality was not the primary endpoint) 
for results to change treatment policy globally, hence larger treatment trials 
to explore intravenous strategies further are warranted. 
Recent studies suggest that host genetic variability may influence the 
response to adjunctive corticosteroid treatment in TBM 18. Leukotriene 
A4 hydrolase (LTA4H) controls the balance of pro- and anti-inflammatory 
eicosanoids; an excess of LTA4H results in increased TNF and excessive 
inflammation, whilst a deficiency of LTA4H results in decreased TNF and 
attenuated inflammation. In both zebrafish and TBM patients, a single 
nucleotide polymorphism (SNP) in the LTA4H promoter (rs17525495) was 
associated with hyperinflammatory (TT homozygous) and hypoinflammatory 
(CC homozygous) phenotypes. Heterozygosity (CT) for the SNP resulted 
in an intermediate inflammatory phenotype. Survival analysis of the TBM 
patients revealed that homozygosity (both TT and CC) was associated 
with the highest mortality. In a subgroup of patients who received 
dexamethasone, an associated survival benefit was observed in those 
with the hyperinflammatory phenotype, whilst being detrimental in those 
with the hypoinflammatory phenotype. These findings raise important 
questions of our current generalized approach with regards to adjunctive 
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corticosteroids in TBM. As the authors suggest, it may be advantageous to 
use opposite immunomodulatory strategies depending on a patient’s LTA4H 
genotype, with those with the TT genotype receiving immunosuppressive 
therapy, whilst those with the CC genotype receiving drugs that augment 
immune responses. However, only Vietnamese patients were included 
in these studies and the results need to be confirmed in different ethnic 
populations. Furthermore, due to high costs, limited availability and the 
time it may take for results to become available, such genetic testing is not 
currently feasible in resource-poor settings.  
An ironic contribution to poor outcome in HIV-associated TBM is neurological 
TB-IRIS, which typically occurs within weeks after ART initiation. Both 
TB treatment and ART are life-saving in TB/HIV co-infected patients but 
in patients with TBM the combination of these two therapies may result 
in recurrent CNS inflammation and, as a consequence, death. Neither 
prevention nor treatment trials, which are imperative to inform optimal 
management strategies in HIV-associated TBM, have been performed for 
neurological TBM-IRIS. Trials to compare corticosteroids with placebo 
for the treatment of neurological TB-IRIS would be unethical, given the 
suggested benefit of corticosteroids in this context. However, trials could 
potentially compare the safety and benefit of different corticosteroid doses 
and routes of administration (intravenous versus oral), neither of which are 
standardized in neurological TB-IRIS treatment. There is a paucity of data 
in the literature regarding the roles of other drugs in the treatment of TB-
IRIS; only case reports of the benefit of immunomodulatory agents such 
as thalidomide and leukotriene antagonists exist 19. Thalidomide is not 
consistently associated with improvement in neurological TB-IRIS cases 
20, and its use is further limited by its strong association with teratogenicity 
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and potential toxicities, such as peripheral neuropathy. The leukotriene 
antagonist montelukast has a favorable side effect profile compared to 
corticosteroids, making it a good candidate for prevention and treatment trials 
in neurological TB-IRIS. TNF blockers such as infliximab and adalimumab 
are further potential treatment options as infliximab has shown benefit in 
steroid-resistant paradoxical CNS TB reactions in HIV-uninfected patients 
21, and adalimumab has been used with success in a case of CM-IRIS 22. 
However, a serious concern in HIV-infected TBM patients, most of whom 
are severely immunosuppressed, is the increased risk of severe infections 
that is associated with TNF blocker use, particularly when considering the 
long half lives (10-20 days) of these agents. Given the limited evidence for 
the benefit of these alternative immunomodulatory drugs in neurological 
TB-IRIS, and considering the potential serious adverse events associated 
with many of these agents, it may be advantageous to first perform studies 
to assess their immune modulatory effects in animal models of TBM prior 
to conducting human trials in neurological TB-IRIS. 
A better understanding of the immunopathogenesis of TB-IRIS is crucial to 
identifying future drug candidates for patients both at risk of, and affected 
by, neurological TB-IRIS. Studies that explore the cellular sources of 
inflammatory mediators in the CNS of these patients may shed light on 
the sequence of events that ultimately result in TB-IRIS and thus inform on 
crucial steps in the dysregulated immune pathway (s) that might be amenable 
to drug intervention. To this effect, research should include in vivo studies 
to determine types and proportions of CSF white blood cells and their 
contribution to cytokine production by flow cytometric methods in patients 
with TBM and TBM-IRIS, as well as in vitro studies of M. tuberculosis-
induced inflammatory mediator production by cultured human CNS cells 
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such as microglia, astrocytes and neurons. Future research should also 
continue the quest to identify thus far elusive diagnostic biomarkers for 
TB-IRIS, which will likely contribute significantly to improved management 
and outcomes of patients with neurological TB-IRIS.  
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